IMPORTANT NOTE: You may submit your article only through our online submission systemSubmit your manuscript
  • Slider Image

Reviews 2005-2024

Advances in Spinal Neuromodulation for Chemotherapy-induced Peripheral Neuropathy. P. GUPTA, K. PATEL, G. PAUL (Washington, DC, USA). Anticancer Res 44:3223-3230, 2024.
Advances in Spinal Neuromodulation for Chemotherapy-induced Peripheral Neuropathy. P. GUPTA, K. PATEL, G. PAUL (Washington, DC, USA). Anticancer Res 44:2769-2774, 2024.
Proceedings of the Think Tank for Osteosarcoma. S.P. CHAWLA, B. VAN TINE, N. FEDERMAN, J. SCHWAB, R. JONES, V. SUBBIAH, N.S. CHAWLA, N. AFSHAR, W. HOOS, N. FELDMAN, H.T. SPENCER, W. SWANEY, E.M. GORDON (Santa Monica; Los Angeles; Duarte; San Francisco, CA; St. Louis, MO; Nashville, TN; Raleigh-Durham Chapel Hill, NC; Atlanta, GA; Cincinnati, OH, USA; London, UK). Anticancer Res 44:2765-2768, 2024.
Systematic Review of the First 40 Cases of 177Lu-PSMA Therapy in the Treatment of Non-prostatic Cancer. H. GOLAN, K.K. TURSUNOV, O. VOLKOV (Tel Aviv; Ramat Gan, Israel; Andijan, Uzbekistan). Anticancer Res 44:2297-2305, 2024.
Harnessing Micronutrient Power: Vitamins, Antioxidants and Probiotics in Breast Cancer Prevention. KINAN MOKBEL, KEFAH MOKBEL (London; Exeter, UK). Anticancer Res 44:2287-2295, 2024.
Intratumoral Microbiota: Unraveling their Oncogenic Impact on Cancer Progression With Focus on Breast Cancer Therapeutic Outcomes. C.M. CHANG, H.Y.P. LAM (Hualien, Taiwan, ROC). Anticancer Res 44:2271-2285, 2024.
Breath of Danger: Unveiling PM2.5’s Stealthy Impact on Cancer Risks. K. MOKBEL (London, UK). Anticancer Res 44:1365-1368, 2024.
Therapeutic Options Targeting the Ataxia-Telangiectasia Mutated (ATM)-mediated DNA Damage Response, Macropinocytosis, and Adaptive Immunity in Ovarian Cancer. C-C. TSENG, M-H. KU, Y-C. WU, W-L. HUANG, W-M. WU, C.H. PAI, C-W. CHEN (Hualien, Taiwan, ROC; Sault Ste. Marie, MI, USA). Anticancer Res 44:1353-1364, 2024.
Clinical Impact of Nutrition and Inflammation Assessment Tools in Colorectal Cancer Treatment. T. AOYAMA, N. YUKAWA, A. SAITO (Yokohama, Japan). Anticancer Res 44:1335-1351, 2024.
Adenoid Cystic Carcinoma, Clinical Presentation, Current Treatment and Approaches Towards Novel Therapies. M. ZUPANCIC, A. NÄSMAN, S. FRIESLAND, T. DALIANIS (Stockholm, Sweden). Anticancer Res 44:1325-1334, 2024.
Cannabinoids for Cancer-related Pain Management: An Update on Therapeutic Applications and Future Perspectives. S. BIMONTE, D. NOCERINO, D. SCHIAVO, M. CRISCI, M. CASCELLA, A. CUOMO (Naples; Baronissi, Italy). Anticancer Res 44:895-900, 2024
Efficacy and Safety of Anti-angiogenic Agents for Cancer Patients With Proteinuria or a History of Proteinuria: A Systematic Review. T. KATO, S. KURASAWA, K. TAKEZAWA, Y. FUJIWARA, Y. YASUDA, Y. ANDO (Suita; Nagoya, Japan). Anticancer Res 44:889-894, 2024.
Current Status of Prostate-specific Membrane Antigen-targeted Alpha Radioligand Therapy in Prostate Cancer. G. YAMAMICHI, T. KATO, T. WATABE, K. HATANO, M. UEMURA, N. NONOMURA (Osaka; Fukushima, Japan). Anticancer Res 44:879-888, 2024.
Immunotherapy Combined With Standard Therapies in Head and Neck Squamous Cell Carcinoma – A Meta-analysis. D. EDEN, A. GHOSE, M. MOSCHETTA, J.A. PÉREZ-FIDALGO, E. RASSY, S. BOUSSIOS (London; Gillingham; Liverpool; Canterbury, UK; Basel, Switzerland; Valencia, Spain; Villejuif, France; Thessaloniki, Greece). Anticancer Res 44:861-878, 2024
An Overview of Introductory and Advanced Survival Analysis Methods in Clinical Applications: Where Have we Come so far? G. BEIS, A. ILIOPOULOS, I. PAPASOTIRIOU (Florina, Greece; Zug, Switzerland). Anticancer Res 44:471-487, 2024.
Biparametric MRI for Local Staging of Prostate Cancer: Current Status and Future Applications. L. DELL’ATTI (Ancona, Italy). Anticancer Res 44:463-470, 2024.
Intraventricular Cerebral Metastases: A Comprehensive Systematic Review. G. SCALIA, M.P. SILVEN, R. COSTANZO, M. PORZIO, R. MAUGERI, D.G. IACOPINO, G.F. NICOLETTI, G.E. UMANA (Catania; Palermo, Italy). Anticancer Res 44:453-462, 2024.
Integration of the Molecular Classification of Endometrial Carcinoma to Select Patients for Fertility Sparing Strategies. M.A. BANI, A. MAULARD, P. MORICE, C. CHARGARI, C. GENESTIE (Villejuif, France). Anticancer Res 44:445-452, 2024.
Proteinase-activated Receptor 2: Springboard of Tumors. D. VETVICKA, P. SUHAJ, T. OLEJAR, L. SIVAK, J. BENES, P. POUCKOVA (Prague; Brno, Czech Republic). Anticancer Res 43:1-12, 2024.
Mechanism of CDK4/6 Inhibitor Resistance in Hormone Receptor-positive Breast Cancer and Alternative Treatment Strategies. C.-M. CHANG, H.Y.P. LAM (Hualien, Taiwan, ROC). Anticancer Res 43:5283-5298, 2023.
Suppression of Kynurenine 3-Monooxygenase as a Treatment for Triple-negative Breast Carcinoma. L.A. SORDILLO, P.P. SORDILLO (New York, NY, USA). Anticancer Res 43:5275-5282, 2023.
Renal Cell Cancer – Insights in Drug Resistance Mechanisms. H. AWEYS, D. LEWIS, M. SHERIFF, R.D. RABBANI, P. LAPITAN, E. SANCHEZ, V. PAPADOPOULOS, A. GHOSE, S. BOUSSIOS (Kent; Manchester; London; Surrey, UK; Thessaloniki, Greece). Anticancer Res 43:4781-4792, 2023.
Circulating Tumor Cells and Tumor Progression, Metastasis, and Poor Prognosis in Patients With Neuroblastoma. M. KOJIMA, E. HIYAMA (Hiroshima, Japan). Anticancer Res 43:4327-4331, 2023.
Vascular Endothelial Growth Factor Family and Head and Neck Squamous Cell Carcinoma. C.-S. DUMITRU, MARIUS RAICA (Timisoara, Romania). Anticancer Res 43:4315-4326, 2023.
Prognostic Value of HER2-low Status in ER+ Early Breast Cancer: A Systematic Review and Meta-Analysis. F. PETRELLI, C. REA, M.C. PARATI, K. BORGONOVO, M. GHILARDI, L. DOTTORINI, A. LUCIANI, M. GHIDINI, F. RUATTA, O. GARRONE, G. TOMASELLO (Treviglio; Milan, Italy). Anticancer Res 43:4303-4313, 2023.
Biology and Management of Deep-seated Atypical Lipomatous Tumor of the Extremities. J. NISHIO, S. NAKAYAMA, Y. CHIJIIWA, M. AOKI (Fukuoka, Japan). Anticancer Res 43:4295-4301, 2023.
Surgery for Hepatocellular Carcinoma With Macroscopic Vascular Invasion in the Era of Modern Molecular Therapy. K. YAMAMURA, T. BEPPU, T. MIYATA, K. MIMA, H. OKABE, H. NITTA, K. IMAI, H. HAYASHI, E. ODA, R. KARASHIMA, N. OZAKI, T. ISIKO (Yamaga; Kumamoto, Japan). Anticancer Res 43:4285-4293, 2023.
High Clinical Concordance of Drug Resistance in Patient-derived Orthotopic Xenograft (PDOX) Mouse Models: First Step to Validated Precise Individualized Cancer Chemotherapy. T. HIGUCHI, N. YAMAMOTO, K. HAYASHI, S. MIWA, K. IGARASHI, H. TSUCHIYA, R.M. HOFFMAN (San Diego, CA, USA; Kanazawa, Japan). Anticancer Res 43:4277-4284, 2023.
The Influence of Statin Use on Chemotherapeutic Efficacy in Studies of Mouse Models: A Systematic Review. A. TULK, R. WATSON, J. ERDRICH (Tucson, AZ; Kirksville, MO, USA). Anticancer Res 43:4263-4275, 2023.
Tonsillectomy as Prevention of Tonsil and Base of Tongue Cancer: Systematic Review and Meta-analysis on the Immuno-Oncological Effect of One Among the Most Common Surgeries in the World. E. VIRGILIO, D. BONFILI, S. BETTONI, L. VONA, J. MERCURI, F. D’AGOSTINO, M. BALDINU, C. SALVEMINI, F. MONTALI, R. COSTI (Parma; Fidenza, Italy). Anticancer Res 43:993-1000, 2023.
Gestational Renal Cell Cancer – An Update. A. CAGLAYAN, R.D. RABBANI, E. SANCHEZ, S. CHOI, A. ISMAIL, V. PAPADOPOULOS, S. ADELEKE, A. GHOSE, S. BOUSSIOS (Kent; London; Gillingham, UK; Thessaloniki, Greece). Anticancer Res 43:3871-3880, 2023
Liver Cancer and Pregnancy: A Review of the Literature. I. PSILOPATIS, N. GARMPIS, A. GARMPI, K. VRETTOU, P. SARANTIS, E. KOUSTAS, K. NIKOLETTOS, E.A. ANTONIOU, D. DIMITROULIS, G. KOURAKLIS, M.V. KARAMOUZIS, N. NIKOLETTOS, K. KONTZOGLOU, C. DAMASKOS (Berlin, Germany; Athens; Alexandroupolis, Greece). Anticancer Res 43:3861-3869, 2023.
Clinical Impact of Nutrition and Inflammation Assessment Tools in Pancreatic Cancer Treatment. T. AOYAMA, Y. MAEZAWA, I. HASHIMOTO, Y. RINO, T. OSHIMA (Yokohama, Japan). Anticancer Res 43:3849-3860, 2023.
Second-Line Systemic Therapy for Highly Aggressive Neuroendocrine Prostate Cancer. N. FUJIMOTO, Y. TSUBONUMA, Y. NAGATA, A. MINATO, I. TOMISAKI, K. HARADA, H. MIYAMOTO (Kitakyushu, Japan; Rochester, NY, USA). Anticancer Res 43:3841-3847, 2023.
New Approaches Towards Targeted Therapy for Childhood Neuroblastoma. T. DALIANIS, M. LUKOSEVICIUTE, S. HOLZHAUSER, O.N. KOSTOPOULOU (Stockholm, Sweden). Anticancer Res 43:3829-3839, 2023.
Ovarian Clear Cell Carcinoma: Genomic Characterization, Pathogenesis and Targeted Therapy. Y. XIE, W. KONG, D. LUO, S. CHEN, X. ZHAO, H. ZHANG (Beijing, PR China). Anticancer Res 43:3401-3410, 2023.
Irreversible Electroporation Combined With Dendritic Cell-based Vaccines for the Treatment of Osteosarcoma. C. SUN, X. MA, C. ZHOU, Z. ZHANG, J. GUO (Qingdao, PR China; Irvine, CA, USA). Anticancer Res 43:3583-3588, 2023.
A Systematic Review of Microwave Ablation for Colorectal Pulmonary Metastases. C.Q.Y. TAN, A. HO, H.A. ROBINSON, L. HUANG, P. RAVINDRAN, D.L. CHAN, N. ALZAHRANI, D.L. MORRIS (Sydney, NSW, Australia; Riyadh, Kingdom of Saudi Arabia). Anticancer Res 43:2899-2907, 2023.
Treatment Algorithm for Patients With Gastric Adenocarcinoma: Austrian Consensus on Systemic Therapy – An Update. E. WÖLL, A. AMANN, W. EISTERER, A. GERGER, B. GRÜNBERGER, H. RUMPOLD, L. WEISS, T. WINDER, R. GREIL, G.W. PRAGER (Zams; Innsbruck; Klagenfurt am Wörthersee; Graz; Wiener Neustadt; Linz; Salzburg; Feldkirch; Vienna, Austria). Anticancer Res 43:2889-2897, 2023.
Early-stage CCNG1+ HR+ HER2+ Invasive Breast Carcinoma in Older Women: Current Treatment and Future Perspectives for DeltaRex-G, a CCNG1 Inhibitor. S.P. CHAWLA, O. OLEVSKY, G. IYENGAR, D.A. BRIGHAM, N. OMELCHENKO, S. THOMAS, K. SURYAMOHAN, L. FOSHAG, F.L. HALL, E.M. GORDON (Santa Monica, CA; Waltham, MA, USA). Anticancer Res 43:2383-2391, 2023.
The Clinical Impact of the Tumor Stroma Ratio in Gastrointestinal Cancer Treatment. T. AOYAMA, I. HASHIMOTO, T. OSHIMA (Yokohama, Japan). Anticancer Res 43:1877-1883, 2023.
Recent Advances in the Management of Small Cell Carcinoma of the Uterine Cervix. A. MIYOSHI, Y. UEDA, T. KURITA, T. KIMURA, K. YOSHINO (Osaka; Kitakyushu, Japan). Anticancer Res 43:1397-1405, 2023.
Personalized Palliative and Survivorship Care for Patients With Metastatic Cancer Treated With Radiation Therapy. S. SIDDIQUI, L. ROWLAND, E. COPEL, A. SANGAL, V. SONI, P. ECKARDT, J. KAO (West Islip, NY, USA). Anticancer Res 43:1387-1395, 2023.
Phytocannabinoids in Triple Negative Breast Cancer Treatment: Current Knowledge and Future Insights. S. BIMONTE, G. PALMA, M. CASCELLA, A. CUOMO (Naples, Italy). Anticancer Res 43:993-1000, 2023.
The Potential Impact of New Drug and Therapeutic Modalities on Drug Resistance to Renal Cell Carcinoma. P.C. PINTO (Greifswald, Germany). Anticancer Res 43:983-991, 2023.
Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides BRCA1 and BRCA2 as Breast Cancer Biomarkers for PARP Inhibitors and Other DDR Targeting Therapies. I.A. VOUTSADAKIS, A. STRAVODIMOU (Sault Ste Marie; Sudbury, ON, Canada; Lausanne, Switzerland). Anticancer Res 43:967-981, 2023.
Lung Cancer – Standard Therapy and the Use of a Novel, Highly Effective, Well Tolerated, Treatment With Progesterone Receptor Modulators. J.H. CHECK, T. PORETTA, D. CHECK, M. SRIVASTAVA (Camden; Mt. Laurel; Voorhees, NJ; Buffalo, NY, USA). Anticancer Res 43:951-965, 2023.
Intramedullary Spinal Cord Metastases from Breast Cancer: A Systematic Review. G. SCALIA, R. COSTANZO, A. VIOLA, L. BONOSI, M. PORZIO, A. GIOVANNINI, F. GRAZIANO, D.G. IACOPINO, R. MAUGERI, G.F. NICOLETTI, G.E. UMANA (Catania; Palermo; Viagrande, Italy). Anticancer Res 43:523-535, 2023.
The Latest Treatments for Cancer Cachexia: An Overview. H. WATANABE, T. OSHIMA (Yokohama, Japan). Anticancer Res 43:511-521, 2023.
Evolution of Models of Prostate Cancer: Their Contribution to Current Therapies. A.I. FAUSTINO-ROCHA, C. JOTA-BAPTISTA, E. NASCIMENTO-GONÇALVES, P.A. OLIVEIRA (Vila Real; Évora; Aveiro, Portugal; Léon, Spain). Anticancer Res 43:323-333, 2023.
The Role of Genetic Polymorphisms in the Diagnosis and Management of Prostate Cancer: An Update. L. DELL’ATTI, G. AGUIARI (Ancona; Ferrara, Italy). Anticancer Res 43:317-322, 2023.
Radiotherapy in Prostate Brain Metastases: A Review of the Literature. C. DE LA PINTA (Madrid, Spain). Anticancer Res 43:311-315, 2023.
Renal Impairment: A Major Adverse Event in Prostate Cancer Patients Treated With Androgen Deprivation Therapy. H. MASUDA (Chiba, Japan). Anticancer Res 43:305-309, 2023.
S-PI-RADS and PI-RRADS for Biparametric MRI in the Detection of Prostate Cancer and Post-treatment Local Recurrence. M. SCIALPI, E. MARTORANA, P. SCIALPI, G.B. SCALERA, E. BELATTI, M.C. AISA, A. D’ANDREA, F.M. MANCIOLI, A. DI MARZO, F. TRIPPA, A. DI BLASI (Perugia; Modena; Venice; Caserta; Terni; Tivoli, Italy). Anticancer Res 43:297-303, 2023

Transglutaminase-4 (Prostate Transglutaminase), a Potential Biological Factor and Clinical Indicator for the Diagnosis and Prognosis of Prostate Cancer. L. YE, A.J. SANDERS, W.G. JIANG (Cardiff; Cheltenham, UK). Anticancer Res 43:291-296, 2023.
Diagnosing and Prognosing Bone Metastasis in Prostate Cancer: Clinical Utility of Blood Biomarkers. G. YAMAMICHI, T. KATO, M. UEMURA, N. NONOMURA (Osaka; Fukushima, Japan). Anticancer Res 43:283-290, 2023.
Appraising Animal Models of Prostate Cancer for Translational Research: Future Directions. E. NASCIMENTO-GONCALVES, F. SEIXAS, R.M.G. DA COSTA, M.J. PIRES, M.J. NEUPARTH, D. MOREIRA-GONCALVES, M. FARDILHA, A.I. FAUSTINO-ROCHA, B. COLACO, R. FERREIRA, P.A. OLIVEIRA (Vila Real; Aveiro; Porto; Gandra; Évora, Portugal; São Luís, Brazil). Anticancer Res 43:275-281, 2023.
Phase I CAR-T Clinical Trials Review. S. BULSARA, M. WU, T. WANG (Houston, TX, USA). Anticancer Res 42:5673-5684, 2022.
Management of Resistant Post-transplant Lymphoproliferative Disorder: CAR-T Is a New Option. J. STYCZYNSKI, J. SADLOK, T. STYCZYNSKI, A. MARJANSKA, M. RICHERT-PRZYGONSKA (Bydgoszcz, Poland). Anticancer Res 42:5181-5186, 2022.
Clinical Impact of Nutrition and Inflammation Assessment Tools in Gastric Cancer Treatment. T. AOYAMA, K. HARA, K. KAZAMA, Y. MAEZAWA (Yokohama; Kanagawa; Tokyo, Japan). Anticancer Res 42:5167-5180, 2022.
Pathophysiology and Therapeutic Perspectives for Chemotherapy-induced Peripheral Neuropathy. A. AVALLONE, S. BIMONTE, C. CARDONE, M. CASCELLA, A. CUOMO (Νaples, Italy). Anticancer Res 42:4667-4678, 2022.
Hyperthermic Intraperitoneal Chemotherapy in the Management of Primary Epithelial Ovarian Cancer: A Debated Issue for Gynecologic Oncologists. A. GADDUCCI, S. COSIO, P.V. LIPPOLIS (Pisa, Italy). Anticancer Res 42:1661-1669, 2022. Anticancer Res 42:4659-4665, 2022
Evidence of Potential Plant-derived Compounds With Anticancer Effects on Lung Cancer: Clinical and Molecular Pharmacology Approaches. M. SUKPRASANSAP, P. CHANVORACHOTE (Phutthamonthon; Bangkok, Thailand). Anticancer Res 42:4247-4258, 2022.
Epithelial to Mesenchymal Transition in Lung Cancer: Potential EMT-Targeting Natural Product-derived Compounds. P. CHANVORACHOTE, K. PETSRI, S. THONGSOM (Bangkok, Thailand). Anticancer Res 42:4237-4246, 2022.
Comparison of Proportion of Elevated Carcinoembryonic Antigen Levels in Patients With Appendiceal and Colorectal Adenocarcinoma: A Systematic Review and Meta-analysis. A.T. CRISTAUDO, S.B. JENNINGS, D.L. MORRIS (Kogarah; Sydney, NSW, Australia). Anticancer Res 42:4217-4235, 2022.
Screening for Ovarian Cancer in the General Population: State of Art and Perspectives of Clinical Research. A. GADDUCCI, S. COSIO (Pisa, Italy). Anticancer Res 42:4207-4216, 2022.
Applicability of a Host-mediated In Vivo/In Vitro Model in Screening for the Carcinogenic Potential of Chemicals. K. SCHLATTERER, A. ESMAEILI, T. MASSA, S. APOSTOLIDIS, P. CHANDRA (Berlin; Neuruppin; Frankfurt, Germany). Anticancer Res 42:4199-4206, 2022.
Craniopharyngiomas Invading the Ventricular System: A Systematic Review. P. PALMISCIANO, K. YOUNG, M. OGASAWARA, O. YOUSEFI, C. OGASAWARA, G. FERINI, O. BIN-ALAMER, M. SHARMA, G.E. UMANA, K. YU, A.A. COHEN-GADOL, T.Y. EL AHMADIEH, A.S. HAIDER (Cincinnati, OH; Honolulu, HI; Berkeley, CA; Galveston; Houston, TX; Pittsburgh, PA; Louisville, KY; New York, NY; Indianapolis, IN, USA; Shiraz, Iran; Viagrande; Catania, Italy). Anticancer Res 42:4189-4197, 2022.
Radiotherapy in Metastatic Urothelial Carcinoma: Rationale and Clinical Applications. V. VASSILIOU, T. KATSILA, S.C. SODERGREN, D. KARDAMAKIS (Nicosia, Cyprus; Athens; Patras, Greece; Southampton, UK). Anticancer Res 42:3767-3778, 2022.
Postoperative Pancreatic Fistula: Is Minimally Invasive Surgery Better than Open? A Systematic Review and Meta-analysis. N. PETRUCCIANI, A. CROVETTO, F. DE FELICE, M. PACE, D. GIULITTI, M. YUSEF, G. NIGRI, S. VALABREGA, R. KASSIR, F. D’ANGELO, T. DEBS, G. RAMACCIATO, P. AURELLO (Rome, Italy; Nice; Saint Denis, France). Anticancer Res 42:3285-3298, 2022
Immunotherapy for Non-small Cell Lung Cancer: Current Agents and Potential Molecular Targets. N.O. SHAM, L. ZHAO, Z. ZHU, T.M. ROY, H. XIAO, Q. BAI, M.R. WAKEFIELD, Y. FANG (Des Moines, IA; Columbia, MO, USA; Hefei, PR China). Anticancer Res 42:3275-3284, 2022.
Thromboembolic Disease in Patients With Cancer and COVID-19: Risk Factors, Prevention and Practical Thromboprophylaxis Recommendations–State-of-the-Art. E. DIMAKAKOS, G. GOMATOU, M. CATALANO, D.-M. OLINIC, A.C. SPYROPOULOS, A. FALANGA, A. MARAVEYAS, A. LIEW, S. SCHULMAN, J. BELCH, G. GEROTZIAFAS, P. MARSCHANG, B. COSMI, J. SPAAK, K. SYRIGOS (Athens, Greece; Milan; Bergamo; Bolzano; Bologna, Italy; Cluj-Napoca, Romania; Hempstead; New York, NY, USA; Cottingham; Hull; Dundee, UK; Galway, Ireland; Hamilton, ON, Canada; Paris, France; Stockholm, Sweden). Anticancer Res 42:3261-3274, 2022.
Intradural Extramedullary Spinal Metastases from Non-neurogenic Primary Tumors: A Systematic Review. P. PALMISCIANO, A.L. CHEN, M. SHARMA, O. BIN-ALAMER, G. FERINI, G.E. UMANA, S.G. AOUN, A.S. HAIDER (Cincinnati, OH; Dallas; Houston, TX; Louisville, KY; Pittsburgh, PA, USA; Viagrande; Catania, Italy). Anticancer Res 42:3251-3259, 2022.
Long Non-coding RNAs Sponging MicroRNAs With Efficacy in Preclinical In Vivo Models of Esophageal Squamous Cell Cancer. U.H. WEIDLE, A. NOPORA (Penzberg, Germany). Anticancer Res 42:3233-3249, 2022.
The Role of Toll-like Receptors in Esophageal Cancer. S. DAVAKIS, A. KAPELOUZOU, T. LIAKAKOS, M. MPOURA, D. STERGIOU, S. SAKELLARIOU, A. CHARALABOPOULOS (Athens, Greece). Anticancer Res 42:2813-2818, 2022.
Adverse Events in Placebo Arms of Cancer Trials. J.E. WOLFF, B.J. WOLFF, M.M. THIELEN, H. HAUCH (North Chicago; Chicago, IL, USA; Hesse, Germany). Anticancer Res 42:2805-2812, 2022.
The Implication of X-Linked Genetic Polymorphisms in Susceptibility and Sexual Dimorphism of Cancer. C. ACHILLA, T. PAPAVRAMIDIS, L. ANGELIS, A. CHATZIKYRIAKIDOU (Thessaloniki, Greece). Anticancer Res 42:2261-2276, 2022.
Exosomal Functional Cargoes from Liquid Biopsy of Gastric Cancer: A Systematic Review of Studies With Potential Clinical Relevance. E. VIRGILIO, F. MONTALI, A. ANNICCHIARICO, C. SALVEMINI, M. BALDINU, E. GIARNIERI, M. MONTAGNINI, S. VILLANI, A. PROIETTI, R. D’URSO, R. COSTI (Parma; Fidenza; Rome, Italy). Anticancer Res 42:2249-2259, 2022.
Radiotherapy and Immunotherapy: The Power of the Teamwork for the Treatment of NSCLC. M. BASSANELLI, S. RAMELLA, M. ZEULI, A. CERIBELLI (Rome; Rieti, Italy). Anticancer Res 42:2241-2247, 2022.
Molecular Stratification of Medulloblastoma: Clinical Outcomes and Therapeutic Interventions. T. SURSAL, J.S. RONECKER, A.J. DICPINIGAITIS, A.L. MOHAN, M.E. TOBIAS, C.D. GANDHI, M. JHANWAR-UNIYAL (Valhalla, NY, USA). Anticancer Res 42:2225-2239, 2022.
Accuracy of Serum Biomarker Panel (GastroPanel®) in the Diagnosis of Atrophic Gastritis of the Corpus. Systematic Review and Meta-analysis. K. SYRJÄNEN (Kaarina, Finland; Barretos, SP, Brazil). Anticancer Res 42:1679-1696, 2022.
Sun Exposure - Hazards and Benefits. P.G. LINDQVIST, E. EPSTEIN, M. LANDIN-OLSSON (Stockholm; Lund, Sweden). Anticancer Res 42:1671-1677, 2022.
Intradural Cauda Equina Metastases: A Systematic Review of Clinico-radiological Features, Management, and Treatment Outcomes. P. PALMISCIANO, S.E. ZAIDI, N.A. SHLOBIN, N.S. SAGOO, O.B. ALAMER, G. SCALIA, G. FERINI, G.E. UMANA, S.G. AOUN, A.S. HAIDER (Catania; Viagrande, Italy; Paris, France; Chicago, IL; Dallas; Houston, TX, USA; Riyadh, Kingdom of Saudi Arabia). Anticancer Res 42:1661-1669, 2022
Pineal Region Gliomas: A Systematic Review of Clinical Features and Treatment Outcomes. O. BIN ALAMER, P. PALMISCIANO, S.E. ROWE, A.D. GUPTA, M. HAIDER, M. ALDUHAYMI, A.A. COHEN-GADOL, K. YU, T.Y. EL AHMADIEH, A.S. HAIDER (Riyadh, Kingdom of Saudi Arabia; Catania, Italy; Fort Lauderdale, FL; Houston, TX; Indianapolis, IN; New York, NY, USA). Anticancer Res 42:1189-1198, 2022.
Leptomeningeal Metastases of the Spine: A Systematic Review. P. PALMISCIANO, N.S. SAGOO, A.F. KHARBAT, Y.J. KENFACK, O.B. ALAMER, G. SCALIA, G.E. UMANA, S.G. AOUN, A.S. HAIDER (Catania, Italy; Dallas; Lubbock; Houston, TX, USA; Riyadh, Kingdom of Saudi Arabia). Anticancer Res 42:619-628, 2022.
The Role of Surgery for Pancreatic Neuroendocrine Tumors. I.A. ZIOGAS, R. SCHMITZ, D. MORIS, C.J. VATSAAS (Nashville, TN; Durham, NC, USA). Anticancer Res 42:629-639, 2022.
Methionine Restriction: Ready for Prime Time in the Cancer Clinic? J. YAMAMOTO, Q. HAN, M. SIMON, D. THOMAS, R.M. HOFFMAN (San Diego; La Jolla; Westlake Village, CA; Mount Dora, FL, USA; Yokohama, Japan). Anticancer Res 42:641-644, 2022.
Challenges of Surgical Resection of Carotid Body Tumors - Multiple Feeding Arteries and Preoperative Embolization. K. SHIGA, K. KATAGIRI, A. IKEDA, D. SAITO, S.-I. OIKAWA, K. TSHUCHIDA, J. MIYAGUCHI, T. KUSAKA, A. TAMURA (Yahaba, Japan). Anticancer Res 42:645-652, 2022.
A Systematic Review of Minimally Invasive Versus Open Radical Antegrade Modular Pancreatosplenectomy for Pancreatic Cancer. K. TAKAGI, Y. UMEDA, R. YOSHIDA, T. YAGI, T. FUJIWARA (Okayama, Japan). Anticancer Res 42:653-660, 2022.
The Role of Community Pharmacists in Addressing Medication-related Issues for Breast Cancer Patients Receiving Adjuvant Endocrine Therapy. K. MOKBEL, K. MOKBEL (Exeter; London, UK). Anticancer Res 42:661-666, 2022.
SBRT in Localized Renal Carcinoma: A Review of the Literature. C. DE LA PINTA, R.G. LATORRE, R. FUENTES (Madrid, Spain). Anticancer Res 42:667-674, 2022.
Minimally Invasive Transcervical Esophagectomy With Mediastinal Lymphadenectomy for Cancer. A Comparison With Standardized Techniques. S. DAVAKIS, A. CHARALABOPOULOS, E. KYROS, P. SAKARELLOS, G. TSOUROUFLIS, D. DIMITROULIS, N. NIKITEAS (Athens, Greece). Anticancer Res 42:675-680, 2022.
Fatigue in Cancer Treatment Studies: Analysis of Placebo Arms. H. HAUCH, B.J. WOLFF, J.E. WOLFF (Hesse, Germany; Chicago; North Chicago, IL, USA). Anticancer Res 42:45-52, 2022.
Conversion Surgery for Hepatocellular Carcinoma Following Molecular Therapy. K. YAMAMURA, T. BEPPU, T. MIYATA, H. OKABE, H. NITTA, K. IMAI, H. HAYASHI, S. AKAHOSHI (Yamaga; Kumamoto, Japan). Anticancer Res 42:35-44, 2022.
The Role of Surgery in the Treatment of Metachronous Liver Metastasis from Gastric Cancer: A Systematic Review. P. AURELLO, A. MINERVINI, M. PACE, F. D’ANGELO, G. NIGRI, L. ANTOLINO, S. VALABREGA, G. RAMACCIATO, N. PETRUCCIANI (Rome, Italy). Anticancer Res 42:25-33, 2022.
Current Status of Metastatic Cardiophrenic Lymph Nodes (CPLNs) in Patients With Ovarian Cancer: A Review. M. ACS, P. PISO, S. PRADER (Regensburg; Essen, Germany; Brixen, Italy). Anticancer Res 42:13-24, 2022.
Prospects of Improving Early Ovarian Cancer Diagnosis Using Cervical Cell Swabs. E. BISKUP, R.S. WILS, C. HOGDALL, E. HOGDALL (Herlev; Copenhagen, Denmark). Anticancer Res 42:1-12, 2022.
Repurposing Metformin for Cancer Treatment: A Great Challenge of a Promising Drug. C. SAENGBOONMEE, T. SANLUNG, S. WONGKHAM (Khon Kaen, Thailand; Kumamoto, Japan). Anticancer Res 41:5913-5918, 2021.
Effects of Circulating 25(OH)D Status in Advanced Colorectal Cancer Patients Undergoing Chemotherapy: A Systematic Review. X. ZENG, L. ZHANG, S. JIA, T. LIN, G. LIU, J. YUE, X. HUANG (Chengdu, PR China). . Anticancer Res 41:5903-5912, 2021.
Targeting Production of Reactive Oxygen Species as an Anticancer Strategy. G.-K. MARIOLI-SAPSAKOU, M. KOURTI (Nicosia, Cyprus). Anticancer Res 41:5881-5902, 2021.
New Insights as to Why Progesterone Receptor Modulators, such as Mifepristone, Seem to Be More Effective in Treating Cancers that Are Devoid of the Classical Nuclear Progesterone Receptor. J.H. CHECK, D. CHECK (Camden; Mt. Laurel, NJ, USA). Anticancer Res 41:5873-5880, 2021.
Osteosarcoma Patient-derived Orthotopic Xenograft (PDOX) Models Used to Identify Novel and Effective Therapeutics: A Review. T. HIGUCHI, K. IGARASHI, N. YAMAMOTO, K. HAYASHI, H. KIMURA, S. MIWA, M. BOUVET, H. TSUCHIYA, R.M. HOFFMAN (San Diego, CA, USA; Kanazawa, Japan). Anticancer Res 41:5865-5871, 2021.
Systematic Reviews and Quality Appraisal of In Vitro Cancer Studies: Investigation of Current Practice. M. BRACHER, G.J. PILKINGTON, K. PILKINGTON (Southampton; Portsmouth, UK). Anticancer Res 41:5377-5391, 2021.
Difficulties of Breast Reconstruction – Problems That No One Likes to Face. M. FRIEDRICH, S. KRÄMER, D. FRIEDRICH, C. KRAFT, N. MAASS, C. ROGMANS (Krefeld; Kiel, Germany). Anticancer Res 41:5365-5375, 2021.
Cardio-Oncology Preclinical Models: A Comprehensive Review. W. BOULEFTOUR, B. MERY, E. ROWINSKI, C. RIVIER, E. DAGUENET, N. MAGNE (Saint Priest en Jarez; Lyon, France). Anticancer Res 41:5355-5364, 2021.
Large Animal Models of Glioma: Current Status and Future Prospects. W.H. HICKS, C.E. BIRD, M.N. PERNIK, A.S. HAIDER, A. DOBARIYA, K.G. ABDULLAH, S.G. AOUN, R.T. BENTLEY, A.A. COHEN-GADOL, R.M. BACHOO, B.E. MICKEY, J.M. PASCUAL, T.Y. EL AHMADIEH (Dallas; Houston, TX; West Lafayette; Indianapolis, IN, USA). Anticancer Res 41:5343-5353, 2021
The Role of Immune Checkpoint Inhibitors in Leptomeningeal Disease: A Systematic Review. P. PALMISCIANO, A.S. HAIDER, C.D. NWAGWU, W. WAHOOD, K. YU, C.I. ENE, B.J. O’BRIEN, S.G. AOUN, A.A. COHEN-GADOL, T.Y. EL AHMADIEH (Catania, Italy; Houston; Dallas, TX; Atlanta, GA; Davie, FL; New York, NY; Indianapolis, IN, USA). Anticancer Res 41:5333-5342, 2021.
Fascial Organisation and Lymphatic Systems Around the Pelvic Floor: A Literature Review. K. SATO, T. MIURA, Y. SAKAMOTO, H. MOROHASHI, K. HAKAMADA (Aomori; Hokkaido, Japan). Anticancer Res 41:4705-4714, 2021.
Adjuvant Radiotherapy in Patients With Pancreatic Adenocarcinoma. Is It Still Appealing in Clinical Trials? A Meta-analysis and Review of the Literature. F. PASQUALETTI, A. SAINATO, R. MORGANTI, C. LALISCIA, E. VASILE, A. GONNELLI, S. MONTRONE, G. GADDUCCI, N. GIANNINI, N. COCCIA, T. FUENTES, S. ZANOTTI, M. FALCONI, F. PAIAR (Oxford, UK; Pisa; Milan, Italy). Anticancer Res 41:4697-4704, 2021.
Treatment of Metastatic Castration-resistant Prostate Cancer: Are PARP Inhibitors Shifting the Paradigm? N. FUJIMOTO, K. HARADA, M. SHIOTA, I. TOMISAKI, A. MINATO, Y. NAGATA, R. KIMURO, M. HARADA, M. FUJISAWA (Kitakyushu; Kobe; Fukuoka, Japan). Anticancer Res 41:4687-4695, 2021.
Randomized Clinical Trials and Real World Prospective Observational Studies on Bevacizumab, PARP Inhibitors, and Immune Checkpoint Inhibitors in the First-Line Treatment of Advanced Ovarian Carcinoma: A Critical Review. A. GADDUCCI, S. COSIO (Pisa, Italy). Anticancer Res 41:4673-4685, 2021.
Common Pitfalls in the Management of Bone Metastasis of the Extremities - a Current Concept and Systematic Review of the Literature. D. DAMMERER, P. BLUM, D. KRAPPINGER, A. KEILER (Innsbruck, Austria). Anticancer Res 41:4665-4672, 2021.
Does Panoramic X-ray Induce Cytogenetic Damage to Oral Cells? A Systematic Review With Meta-analysis. D.V. DE SOUZA, M.E. SUAREZ ALPIRE, I.T. MALACARNE, G.M. DE CASTRO, M. DE BARROS VIANA, R.C.B. DA SILVA, G.N. DA SILVA, A.C. MUNIZ RENNO, D.A. RIBEIRO (Santos, SP; Ouro Preto, MG, Brazil). Anticancer Res 41:4203-4210, 2021
Down-regulated MicroRNAs in Gastric Carcinoma May Be Targets for Therapeutic Intervention and Replacement Therapy. U.H. WEIDLE, F. BIRZELE, S. AUSLAENDER, U. BRINKMANN (Penzberg, Germany; Basel, Switzerland). Anticancer Res 41:4185-4202, 2021.
Is There a Role for Sex Hormone Receptors in Head-and-neck Cancer? Links with HPV Infection and Prognosis. C.P. DE OLIVEIRA NETO, H. OLIVEIRA BRITO, R.M. GIL DA COSTA, L.M. OLIVEIRA BRITO (São Luis, Brazil; Vila Real; Porto, Portugal). Anticancer Res 41:3707-3716, 2021.
Proteolytic Enzyme Therapy in Complementary Oncology: A Systematic Review. L. GREMMLER, S. KUTSCHAN, J. DÖRFLER, J. BÜNTZEL, J. BÜNTZEL, J. HÜBNER (Jena; Göttingen; Nordhausen, Germany). Anticancer Res 41:3213-3232, 2021.
Integrated Treatment of Breast Cancer-related Lymphedema: A Descriptive Review of the State of the Art. P. MARCHICA, S. D’ARPA, S. MAGNO, C. ROSSI, L. FORCINA, V. CAPIZZI, S. OIENI, C. AMATO, D. PIAZZA, V. GEBBIA (Padua; Palermo; Rome, Italy). Anticancer Res 41:3233-3246, 2021.
Cytokine-based Cancer Immunotherapy: Challenges and Opportunities for IL-10. K.S. RALLIS, A.E. CORRIGAN, H. DADAH, A.M. GEORGE, S.M. KESHWARA, M. SIDERIS, B. SZABADOS (London; Birmingham; Liverpool, UK). Anticancer Res 41:3247-3252, 2021.
Multimodal Treatment of Primary Advanced Ovarian Cancer. M. FRIEDRICH, D. FRIEDRICH, C. KRAFT, C. ROGMANS (Krefeld; Kiel, Germany). Anticancer Res 41:3253-3260, 2021.
Targeting the Supply Lines of Cancer – A Possible Strategy for Combating the Disease? O. ABRAHAMSEN, E. BALSLEV, E. HØGDALL (Copenhagen, Denmark). Anticancer Res 41:2737-2744, 2021.
The Holocaust Is a Significant and Independent Risk Factor of Late-Onset Cancers: A Systematic Review of the Literature and Original Data on Jewish Israeli, Jewish Non-Israeli and Non-Jewish Non-Israeli Survivors. E. VIRGILIO, D. CAMILLI, G. GILI, F. MONTALI, C. SALVEMINI, A. ANNICCHIARICO, L. PAGLIAI, A. MORINI, A. ROMBOLI, R. COSTI (Parma; Fidenza; Viterbo; Pesaro; L’Aquila; Piacenza, Italy). Anticancer Res 41:2745-2757, 2021.
Diet, Probiotics and Physical Activity: The Right Allies for a Healthy Microbiota. R. DIVELLA, G. DE PALMA, A. TUFARO, G. PELAGIO, G. GADALETA-CALDAROLA, R. BRINGIOTTI, A. PARADISO (Bari; Barletta, Italy). Anticancer Res 41:2759-2772, 2021.
Impact of Topoisomerases Complex Deregulation on Head and Neck Carcinoma Genomic Instability. E. KYRODIMOS, A. CHRYSOVERGIS, N. MASTRONIKOLIS, E. TSIAMBAS, V. RAGOS, D. PESCHOS, D. SPYROPOULOY, P. PANTOS, A. NIOTIS, V. PAPANIKOLAOU (Athens; Patras; Ioannina, Greece). Anticancer Res 41:2773-2779, 2021.
Current Update on the Diagnosis, Management and Pathogenesis of Elastofibroma Dorsi. J. NISHIO, S. NAKAYAMA, K. NABESHIMA, T. YAMAMOTO (Fukuoka, Japan). Anticancer Res 41:2211-2215, 2021.
Medical Thoracoscopy, Computed Tomography-guided Biopsy, and Ultrasound-guided Biopsy for Malignant Pleural Mesothelioma: A Systematic Review. A. SHIROSHITA, M. KUROSAKI, M. TAKESHITA, Y. KATAOKA (Ichinomiya; Kamogawa; Amagasaki, Japan). Anticancer Res 41:2217-2225, 2021.
Obesity and Liver Cancer in Japan: A Comprehensive Review. H. NISHIKAWA, S. FUKUNISHI, A. ASAI, S. NISHIGUCHI, K. HIGUCHI (Takatsuki; Nishinomiya; Osaka, Japan). Anticancer Res 41:2227-2237, 2021.
New Approaches in Targeted Therapy for Medulloblastoma in Children. H. MAIER, T. DALIANIS, O.N. KOSTOPOULOU (Stockholm, Sweden). Anticancer Res 41:1715-1726, 2021.
Clinical Impact of Perioperative Oral Nutritional Treatment for Body Composition Changes in Gastrointestinal Cancer Treatment. T. AOYAMA, M. NAKAZONO, S. NAGASAWA, K. SEGAMI (Yokohama, Japan). Anticancer Res 41:1727-1732, 2021.
Pre-treatment Apparent Diffusion Coefficient Does Not Predict Therapy Response to Radiochemotherapy in Cervical Cancer: A Systematic Review and Meta-analysis. H.-J. MEYER, A. WIENKE, A. SUROV (Leipzig; Halle (Saale); Magdeburg, Germany). Anticancer Res 41:1163-1170, 2021.
Tonsillectomy as a Prevention Strategy in the Light of Increasing Incidence of Oropharyngeal Cancer – a Research of Current Literature. A.M. FRANZEN, J.P. WINDFUHR (Neuruppin; Mönchengladbach, Germany). Anticancer Res 41:1157-1161, 2021.
T-cell-based Immunotherapies for Haematological Cancers, Part B: A SWOT Analysis of Adoptive Cell Therapies. K.S. RALLIS, C.R.T. HILLYAR, M. SIDERIS, J.K. DAVIES (London, UK). Anticancer Res 41:1143-1156, 2021.
T-cell-based Immunotherapies for Haematological Cancers, Part A: A SWOT Analysis of Immune Checkpoint Inhibitors (ICIs) and Bispecific T-Cell Engagers (BiTEs). K.S. RALLIS, C.R.T. HILLYAR, M. SIDERIS, J.K. DAVIES (London, UK). Anticancer Res 41:1123-1141, 2021.
Antiangiogenic Tyrosine Kinase Inhibitors in Metastatic Colorectal Cancer: Focusing on Regorafenib. M. PAPADIMITRIOU, C.A. PAPADIMITRIOU (Athens, Greece). Anticancer Res 41:567-582, 2021.
H19 in Endocrine System Tumours. M. ROLLA, A. JAWIARCZYK-PRZYBYŁOWSKA, K. KOLAČKOV, M. BOLANOWSKI (Wroclaw, Poland). Anticancer Res 41:557-565, 2021.
PARP Inhibitors in Prostate Cancer. K. GREWAL, K. GREWAL, I.A. TABBARA (Tallahassee, FL; Fairfax, VA; Washington, DC, USA). Anticancer Res 41:551-556, 2021.
Inguinal GIST: A Systematic Literature Review of Primary and Metastatic Cases. E. VIRGILIO, A. ANNICCHIARICO, L. PAGLIAI, A. MORINI, A. ROMBOLI, F. MONTALI, R. COSTI (Parma; Fidenza; L’Aquila, Italy). Anticancer Res 41:21-25, 2021.
The Prognostic Relevance of Computed Tomography-assessed Skeletal Muscle Index and Skeletal Muscle Radiation Attenuation in Patients With Gynecological Cancer. A. GADDUCCI, S. COSIO (Pisa, Italy). Anticancer Res 41:9-20, 2021.
Chemoradiotherapy in Cancer Treatment: Rationale and Clinical Applications. K.S. RALLIS, T.H.L. YAU, M. SIDERIS (London, UK). Anticancer Res 41:1-7, 2021.
Role of Oncogenes and Tumor-suppressor Genes in Carcinogenesis: A Review. E.N. KONTOMANOLIS, A. KOUTRAS, A. SYLLAIOS, D. SCHIZAS, A. MASTORAKI, N. GARMPIS, M. DIAKOSAVVAS, K. ANGELOU, G. TSATSARIS, A. PAGKALOS, T. NTOUNIS, Z. FASOULAKIS (Alexandroupolis; Athens; Xanthi, Greece). Anticancer Res 40:6009-6015, 2020.
Role of Oncogenes and Tumor-suppressor Genes in Carcinogenesis: A Review. E.N. KONTOMANOLIS, A. KOUTRAS, A. SYLLAIOS, D. SCHIZAS, A. MASTORAKI, N. GARMPIS, M. DIAKOSAVVAS, K. ANGELOU, G. TSATSARIS, A. PAGKALOS, T. NTOUNIS, Z. FASOULAKIS (Alexandroupolis; Athens; Xanthi, Greece). Anticancer Res 40:6009-6015, 2020.
Survival After Primary Surgery Compared With Neoadjuvant Chemotherapy in Early-stage Ovarian Cancer. D. HUFFMAN, R. WEGNER, A. JALIL, T. KRIVAK, E. MILLER (Pittsburgh, PA, USA). Anticancer Res 40:6003-6008, 2020.
Estro-progestin Contraceptives and Risk of Cervical Cancer: A Debated Issue. A. GADDUCCI, S. COSIO, F. FRUZZETTI (Pisa, Italy). Anticancer Res 40:5995-6002, 2020.
Potential for Treatment of Glioblastoma: New Aspects of Superparamagnetic Iron Oxide Nanoparticles. D. MAREKOVA, K. TURNOVCOVA, T.H. SURSAL, C.D. GANDHI, P. JENDELOVA, M. JHANWAR-UNIYAL (Prague, Czech Republic; New York, NY, USA). Anticancer Res 40:5989-5994, 2020.
The Role of Zyxin in Carcinogenesis. A. PARTYNSKA, A. GOMULKIEWICZ, P. DZIEGIEL, M. PODHORSKA-OKOLOW (Wroclaw, Poland). Anticancer Res 40:5981-5988, 2020
Dickkopf-3 in Human Malignant Tumours: A Clinical Viewpoint. E.-J. LEE, Q.T.T. NGUYEN, M. LEE (Seoul, Republic of Korea). Anticancer Res 40:5969-5979, 2020.
EBV Positivity and Programmed Death-ligand 1 Expression in Diffuse Large B-cell Lymphoma: A Systematic Review. G.A. BARZYK, V. SHERIFF (Coventry; London, UK). Anticancer Res 40:5951-5968, 2020.
De-escalation of Axillary Surgery in the Neoadjuvant Chemotherapy (NACT) Setting for Breast Cancer: Is it Oncologically Safe? U. WAZIR, K. MOKBEL (London, UK; Peshawar, Pakistan). Anticancer Res 40:5351-5354, 2020
Systematic Review on the Controlling Nutritional Status (CONUT) Score in Patients Undergoing Esophagectomy for Esophageal Cancer. K. TAKAGI, S. BUETTNER, J.N.M. IJZERMANS, B.P.L. WIJNHOVEN (Rotterdam, the Netherlands; Okayama, Japan). Anticancer Res 40:5343-5349, 2020.
The Development of Next-generation PBMC Humanized Mice for Preclinical Investigation of Cancer Immunotherapeutic Agents. Y.M. MORILLON II, A. SABZEVARI, J. SCHLOM, J.W. GREINER (Bethesda, MD, USA). Anticancer Res 40:5329-5341, 2020.
Inhibitors of Fatty Acid Synthesis and Oxidation as Potential Anticancer Agents in Colorectal Cancer Treatment. P. MOZOLEWSKA, K. DUZOWSKA, A. PAKIET, A. MIKA, T. ŚLEDZIŃSKI (Gdansk, Poland). Anticancer Res 40:4843-4856, 2020.
The Future of ER+/HER2– Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors. A. STRAVODIMOU, I.A. VOUTSADAKIS (Lausanne, Switzerland; Sault Ste Marie; Sudbury, ON, Canada). Anticancer Res 40:4829-4841, 2020.
Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer: Review of the Literature and Perspectives of Clinical Research. A. GADDUCCI, STEFANIA COSIO (Pisa, Italy). Anticancer Res 40:4819-4828, 2020.
The Role of the Microbiome in Cancer and Therapy Efficacy: Focus on Lung Cancer. A. HALLEY, A. LEONETTI, A. GREGORI, M. TISEO, D.M. DENG, E. GIOVANNETTI, G.J. PETERS (Amsterdam, the Netherlands; Parma; Pisa, Italy; Gdańsk, Poland). Anticancer Res 40:4807-4818, 2020.
Current Status of Therapeutic Drug Monitoring of 5-Fluorouracil Prodrugs. Y. HASHIMOTO, Y. YOSHIDA, T. YAMADA, N. AISU, G. YOSHIMATSU, F. YOSHIMURA, S. HASEGAWA (Fukuoka, Japan). Anticancer Res 40:4655-4661, 2020.
Minimizing Fertility-sparing Treatment for Low Volume Early Stage Cervical Cancer; Is Less the (R)Evolution? C. THEOFANAKIS, D. HAIDOPOULOS, N. THOMAKOS, A. RODOLAKIS, C. FOTOPOULOU (Athens, Greece; London, UK). Anticancer Res 40:3651-3658, 2020.
FGD3 Gene as a New Prognostic Factor in Breast Cancer. T. SUSINI, I. RENDA (Florence, Italy). Anticancer Res 40:3645-3649, 2020.
Savi Scout® Radar Localisation of Non-palpable Breast Lesions: Systematic Review and Pooled Analysis of 842 Cases. I. KASEM, K. MOKBEL (London, UK). Anticancer Res 40:3633-3643, 2020.
Gene Polymorphisms and Circulating Levels of MMP-2 and MMP-9: A Review of Their Role in Breast Cancer Risk. S.G. DOFARA, S.-L. CHANG, C. DIORIO (Quebec City, QC, Canada). Anticancer Res 40:3619-3631, 2020.
Review of the Role of Radiomics in Tumour Risk Classification and Prognosis of Cancer. Y.L. WEN, M. LEECH (Dublin, Ireland; Singapore, Singapore). Anticancer Res 40:3605-3618, 2020
Fecal Occult Blood Tests in Colorectal Cancer Screening: Systematic Review and Meta-analysis of Traditional and New-generation Fecal Immunochemical Tests. J. MEKLIN, K. SYRJÄNEN, M. ESKELINEN (Kuopio; Kaarina, Finland; Barretos, Brazil). Anticancer Res 40:3591-3604, 2020.
Surgical Versus Conservative Treatment for Endometrial Cancer in Women of Reproductive Age: Incidence of Urinary Tract Symptoms. A. KOUTRAS, A. PETEINARIS, S. DAVAKIS, G. KALINTERAKIS, I. TSILIKIS, N. GARMPIS, P.-A. ZOTOS, A. CHIONIS, D. SCHIZAS, I. KARAVOKYROS, N. THOMAKOS, E. KONTOMANOLIS, A. SYLLAIOS (Athens; Patras; Larisa; Alexandroupolis, Greece). Anticancer Res 40:3065-3069, 2020.
PARP Inhibitors as Therapeutic Options for Tyrosine Kinase-dependent Leukemia: A Review. C.B. MACHADO, E.L. DA SILVA, M.O. DE MORAES FILHO, M.E. AMARAL DE MORAES, C.A. MOREIRA-NUNES (Fortaleza, Brazil). Anticancer Res 40:3055-3063, 2020.
Tumor Handling of Early-stage Cervical Cancer: A Literature Analysis of Villoglandular Adenocarcinoma of the Cervix. A. DIETL, K. AUMANN, M.W. BECKMANN (Erlangen; Freiburg, Germany). Anticancer Res 40:3049-3053, 2020.
The Role of MSCs in the Tumor Microenvironment and Tumor Progression. S.Y. AHN (Seoul, Republic of Korea). Anticancer Res 40:3039-3047, 2020.
Is Perineural Invasion a Novel Prognostic Factor Useful to Tailor Adjuvant Treatment in Patients Treated With Primary Surgery for Cervical and Vulvar Carcinoma? A. GADDUCCI, S. PISTOLESI, S. COSIO, A.G. NACCARATO (Pisa, Italy). Anticancer Res 40:3031-3037, 2020.
Second-line Treatment in Advanced Biliary Tract Cancer: Today and Tomorrow. A. RIZZO, A.D. RICCI, N. TOBER, M.C. NIGRO, M. MOSCA, A. PALLONI, F. ABBATI, G. FREGA, S. DE LORENZO, S. TAVOLARI, G. BRANDI (Bologna, Italy). Anticancer Res 40:3013-3030, 2020.
ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives. M. MASSIMINO, S. STELLA, E. TIRRÒ, M.S. PENNISI, S.R. VITALE, A. PUMA, C. ROMANO, S. DI GREGORIO, C. TOMARCHIO, F. DI RAIMONDO, L. MANZELLA (Catania, Italy). Anticancer Res 40:2457-2465, 2020.
The Licensing Factor Cdt1 Links Cell Cycle Progression to the DNA Damage Response. A. KANELLOU, N.N. GIAKOUMAKIS, A. PANAGOPOULOS, S.C. TSANIRAS, Z. LYGEROU (Patras, Greece). Anticancer Res 40:2449-2456, 2020.
Urinary Tract Large Cell Neuroendocrine Carcinoma: Diagnostic, Prognostic and Therapeutic Issues. F. SANGUEDOLCE, B. CALÒ, M. CHIRICO, S. TORTORELLA, G. CARRIERI, L. CORMIO (Foggia, Italy). Anticancer Res 40:2439-2447, 2020.
Endometriosis-associated Extraovarian Malignancies: A Challenging Question for the Clinician and the Pathologist. A. GADDUCCI, G.F. ZANNONI (Pisa; Rome, Italy). Anticancer Res 40:2429-2438, 2020.
A Review of Stereotactic Body Radiation Therapy in the Management of Oligometastatic Prostate Cancer. B. ZHANG, M. LEECH (Dublin, Ireland; Singapore, Singapore). Anticancer Res 40:2419-2428, 2020.
Skeletal Muscle Mass Change During Chemotherapy: A Systematic Review and Meta-analysis. M.K. JANG, C. PARK, S. HONG, H. LI, E. RHEE, A.Z. DOORENBOS (Chicago, IL, USA). Anticancer Res 40:2409-2418, 2020.
New Frontiers in Therapy of Peripheral Nerve Sheath Tumors in Patients With Neurofibromatosis Type 1: Latest Evidence and Clinical Implications. A. MARJANSKA, P. GALAZKA, M. WYSOCKI, J. STYCZYNSKI (Bydgoszcz, Poland). Anticancer Res 40:1817-1831, 2020.
Evolving Role of Magseed in Wireless Localization of Breast Lesions: Systematic Review and Pooled Analysis of 1,559 Procedures. R. GERA, S. TAYEH, S. AL-REEFY, K. MOKBEL (London, UK; Manama, Bahrain). Anticancer Res 40:1809-1815, 2020.
Association Between BMI and DNA Methylation in Blood or Normal Adult Breast Tissue: A Systematic Review. D. DRAGIC, K. ENNOUR-IDRISSI, A. MICHAUD, S.-L. CHANG, F. DUROCHER, C. DIORIO (Quebec City, QC, Canada). Anticancer Res 40:1797-1808, 2020.
Pathogenesis and Treatment of Pancreatic Cancer Related Pain. I. LOHSE, S.P. BROTHERS (Miami, FL, USA). Anticancer Res 40:1789-1796, 2020.
Recurrent Uterine Smooth-Muscle Tumors of Uncertain Malignant Potential (STUMP): State of The Art. A. RIZZO, A.D. RICCI, M. SAPONARA, A. DE LEO, A.M. PERRONE, P. DE IACO, M.A. PANTALEO, M. NANNINI (Bologna, Italy). Anticancer Res 40:1229-1238, 2020.
Immune-related Adverse Effects and Outcome of Patients With Cancer Treated With Immune Checkpoint Inhibitors. O. FIALA, O. SOREJS, J. SUSTR, R. KUCERA, O. TOPOLCAN, J. FINEK (Pilsen, Czech Republic). Anticancer Res 40:1219-1227, 2020.
Systematic Review on Infusion Reactions to and Infusion Rate of Monoclonal Antibodies Used in Cancer Treatment. M.D. ROMBOUTS, E.L. SWART, A.J.M. VAN DEN EERTWEGH, M. CRUL (Amsterdam, the Netherlands). Anticancer Res 40:1201-1218, 2020.
The Mystery of Chemotherapy Brain: Kynurenines, Tubulin and Biophoton Release. P.P. SORDILLO, L.A. SORDILLO (New York, NY, USA). Anticancer Res 40:1189-1200, 2020
Primary Angiosarcoma of the Kidney: Literature Review of a Rare Nosologic Entity. A. MASTORAKI, D. SCHIZAS, T. GIANNAKAS, P.P. PAPADOPOULOS, L. NAAR, C. VERGADIS, I. ANASTASIOU, P. VASSILIU, E. PIKOULIS, T. LIAKAKOS (Athens, Greece). Anticancer Res 40:625-633, 2020.
Impact of Anastomotic Leakage on Overall and Disease-free Survival After Surgery for Gastric Carcinoma: A Systematic Review. P. AURELLO, M. CINQUEPALMI, N. PETRUCCIANI, G. MOSCHETTA, L. ANTOLINO, F. FELLI, D. GIULITTI, G. NIGRI, F. D’ANGELO, S. VALABREGA, G. RAMACCIATO (Rome, Italy). Anticancer Res 40:619-624, 2020.
C-myc Contributes to Malignancy of Lung Cancer: A Potential Anticancer Drug Target. P. CHANVORACHOTE, N. SRIRATANASAK, N. NONPANYA (Bangkok, Thailand). Anticancer Res 40:609-618, 2020.
Specific Toxicity of Maintenance Olaparib Versus Placebo in Advanced Malignancies: A Systematic Review and Meta-analysis. A.D. RICCI, A. RIZZO, M. NOVELLI, S. TAVOLARI, A. PALLONI, N. TOBER, F. ABBATI, V. MOLLICA, S. DE LORENZO, D. TURCHETTI, M. DI MARCO, G. BRANDI (Bologna, Italy). Anticancer Res 40:597-608, 2020
Association of Vitamin D Receptor Gene Polymorphisms With Melanoma Risk: A Meta-analysis and Systematic Review. M. BIRKE, J. SCHÖPE, S. WAGENPFEIL, T. VOGT, J. REICHRATH (Homburg, Germany). Anticancer Res 40:583-595, 2020.
Colorectal Cancer Screening With Traditional and New-generation Fecal Immunochemical Tests: A Critical Review of Fecal Occult Blood Tests. J. MEKLIN, K. SYRJÄNEN, M. ESKELINEN (Kuopio; Kaarina, Finland; Barretos, Brazil). Anticancer Res 40:575-581, 2020.
Current Treatment of Colorectal Liver Metastasis as a Chronic Disease. N.M. DÖRR, M. BARTELS, M.H. MORGUL (Leipzig; Münster, Germany). Anticancer Res 40:1-7, 2020.
Establishment of Drug-resistant Cell Lines as a Model in Experimental Oncology: A Review. M.V. SALES AMARAL, A.J. DE SOUSA PORTILHO, E.L. DA SILVA, L. DE OLIVEIRA SALES, J.H. DA SILVA MAUÉS, M.E. AMARAL DE MORAES, C.A. MOREIRA-NUNES (Fortaleza; Belém, Brazil). Anticancer Res 39:6443-6455, 2019.
Microsatellite Instability and Survival in Stage II Colorectal Cancer: A Systematic Review and Meta-analysis. F. PETRELLI, M. GHIDINI, M. CABIDDU, E. PEZZICA, D. CORTI, L. TURATI, A. COSTANZO, A. VARRICCHIO, A. GHIDINI, S. BARNI, G. TOMASELLO (Treviglio; Milan, Italy). Anticancer Res 39:6431-6441, 2019.
Frequency of Polyps and Adenocarcinoma in Colon Interposition After Esophagectomy in Adulthood – A Systematic Review. M. SOHN, A. AGHA, S. TRUM, C. MOSER, F. GUNDLING, A. HOCHREIN, J. PRATSCHKE, F. AIGNER, P. RITSCHL (Munich; Berlin, Germany). Anticancer Res 39:6419-6430, 2019.
Minimally Invasive Surgery in Pediatric Oncology: Proposal of Guidelines. P. GALAZKA, K. CZYZEWSKI, A. MARJANSKA, I. DANILUK-MATRAS, J. STYCZYNSKI (Bydgoszcz, Poland). Anticancer Res 39:5853-5859, 2019.
Triple-Negative Breast Cancer: The Progress of Targeted Therapies and Future Tendencies. C. DAMASKOS, A. GARMPI, K. NIKOLETTOS, M. VAVOURAKIS, E. DIAMANTIS, A. PATSOURAS, P. FARMAKI, A. NONNI, D. DIMITROULIS, D. MANTAS, E.A. ANTONIOU, N. NIKOLETTOS, K. KONTZOGLOU, N. GARMPIS (Athens; Alexandroupolis, Greece). Anticancer Res 39:5285-5296, 2019.
Therapeutic Application of Diverse Marine-derived Natural Products in Cancer Therapy. C.W. YUN, H.J. KIM, S.H. LEE (Seoul; Cheonan, Republic of Korea). Anticancer Res 39:5261-5284, 2019.
Chemoprevention of Prostate Cancer by Natural Agents: Evidence from Molecular and Epidemiological Studies. KEFAH MOKBEL, U. WAZIR, KINAN MOKBEL (London, UK). Anticancer Res 39:5231-5259, 2019.
Vitamin D and Cardiovascular Disease: An Update. A. ZITTERMANN, S. PILZ (Bad Oeynhausen, Germany; Graz, Austria). Anticancer Res 39:4627-4635, 2019.
Arterial Thrombosis in Cancer: Spotlight on the Neglected Vessels. M.L. CANALE, I. BISCEGLIA, C. LESTUZZI, I. PARRINI (Lido di Camaiore; Rome; Aviano; Turin, Italy). Anticancer Res 39:4619-4625, 2019.
The Role of Particle Therapy in the Risk of Radio-induced Second Tumors: A Review of Literature. A. FACOETTI, A. BARCELLINI, F. VALVO, M. PULLIA (Pavia, Italy). Anticancer Res 39:4613-4617, 2019.
Sarcopenia as Prognostic Factor in Lung Cancer Patients: A Systematic Review and Meta-analysis. J. BUENTZEL, J. HEINZ, A. BLECKMANN, C. BAUER, C. RÖVER, H. BOHNENBERGER, S. SAHA, M. HINTERTHANER, H. BARAKI, I. KUTSCHKA, A. EMMERT (Göttingen; Münster; Fulda, Germany). Anticancer Res 39:4603-4612, 2019.
Renin–Angiotensin Inhibition in Combating Malignancy: A Review. T. ROSENTHAL, I. GAVRAS (Tel-Aviv, Israel; Boston, MA, USA). Anticancer Res 39:4597-4602, 2019.
Treatment Algorithm for Patients With Gastric Adenocarcinoma: An Austrian Consensus on Systemic Therapy. E. WÖLL, W. EISTERER, A. GERGER, T. KÜHR, G.W. PRAGER, H. RUMPOLD, H. ULRICH-PUR, U. VOGL, T. WINDER, L. WEISS, R. GREIL (Zams; Klagenfurt; Graz; Wels; Vienna; Feldkirch; Salzburg, Austria). Anticancer Res 39:4589-4596, 2019.
Advances in Intraluminal Exfoliative Cytology of Gastric Cancer: Oncologic Implication of the Sixth Metastatic Route (Metastasis VI). E. VIRGILIO, E. GIARNIERI, M. MONTAGNINI, S. VILLANI, M.R. GIOVAGNOLI, P. MERCANTINI, G. BALDUCCI, M. CAVALLINI (Rome, Italy). Anticancer Res 39:4019-4022, 2019.
The Use of Single-Cell Comet Assay on Oral Cells: A Critical Review. A.C.F. SOUZA, V.Q. YUJRA, L.P. PISANI, M. DE BARROS VIANA, G.M. DE CASTRO, D.A. RIBEIRO (Santos, SP, Brazil). Anticancer Res 39:4011-4017, 2019.
Novel Therapeutic Approaches for Epstein-Barr Virus Associated Gastric Cancer. B.W. KANG, D.W. BAEK, H. KANG, J.H. BAEK, J.G. KIM (Daegu, Republic of Korea). Anticancer Res 39:4003-4010, 2019
Unilaterally Enlarged Mandibular Foramina and Canal Associated With Hyperplastic Lymphatic Tissue of Inferior Alveolar Nerve: Case Report and Short Literature Survey. R.E. FRIEDRICH, J. MATSCHKE, W. WILCZAK (Hamburg, Germany). Anticancer Res 39:3991-4002, 2019.
Circulating Protein Biomarkers to Differentiate Uterine Sarcomas from Leiomyomas. N. GLORIE, T. BAERT, T. VAN DEN BOSCH, A. COOSEMANS (Leuven; Tienen, Belgium; Essen, Germany). Anticancer Res 39:3981-3989, 2019.
In Vitro Anticancer Activities of B6 Vitamers: A Mini-review. T. MATSUO, Y. SADZUKA (Iwate, Japan). Anticancer Res 39:3429-3432, 2019.
Pleiotropic Chemotherapy to Abrogate Glioblastoma Multiforme Migration/Invasion. L. HELSON, M. MAJEED (East Windsor, NJ, USA). Anticancer Res 39:3423-3427, 2019.
Is There Any Room for Pharmacometrics With Immuno-Oncology Drugs? Input from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology. A. RODALLEC, R. FANCIULLINO, S. BENZEKRY, J. CICCOLINI (Marseille; Bordeaux, France; Brussels, Belgium). Anticancer Res 39:3419-3422, 2019.
A Brief Guide to Performing Pharmacological Studies In Vitro: Reflections from the EORTC-PAMM Course “Preclinical and Early-phase Clinical Pharmacology”. M. CAPULA, C. CORNO, B. EL HASSOUNI, G. LI PETRI, S. ARANĐELOVIĆ (Pisa; Milan; Palermo, Italy; Amsterdam, the Netherlands; Belgrade, Serbia). Anticancer Res 39:3413-3418, 2019.
State of the Art for Metastatic Pancreatic Cancer Treatment: Where Are We Now? R. BALSANO, C. TOMMASI, I. GARAJOVA (Parma, Italy). Anticancer Res 39:3405-3412, 2019.
Extracellular Vesicles: Subcellular Organelles With the Potential to Spread Cancer Resistance. F. ENDER, N. VON BUBNOFF, F. GIESELER (Luebeck, Germany). Anticancer Res 39:3395-3404, 2019.
Acyl-Coenzyme A: Cholesterol Acyltransferase Inhibition in Cancer Treatment. J. ZABIELSKA, T. SLEDZINSKI, E. STELMANSKA (Gdansk, Poland). Anticancer Res 39:3385-3394, 2019.
Inhibitors of Protein Tyrosine Phosphatase PTP1B With Anticancer Potential. T. KOSTRZEWA, J. STYSZKO, M. GORSKA-PONIKOWSKA, T. SLEDZINSKI, A. KUBAN-JANKOWSKA (Gdansk, Poland). Anticancer Res 39:3379-3384, 2019.
Glucans as New Anticancer Agents. P. SIMA, J. RICHTER, V. VETVICKA (Prague; Ústí nad Labem, Czech Republic; Louisville, KY, USA). Anticancer Res 39:3373-3378, 2019.
Therapy Aimed to Suppress the Production of the Immunosuppressive Protein Progesterone Induced Blocking Factor (PIBF) May Provide Palliation and/or Increased Longevity for Patients With a Variety of Different Advanced Cancers – A Review. J.H. CHECK, D. CHECK (Camden; Mt. Laurel, NJ, USA). Anticancer Res 39:3365-3372, 2019.
Potential Molecular Mechanisms of the Anti-cancer Activity of Vitamin D. D. SKRAJNOWSKA, B. BOBROWSKA-KORCZAK (Warsaw, Poland). Anticancer Res 39:3353-3363, 2019.
Regulation of BS69 Expression in Cancers. Y. CHEN, Y.-H. TSAI, S.-H. TSENG (New Taipei; Taoyuan; Taipei, Taiwan, ROC). Anticancer Res 39:3347-3351, 2019.
From ‘Targeted Therapy’ to Targeted Therapy. G.J. PETERS (Amsterdam, the Netherlands). Anticancer Res 39:3341-3345, 2019.
Drug Delivery Systems for Phthalocyanines for Photodynamic Therapy. J. RAK, P. POUCKOVA, J. BENES, D. VETVICKA (Klecany; Prague, Czech Republic). Anticancer Res 39:3323-3339, 2019.
The Hippo Signaling Pathway in Pancreatic Cancer. D. ANSARI, H. OHLSSON, C. ALTHINI, M. BAUDEN, Q. ZHOU, D. HU, R. ANDERSSON (Lund, Sweden; Zhejiang; Wenzhou, PR China). Anticancer Res 39:3317-3321, 2019.
The Role of PEDF in Pancreatic Cancer. D. ANSARI, C. ALTHINI, H. OHLSSON, M. BAUDEN, R. ANDERSSON (Lund, Sweden). Anticancer Res 39:3311-3315, 2019.
To Combine or Not Combine: Drug Interactions and Tools for Their Analysis. Reflections from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology. B. EL HASSOUNI, G. MANTINI, G. LI PETRI, M. CAPULA, L. BOYD, H.N.W. WEINSTEIN, A. VALLÉS-MARTI, M.C.M. KOUWENHOVEN, E. GIOVANNETTI, B.A. WESTERMAN, G.J. PETERS (Amsterdam, the Netherlands; Pisa, Italy). Anticancer Res 39:3303-3309, 2019.
A Systematic Review and Meta-analysis of the Combination of Vinorelbine and Lapatinib in Patients With Her2-positive Metastatic Breast Cancer. A. STRAVODIMOU, I.A. VOUTSADAKIS (Lausanne, Switzerland; Sault Ste. Marie; Sudbury, ON, Canada). Anticancer Res 39:3295-3301, 2019.
Clinical Significance of Selected Chemokines in Thyroid Cancer. A. MIRONSKA, M. ŁUKASZEWICZ-ZAJAC, B. MROCZKO (Bialystok, Poland). Anticancer Res 39:2715-2720, 2019.
Clinical Impact of Perioperative Oral/Dental Care on Cancer Surgery Outcomes. T. AOYAMA, A. TAMAGAWA (Yokohama, Japan). Anticancer Res 39:2711-2714, 2019.
Metastatic Carcinomas of the Adrenal Glands: From Diagnosis to Treatment. E. SPARTALIS, I. DRIKOS, A. IOANNIDIS, D. CHRYSIKOS, D.I. ATHANASIADIS, M. SPARTALIS, D. AVGERINOS (Athens; Thessaloniki, Greece; New York, NY, USA). Anticancer Res 39:2699-2710, 2019.
The Essential Role of DCLK1 in Pathogenesis, Diagnostic Procedures and Prognostic Stratification of Colorectal Cancer. A. GZIL, Ł. SZYLBERG, D. JAWORSKI, J. DOMINIAK, I. ZARĘBSKA, D. GRZANKA (Bydgoszcz, Poland). Anticancer Res 39:2689-2697, 2019.
The Past, Present and Future of Immunotherapy for Metastatic Renal Cell Carcinoma. A.J. CHANG, L. ZHAO, Z. ZHU, K. BOULANGER, H. XIAO, M.R. WAKEFIELD, Q. BAI, Y. FANG (Des Moines, IA; Columbia, MO, USA; Hefei; Chenzhou, PR China). Anticancer Res 39:2683-2687, 2019.
11Boron Delivery Agents for Boron Proton-capture Enhanced Proton Therapy. K. HIDEGHÉTY, S. BRUNNER, A. CHEESMAN, E.R. SZABÓ, R. POLANEK, D. MARGARONE, T. TŐKÉS, K. MOGYORÓSI (Szeged, Hungary; Prague, Czech Republic). Anticancer Res 39:2265-2276, 2019.
Clinical Outcomes of Recombinant Human-soluble Thrombomodulin Treatment for Disseminated Intravascular Coagulation in Solid Tumors. S. KASHIWAGI, Y. ASANO, K. TAKAHASHI, M. SHIBUTANI, R. AMANO, S. TOMITA, K. HIRAKAWA, M. OHIRA (Osaka, Japan). Anticancer Res 39:2259-2264, 2019.
NEK2 Is an Effective Target for Cancer Therapy With Potential to Induce Regression of Multiple Human Malignancies. T. KOKURYO, Y. YOKOYAMA, J. YAMAGUCHI, N. TSUNODA, T. EBATA, M. NAGINO (Nagoya, Japan). Anticancer Res 39:2251-2258, 2019.
Clinical Impact of Sarcopenia on Gastric Cancer. K. KUWADA, S. KURODA, S. KIKUCHI, R. YOSHIDA, M. NISHIZAKI, S. KAGAWA, T. FUJIWARA (Okayama, Japan). Anticancer Res 39:2241-2249, 2019.
Breast Radiotherapy and Early Adverse Cardiac Effects. The Role of Serum Biomarkers and Strain Echocardiography. A. GKANTAIFI, C. PAPADOPOULOS, D. SPYROPOULOU, M. TOUMPOURLEKA, G. ILIADIS, D. KARDAMAKIS, M. NIKOLAOU, N. TSOUKALAS, G. KYRGIAS, M. TOLIA (Thessaloniki; Patras; Athens; Larissa, Greece). Anticancer Res 39:1667-1673, 2019.
The Emerging Role of Calcium-activated Chloride Channel Regulator 1 in Cancer. D. HU, D. ANSARI, M. BAUDEN, Q. ZHOU, R. ANDERSSON (Wenzhou, PR China; Lund, Sweden). Anticancer Res 39:1661-1666, 2019.
Recurrence Following Anastomotic Leakage After Surgery for Carcinoma of the Distal Esophagus and Gastroesophageal Junction: A Systematic Review. P. AURELLO, G. BERARDI, G. MOSCHETTA, M. CINQUEPALMI, L. ANTOLINO, G. NIGRI, F. D’ANGELO, S. VALABREGA, G. RAMACCIATO (Rome, Italy). Anticancer Res 39:1651-1660, 2019.
Health Technology Assessment of Carbon-ion Beam Radiotherapy: A Systematic Review of Clinical Effectiveness and Safety for 54 Oncological Indications in 12 Tumour Regions. G. GOETZ, M. MITIC, T. MITTERMAYR, C. WILD (Vienna; Krems, Austria). Anticancer Res 39:1635-1650, 2019.
Histone Deacetylase Inhibitors and Anaplastic Thyroid Carcinoma. E. SPARTALIS, D.I. ATHANASIADIS, D. CHRYSIKOS, M. SPARTALIS, G. BOUTZIOS, D. SCHIZAS, N. GARMPIS, C. DAMASKOS, S.A. PASCHOU, A. IOANNIDIS, G. TSOUROUFLIS, D. DIMITROULIS, N.I. NIKITEAS (Athens; Thessaloniki, Greece). Anticancer Res 39:1119-1127, 2019.
Bladder Organoids and Spheroids: Potential Tools for Normal and Diseased Tissue Modelling. I. VASYUTIN, L. ZERIHUN, C. IVAN, A. ATALA (Moscow, Russia; New York, NY; Winston-Salem, NC, USA). Anticancer Res 39:1105-1118, 2019.
GastroPanel® Biomarker Assay: The Most Comprehensive Test for Helicobacter pylori Infection and Its Clinical Sequelae. A Critical Review. K. SYRJÄNEN, M. ESKELINEN, A. PEETSALU, T. SILLAKIVI, P. SIPPONEN, M. HÄRKÖNEN, L. PALOHEIMO, M. MÄKI, T. TIUSANEN, O. SUOVANIEMI, F. DiMARIO, Z.P. FAN (Helsinki; Kuopio; Espoo, Finland; Barretos, Brazil; Tartu, Estonia; Parma, Italy; Shanghai, PR China). Anticancer Res 39:1091-1104, 2019.
Integrin as a Molecular Target for Anti-cancer Approaches in Lung Cancer. N. AKSORN, P. CHANVORACHOTE (Bangkok, Thailand). Anticancer Res 39:541-548, 2019.
The Role of KRAS in Endometrial Cancer: A Mini-Review. M. SIDERIS, E.I. EMIN, Z. ABDULLAH, J. HANRAHAN, K.M. STEFATOU, V. SEVAS, E. EMIN, T. HOLLINGWORTH, F. ODEJINMI, S. PAPAGRIGORIADIS, S. VIMPLIS, F. WILLMOTT (London, UK; Patras; Ioannina; Athens, Greece). Anticancer Res 39:533-539, 2019.
MicroRNA-based Targeted Therapeutics in Pancreatic Cancer. N. GURBUZ, B. OZPOLAT (Isparta, Turkey; Houston, TX, USA). Anticancer Res 39:529-532, 2019.
Bioactive Sphingolipids as Biomarkers Predictive of Disease Severity and Treatment Response in Cancer: Current Status and Translational Challenges. M. SEDIĆ, P. GRBČIĆ, S. KRALJEVIĆ PAVELIĆ (Rijeka, Croatia). Anticancer Res 39:41-56, 2019.
MicroRNA Expression in the Progression and Aggressiveness of Papillary Thyroid Carcinoma. A. ZEMBSKA, A. JAWIARCZYK-PRZYBYŁOWSKA, B. WOJTCZAK, M. BOLANOWSKI (Wroclaw, Poland). Anticancer Res 39:33-40, 2019.
Anticoagulant Therapy for Disseminated Intravascular Coagulation After Gastrointestinal Surgery. D. HASHIMOTO, T. OKAWA, R. MARUYAMA, F. MATSUMURA, Y. SHIBATA, H. KOHROGI (Kumamoto; Omuta, Japan). Anticancer Res 39:25-31, 2019.
An Update on the Current Role of High Resolution Anoscopy in Patients With Anal Dysplasia. A. GUDUR, D. SHANMUGANANDAMURTHY, Z. SZEP, J.L. POGGIO (Philadelphia, PA, USA). Anticancer Res 39:17-23, 2019.
Evolution of Cancer Progression in the Context of Darwinism. L. LACINA, M. ČOMA, B. DVOŘÁNKOVÁ, O. KODET, N. MELEGOVÁ, P. GÁL, K. SMETANA JR (Prague; Vestec, Czech Republic; Košice; Bratislava, Slovak Republic). Anticancer Res 39:1-16, 2019.
Does Transdermal Testosterone Increase the Risk of Developing Breast Cancer? A Systematic Review. R. GERA, S. TAYEH, H. EL-HAGE CHEHADE, K. MOKBEL (London, UK). Anticancer Res 38:6615-6620, 2018.
Application of Artificial Intelligence-based Technology in Cancer Management: A Commentary on the Deployment of Artificial Neural Networks. G.V. SHERBET, W.L. WOO, S. DLAY (Huntington Beach, CA, USA; Newcastle upon Tyne, UK). Anticancer Res 38:6607-6613, 2018.
Targeted Therapies for Pancreatic Cancer and Hurdles Ahead. M. ASLAN, R. SHAHBAZI, K. ULUBAYRAM, B. OZPOLAT (Ankara, Turkey; Houston, TX, USA). Anticancer Res 38:6591-6606, 2018.
Collision Tumors of the Gastrointestinal Tract: A Systematic Review of the Literature. D. SCHIZAS, I. KATSAROS, A. MICHALINOS, C. DAMASKOS, N. GARMPIS, V. NTOMI, G. AGROGIANNIS, S. STERGIOPOULOS, A.K. TSAROUCHA (Athens; Alexandroupolis, Greece). Anticancer Res 38:6047-6057, 2018.
Technical Advances in Radiation Therapy for Brain Tumors. C. SCARINGI, L. AGOLLI, G. MINNITI (Rome; Pozzilli, Italy; Dresden, Germany). Anticancer Res 38:6041-6045, 2018.
Molecular Basis of Drug Resistance and Insights for New Treatment Approaches in mCRPC. S. GIACINTI, G. POTI, M. ROBERTO, S. MACRINI, M. BASSANELLI, F. DI PIETRO, A.M. ASCHELTER, A. CERIBELLI, E.M. RUGGERI, P. MARCHETTI (Viterbo; Rome; Rieti, Italy). Anticancer Res 38:6029-6039, 2018.
Spinal Ewing Sarcoma Debuting with Cord Compression: Have We Discovered the Thread of Ariadne? S. BOUSSIOS, C. HAYWARD, D. COOKE, N. ZAKYNTHINAKIS-KYRIAKOU, A.K. TSIOURIS, A.A. CHATZIANTONIOU, F.S. KANELLOS, A. KARATHANASI (Kent; Leicester, UK; Ioannina, Greece). Anticancer Res 38:5589-5597, 2018.
Surgical Endoscopic Vacuum-assisted Closure Therapy (EVAC) in Treating Anastomotic Leakages After Major Resective Surgery of Esophageal and Gastric Cancer. E. VIRGILIO, D. CECI, M. CAVALLINI (Rome, Italy). Anticancer Res 38:5581-5587, 2018.
Immune Therapeutics in the Treatment of Advanced Gastric and Esophageal Cancer. R. PARK, S. WILLIAMSON, A. KASI, A. SAEED (Seoul, Republic of Korea; Kansas City, KS, USA). Anticancer Res 38:5569-5580, 2018.
Radiation-induced Demyelination and Remyelination in the Central Nervous System: A Literature Review. L. HELSON (East Winsdor, NJ, USA). Anticancer Res 38:4999-5002, 2018.
Metastatic Spinal Cord Compression: Unraveling the Diagnostic and Therapeutic Challenges. S. BOUSSIOS, D. COOKE, C. HAYWARD, F.S. KANELLOS, A.K. TSIOURIS, A.A. CHATZIANTONIOU, N. ZAKYNTHINAKIS-KYRIAKOU, A. KARATHANASI (Kent; Leicester, UK; Ioannina, Greece). Anticancer Res 38:4987-4998, 2018.
Whole Lung Irradiation in Patients with Osteosarcoma and Ewing Sarcoma. L. RONCHI, M. BUWENGE, A. CORTESI, I. AMMENDOLIA, R. FRAKULLI, M.E. ABATE, A. ARCELLI, C.M. DONATI, G. MACCHIA, A.G. MORGANTI, S. CAMMELLI (Bologna; Meldola; Campobasso, Italy). Anticancer Res 38:4977-4986, 2018.
Directed Therapies in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer. R.L. MILLETT, J.M. ELKON, I.A. TABBARA (Washington, DC, USA). Anticancer Res 38:4969-4976, 2018.
Relationship Between Metabolic Disorders and Breast Cancer Incidence and Outcomes. Is There a Preventive and Therapeutic Role for Berberine? M. CAZZANIGA, B. BONANNI (Milan, Italy). Anticancer Res 38:4393-4402, 2018.
Contribution of Computed Tomographic Angiography to Pretreatment Planning of Radio-embolization of Liver Tumors. H. MIRKA, P. DURAS, J. BAXA, E. KORCAKOVA, J. FERDA (Pilsen, Czech Republic). Anticancer Res 38:3825-3829, 2018.
The Role of Histone Deacetylase Inhibitors in Uveal Melanoma: Current Evidence. M.M. MOSCHOS, M. DETTORAKI, S. ANDROUDI, D. KALOGEROPOULOS, A. LAVARIS, N. GARMPIS, C. DAMASKOS, A. GARMPI, M. TSATSOS (Athens; Larissa; Ioannina, Greece; Birmingham, UK). Anticancer Res 38:3817-3824, 2018.
Severe Defects in the Macrophage Barrier to Gut Microflora in Inflammatory Bowel Disease and Colon Cancer. C.A. RUBIO, P.T. SCHMIDT (Stockholm, Sweden). Anticancer Res 38:3811-3815, 2018.
Lung Cancer Stem Cells and Cancer Stem Cell-targeting Natural Compounds. A. MAIUTHED, W. CHANTARAWONG, P. CHANVORACHOTE (Bangkok, Thailand). Anticancer Res 38:3797-3809, 2018.
Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC. M. BASSANELLI, S. SIOLETIC, M. MARTINI, S. GIACINTI, A. VITERBO, A. STADDON, F. LIBERATI, A. CERIBELLI (Rieti; Rome; Grosseto, Italy; Dublin, Ireland). Anticancer Res 38:3789-3796, 2018.
The Colorful Palette of Neuroendocrine Neoplasms in the Genitourinary Tract. B. PÓSFAI, L. KUTHI, L. VARGA, I. LACZÓ, J. RÉVÉSZ, R. KRÁNICZ, A. MARÁZ (Szeged; Gyula; Miskolc, Hungary). Anticancer Res 38:3243-3254, 2018.
Multimodal Anti-tumor Approaches Combined with Ιmmunotherapy to Overcome Tumor Resistance in Esophageal and Gastric Cancer. L. BOLM, L. KÄSMANN, A. PAYSEN, C. KARAPETIS, D. RADES, U.F. WELLNER, T. KECK, D.I. WATSON, R. HUMMEL, D.J. HUSSEY (Luebeck, Germany; Bedford Park, Australia). Anticancer Res 38:3231-3242, 2018.
Potentially Malignant Oral Disorders and Cancer Transformation. D. GANESH, P. SREENIVASAN, J. ÖHMAN, M. WALLSTRÖM, P.H. BRAZ-SILVA, D. GIGLIO, G. KJELLER, B. HASSÉUS (Gothenburg, Sweden; Kerala, India; Sao Paulo, Brazil). Anticancer Res 38:3223-3230, 2018.
Dietary Patterns and Breast Cancer Risk: A Systematic Review. A. DANDAMUDI, J. TOMMIE, L. NOMMSEN-RIVERS, S. COUCH (Cincinnati, OH, USA). Anticancer Res 38:3209-3222, 2018.
Molecular Mechanisms of Breast Cancer Metastasis and Potential Anti-metastatic Compounds. S. TUNGSUKRUTHAI, N. PETPIROON, P. CHANVORACHOTE (Bangkok, Thailand). Anticancer Res 38:2607-2618, 2018.
Sinusoidal Obstruction Syndrome (Veno-occlusive Disease) Following Hematopoietic Stem Cell Transplant: Insights and Therapeutic Advances. S. NASSEREDDINE, S. ALSUBAIT, I. TABBARA (Washington, DC; Danbuty, CT, USA). Anticancer Res 38:2597-2606, 2018.
Laparoscopic Intragastric Surgery for Treating Early Gastric Cancer. E. VIRGILIO, G. BALDUCCI, P. MERCANTINI, E. GIARNIERI, M.R. GIOVAGNOLI, M. MONTAGNINI, A. PROIETTI, R. D’URSO, M. CAVALLINI (Rome, Italy). Anticancer Res 38:1911-1916, 2018.
Clinicopathological and Molecular Factors, Risk Factors, Treatment Outcomes and Risk of Recurrence in Mesenteric and Retroperitoneal Extragastrointestinal Stromal Tumors. K.G. APOSTOLOU, D. SCHIZAS, E. VAVOURAKI, A. MICHALINOS, D.I. TSILIMIGRAS, N. GARMPIS, C. DAMASKOS, A. PAPALAMPROS, T. LIAKAKOS (Athens, Greece). Anticancer Res 38:1903-1909, 2018.
Aspirin in the Management of Patients with Prostate Cancer Undergoing Radiotherapy: Friend or Foe? B. MASCAN, L. MARIGNOL (Dublin, Ireland). Anticancer Res 38:1897-1902, 2018.
Radiotherapy May Offer a Recurrence and Survival Benefit in Rectal Cancers Treated Surgically with Transanal Endoscopic Microsurgery: A Systematic Review and Meta-analysis. M. SIDERIS, A.N. DONALDSON, J. HANRAHAN, M. GRUNWALD, S. PAPAGRIGORIADIS (London, UK; New York, NY, USA; Athens, Greece). Anticancer Res 38:1879-1895, 2018.
Molecular Sequence of Events and Signaling Pathways in Cerebral Metastases. J.B. COOPER, J.S. RONECKER, M.E. TOBIAS, A.L. MOHAN, V. HILLARD, R. MURALI, C.D. GANDHI, M.H. SCHMIDT, M. JHANWAR-UNIYAL (Valhalla, NY, USA). Anticancer Res 38:1859-1877, 2018.
Visualizing the Tumor Microenvironment by Color-coded Imaging in Orthotopic Mouse Models of Cancer. A. SUETSUGU, M. SHIMIZU, S. SAJI, H. MORIWAKI, R.M. HOFFMAN (Gifu, Japan; San Diego, CA, USA). Anticancer Res 38:1847-1857, 2018.
Update on Surgical Management of Small Bowel Neuroendocrine Tumors. D. MORIS, I. NTANASIS-STATHOPOULOS, D.I. TSILIMIGRAS, S. VAGIOS, A. KARAMITROS, G. KARAOLANIS, J. GRINIATSOS, A. PAPALAMPROS, I. PAPACONSTANTINOU, G.K. GLANTZOUNIS, E. SPARTALIS, D.G. BLAZER 3rd, E. FELEKOURAS (Durham, NC, USA; Athens; Ioannina, Greece). Anticancer Res 38:1267-1278, 2018.
Is Adjuvant Endocrine Therapy Indicated for DCIS Patients After Complete Surgical Excision? H. EL HAGE CHEHADE, K. MOKBEL (London, UK). Anticancer Res 38:1263-1266, 2018.
Gastric Cancer Cells in Peritoneal Lavage Fluid: A Systematic Review Comparing Cytological with Molecular Detection for Diagnosis of Peritoneal Metastases and Prediction of Peritoneal Recurrences. E. VIRGILIO, E. GIARNIERI, M.R. GIOVAGNOLI, M. MONTAGNINI, A. PROIETTI, R. D’URSO, P. MERCANTINI, S. VALABREGA, G. BALDUCCI, M. CAVALLINI (Rome, Italy). Anticancer Res 38:1255-1262, 2018.
Radiation Therapy for Angiosarcoma of the Scalp: Total Scalp Irradiation and Local Irradiation. M. HATA (Yokohama, Japan). Anticancer Res 38:1247-1254, 2018.
Centrosomal Abnormalities in Pancreatic Cancer: Molecular Mechanisms and Clinical Implications. D. ANSARI, C. DEL PINO BELLIDO, M. BAUDEN, R. ANDERSSON (Lund, Sweden). Anticancer Res 38:1241-1246, 2018.
Stereotactic Body Radiation Therapy for Patients with Early-stage Prostate Cancer. H. LINNEY, S. BARRETT (Dublin, Ireland). Anticancer Res 38:1231-1240, 2018.
Postoperative Hypofractionated Radiation Therapy in Prostate Carcinoma: A Systematic Review. G. SIEPE, M. BUWENGE, N.P. NGUYEN, G. MACCHIA, F. DEODATO, S. CILLA, G.C. MATTIUCCI, I. CAPOCACCIA, S. CAMMELLI, A. GUIDO, A. ARCELLI, M. NTRETA, S. GUERRI, A.G. MORGANTI (Bologna; Campobasso; Rome, Italy; Washington, DC, USA). Anticancer Res 38:1221-1230, 2018.
Dual Role of Mitophagy in Cancer Drug Resistance. C. YAN, T.-S. LI (Sakamoto, Japan). Anticancer Res 38:617-622, 2018.
Gastric Juice MicroRNAs as Potential Biomarkers for Screening Gastric Cancer: A Systematic Review. E. VIRGILIO, E. GIARNIERI, M.R. GIOVAGNOLI, M. MONTAGNINI, A. PROIETTI, R. D’URSO, P. MERCANTINI, G. BALDUCCI, M. CAVALLINI (Rome, Italy). Anticancer Res 38:613-616, 2018.
Neuroendocrine Neoplasms of the Appendix: A Review of the Literature. D. MORIS, D.I. TSILIMIGRAS, S. VAGIOS, I. NTANASIS-STATHOPOULOS, G.-S. KARACHALIOU, A. PAPALAMPROS, A. ALEXANDROU, D.G. BLAZER 3RD, E. FELEKOURAS (Durham, NC, USA; Athens, Greece). Anticancer Res 38:601-612, 2018.
Stereotactic Body Radiation Therapy for Liver Tumors: Current Status and Perspectives. H. DOI, N. BEPPU, K. KITAJIMA, K. KURIBAYASHI (Nishinomiya; Osaka-Sayama, Japan). Anticancer Res 38:591-600, 2018.
Our ACE in the HOLE: Justifying the Use of Angiotensin-converting Enzyme Inhibitors as Adjuvants to Standard Chemotherapy. D.P. RADIN, A. KREBS, A. MAQSUDLU, P. PATEL (Stony Brook; New York, NY; Boston, MA, USA). Anticancer Res 38: 45-49, 2018.
Histone Deacetylase Inhibitors as a Novel Targeted Therapy Against Non-small Cell Lung Cancer: Where Are We Now and What Should We Expect? C. DAMASKOS, I. TOMOS, N. GARMPIS, A. KARAKATSANI, D. DIMITROULIS, A. GARMPI, E. SPARTALIS, C.F. KAMPOLIS, E. TSAGKARI, A.A. LOUKERI, G.-A. MARGONIS, M. SPARTALIS, N. ANDREATOS, D. SCHIZAS, S. KOKKINELI, E.A. ANTONIOU, A. NONNI, G. TSOUROUFLIS, K. MARKATOS, K. KONTZOGLOU, A. KOSTAKIS, P. TOMOS (Athens, Greece; Baltimore, ML, USA). Anticancer Res 38: 37-43, 2018.
Managing Focal Nodular Hyperplasia of the Liver: Surgery or Minimally-invasive Approaches? A Review of the Preferable Treatment Options. E. VIRGILIO, M. CAVALLINI (Rome, Italy). Anticancer Res 38: 33-36, 2018.
Should Adjuvant Radiation Therapy Be Systematically Proposed for Male Breast Cancer? A Systematic Review. P. JARDEL, S. VIGNOT, B. CUTULI, A. CREISSON, S. VASS, E. BARRANGER, J. THARIAT (Saguenay, QC, Canada; Le Coudray; Reims; Nice; Caen, France). Anticancer Res 38: 23-31, 2018.
Regimens of Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis from Colorectal Cancer. K. MURONO, K. KAWAI, K. HATA, S. EMOTO, M. KANEKO, K. SASAKI, T. NISHIKAWA, K. OTANI, T. TANAKA, H. NOZAWA (Tokyo, Japan). Anticancer Res 38: 15-22, 2018.
The Role of Prophylactic Cranial Irradiation for Non-small Cell Lung Cancer. C. PRECIVAL, M. LANDY, C. POOLE, L. MULLANEY (Dublin, Ireland). Anticancer Res 38: 7-14, 2018.
Cancer Progenitor Cells: The Result of An Epigenetic Event? K. LAPINSKA, G. FARIA, S. MCGONAGLE, K.M. MACUMBER, S. HEERBOTH, S. SARKAR (North Haven, CT; Wellesley; Quincy; Boston, MA; Nashville, TN, USA). Anticancer Res 38: 1-6, 2018.
Microsatellite Instability as a Prognostic Factor in Stage II Colon Cancer Patients, a Meta-Analysis of Published Literature. I. GKEKAS, J. NOVOTNY, L. PECEN, K. STRIGÅRD, R. PALMQVIST, U. GUNNARSSON (Umea; Lulea, Sweden; Prague, Czech Republic). Anticancer Res 37: 6563-6574, 2017.
The “Yin and Yang” of Platelet-rich Plasma in Breast Reconstruction After Mastectomy or Lumpectomy for Breast Cancer. E. SPARTALIS, D.I. TSILIMIGRAS, P. CHARALAMPOUDIS, G.-S. KARACHALIOU, D. MORIS, A. ATHANASIOU, M. SPARTALIS, V. BOLKAS, D. DIMITROULIS, N. NIKITEAS (Athens, Greece; London; Birmingham, UK; Columbus, OH, USA). Anticancer Res 37: 6557-6562, 2017.
Risk Factors for Cytomegalovirus Infection After Allogeneic Hematopoietic Cell Transplantation in Malignancies: Proposal for Classification. M. DZIEDZIC, I. SADOWSKA-KRAWCZENKO, J. STYCZYNSKI (Bydgoszcz, Poland). Anticancer Res 37: 6551-6556, 2017.
Clinical, Histopathological and Cytogenetic Prognosticators in Uveal Melanoma – A Comprehensive Review. T. BERUS, A. HALON, A. MARKIEWICZ, J. ORLOWSKA-HEITZMAN, B. ROMANOWSKA-DIXON, P. DONIZY (Wroclaw; Krakow, Poland). Anticancer Res 37: 6541-6549, 2017
The Role of the Androgen Receptor Signaling in Breast Malignancies. P.F. CHRISTOPOULOS, N.I. VLACHOGIANNIS, C.T. VOGKOU, M. KOUTSILIERIS (Athens, Greece). Anticancer Res 37: 6533-6540, 2017.
18F-Fdg-PET-guided Planning and Re-Planning (Adaptive) Radiotherapy in Head and Neck Cancer: Current State of Art. E. FARINA, M. FERIOLI, P. CASTELLUCCI, A. FARINA, G. ZANIRATO RAMBALDI, S. CILLA, S. CAMMELLI, S. FANTI, A.G. MORGANTI (Bologna; Campobasso, Italy). Anticancer Res 37: 6523-6532, 2017.
MiRNA-210: A Current Overview. A. BAVELLONI, G. RAMAZZOTTI, A. POLI, M. PIAZZI, E. FOCACCIA, W. BLALOCK, I. FAENZA (Bologna; Milan, Italy). Anticancer Res 37: 6511-6521, 2017.
Optimising Selenium for Modulation of Cancer Treatments. S.O. EVANS, P.F. KHAIRUDDIN, M.B. JAMESON (Hamilton, New Zealand). Anticancer Res 37: 6497-6509, 2017.
Lipofilling Outcomes Mimicking Breast Cancer Recurrence: Case Report and Update of the Literature. S. GIGLI, M.I. AMABILE, F. DI PASTENA, A. DE LUCA, C. GULIA, L. MANGANARO, M. MONTI, L. BALLESIO (Rome, Italy). Anticancer Res 37: 5395-5398, 2017.
The Role of Toll Like Receptors (TLRs) in Oral Carcinogenesis. L. PELLEGRINI PISANI, D. ESTADELLA, D.A. RIBEIRO (Santos, SP, Brazil). Anticancer Res 37: 5389-5394, 2017.
Do Dental X-Rays Induce Genotoxicity and Cytotoxicity in Oral Mucosa Cells? A Critical Review. F. ANGELIERI, V. QUISPE YUJRA, C.T.F. OSHIMA, D.A. RIBEIRO (Sao Paulo, Brazil). Anticancer Res 37: 5383-5388, 2017.
Mitochondrial Dysfunction and Redox Imbalance as a Diagnostic Marker of “Free Radical Diseases”. E. GEORGIEVA, D. IVANOVA, Z. ZHELEV, R. BAKALOVA, M. GULUBOVA, I. AOKI (Stara Zagora; Sofia, Bulgaria; Chiba, Japan). Anticancer Res 37: 5373-5381, 2017.
Clinical Potential of Statins in Prostate Cancer Radiation Therapy. J. HUTCHINSON, L. MARIGNOL (Dublin, Ireland). Anticancer Res 37: 5363-5372, 2017.
Targeting Histone Deacetylases in Malignant Melanoma: A Future Therapeutic Agent or Just Great Expectations? N. GARMPIS, C. DAMASKOS, A. GARMPI, D. DIMITROULIS, E. SPARTALIS, G.-A. MARGONIS, D. SCHIZAS, I. DESKOU, C. DOULA, E. MAGKOUTI, N. ANDREATOS, E.A. ANTONIOU, A. NONNI, K. KONTZOGLOU, D. MANTAS (Athens, Greece; Baltimore, MD, USA; Nicosia, Cyprus). Anticancer Res 37: 5355-5362, 2017.
Topical Management of Acute Radiation Dermatitis in Breast Cancer Patients: A Systematic Review and Meta-Analysis. F. HARUNA, A. LIPSETT, L. MARIGNOL (Dublin, Ireland). Anticancer Res 37: 5343-5353, 2017.
Adjuvant Endocrine Therapy for Hormone-positive Breast Cancer, Focusing on Ovarian Suppression and Extended Treatment: An Update. D. GLASSMAN, S. HIGNETT, S. REHMAN, R. LINFORTH, M. SALHAB (Bradford, UK). Anticancer Res 37: 5329-5341, 2017.
Human Papillomavirus and Potentially Relevant Biomarkers in Tonsillar and Base of Tongue Squamous Cell Carcinoma. A. NÄSMAN, C. BERSANI, D. LINDQUIST, J. DU, T. RAMQVIST, T. DALIANIS (Stockholm; Umeå, Sweden). Anticancer Res 37: 5319-5328, 2017.
Anticancer Activity of Artemisinin and its Derivatives. S. SLEZAKOVA, J. RUDA-KUCEROVA (Brno, Czech Republic). Anticancer Res 37:5995-6003, 2017.
Possible Biological and Clinical Applications of Phenothiazines. B. VARGA, Á. CSONKA, A. CSONKA, J. MOLNÁR, L. AMARAL, G. SPENGLER (Szeged, Hungary; Lisbon, Portugal). Anticancer Res 37:5983-5993, 2017.
Update on Nanotechnology-based Drug Delivery Systems in Cancer Treatment. B.N. HO, C.M. PFEFFER, A.T.K. SINGH (Kenosha, WI, USA). Anticancer Res 37:5975-5981, 2017.
Perioperative Administration of Traditional Japanese Herbal Medicine Daikenchuto Relieves Postoperative Ileus in Patients Undergoing Surgery for Gastrointestinal Cancer: A Systematic Review and Meta-analysis. M. ISHIZUKA, N. SHIBUYA, H. NAGATA, K. TAKAGI, Y. IWASAKI, H. HACHIYA, T. AOKI, K. KUBOTA (Tochigi, Japan). Anticancer Res 37:5967-5974, 2017.
Immune Checkpoint Inhibitors in Gynecological Cancers: Update of Literature and Perspectives of Clinical Research. A. GADDUCCI, M.E. GUERRIERI (Pisa, Italy). Anticancer Res 37:5955-5965, 2017.
New Drug Combination Strategies in Melanoma: Current Status and Future Directions. A. NAJEM, M. KRAYEM, A. PERDRIX, J. KERGER, A. AWADA, F. JOURNE, G. GHANEM (Brussels; Mons, Belgium; Rouen, France). Anticancer Res 37:5941-5953, 20
Monoclonal Antibodies for the Treatment of Cancer. J.T. PENTO (Oklahoma, OK, USA). Anticancer Res 37:5935-5939, 2017.
A Systematic Review and Meta-analysis of Retrospective Series of Regorafenib for Treatment of Metastatic Colorectal Cancer. J. MERCIER, I.A. VOUTSADAKIS (Sudbury; Sault Ste Marie, ON, Canada). Anticancer Res 37:5925-5934, 2017.
Search for New Type of Anticancer Drugs with High Tumor Specificity and Less Keratinocyte Toxicity. Y. SUGITA, K. TAKAO, Y. UESAWA, H. SAKAGAMI (Sakado; Tokyo, Japan). Anticancer Res 37:5919-5924, 2017.
Therapeutic Innovations for Targeting Childhood Neuroblastoma: Implications of the Neurokinin-1 Receptor System. M. BERGER, D. VON SCHWEINITZ (Munich, Germany). Anticancer Res 37:5911-5918, 2017.
Fluoride Induces Apoptosis in Mammalian Cells: In Vitro and In Vivo Studies. D.A. RIBEIRO, C.M. CARDOSO, V.Q. YUJRA, M.D.B. VIANA, O. AGUIAR JR, L.P. PISANI, C.T.F. OSHIMA (Sao Paulo, Brazil). Anticancer Res 37:4767-4778, 2017.
Colorectal Carcinogenesis: Role of Oxidative Stress and Antioxidants. F. CARINI, M. MAZZOLA, F. RAPPA, A. JURJUS, A.G. GEAGEA, S. AL KATTAR, T. BOU-ASSI, R. JURJUS, P. DAMIANI, A. LEONE, G. TOMASELLO (Palermo, Italy; Beirut; Jal El Dib, Lebanon; Washington, DC, USA). Anticancer Res 37:4759-4766, 2017.
Deepening a Simple Question: Can MSCs Be Used to Treat Cancer? J.P.A. GOMES, A.F. ASSONI, M. PELATTI, G. COATTI, O.K. OKAMOTO, M. ZATZ (Sao Paulo, Brazil). Anticancer Res 37:4747-4758, 2017.
Physical Needs of Long-term Cancer Patients. P. TRALONGO, M.G. PESCARENICO, A. SURBONE, S. BORDONARO, M. BERRETTA, A. DI MARI (Syracuse; Parma; Aviano, Italy; New York, NY, USA). Anticancer Res 37:4733-4746, 2017.
Lidocaine Stimulates the Function of Natural Killer Cells in Different Experimental Settings. J.P. CATA, M.F. RAMIREZ, J.F. VELASQUEZ, A. DI, K.U. POPAT, V. GOTTUMUKKALA, D.M. BLACK, V.O. LEWIS, J.N. VAUTHEY (Houston; Temple, TX; Boston, MA, U.S.A.; Medellin, Colombia). Anticancer Res 37:4727-4732, 2017.
Thrombocytosis Portends Adverse Prognosis in Colorectal Cancer: A Meta-Analysis of 5,619 Patients in 16 Individual Studies. D. GU, A. SZALLASI (Livingston, NJ; Jacksonville, FL, USA). Anticancer Res 37:4717-4726, 2017.
Impact of Parental Cancer on Children. B.K. SHAH, J. ARMALY, E. SWIETER (Sedro-Woolley; Yakima, WA, USA). Anticancer Res 37:4025-4028, 2017.
Genotoxicity Induced by Dental Materials: A Comprehensive Review. D.A. RIBEIRO, V.Q. YUJRA, C.F.G. DE MOURA, B.A. HANDAN, M.D.B. VIANA, L.Y. YAMAUCHI, P.M. CASTELO, O. AGUIAR JR (Sao Paolo, Brazil). Anticancer Res 37:4017-4024, 2017.
Lower Body Lymphedema in Patients with Gynecologic Cancer. N. BIGLIA, V. ZANFAGNIN, A. DANIELE, E. ROBBA, V.E. BOUNOUS (Turin, Italy). Anticancer Res 37:4005-4016, 2017.
Vitamin D Receptor Polymorphism and Cancer: An Update. V. RAI, J. ABDO, S. AGRAWAL, D.K. AGRAWAL (Omaha, NE, USA). Anticancer Res 37:3991-4004, 2017.
BDNF: An Oncogene or Tumor Suppressor? D.P. RADIN, P. PATEL (Stony Brook; New York City, NY, USA). Anticancer Res 37:3983-3990, 2017.
Clinicopathological and Corresponding Genetic Features of Colorectal Signet Ring Cell Carcinoma. K. TAJIRI, T. SUDOU, F. FUJITA, T. HISAKA, T. KINUGASA, Y. AKAGI (Fukuoka, Japan). Anticancer Res 37:3817-3824, 2017.
Clinical Implications of Augmenter of Liver Regeneration in Cancer: A Systematic Review. K.H. NGUYEN, A.H. NGUYEN, D.V. DABIR (Los Angeles, CA, USA). Anticancer Res 37:3379-3384, 2017.
Application of Cancer Cell Reprogramming Technology to Human Cancer Research.  X.-Y. PAN, M.-H. TSAI, K. WUPUTRA, C.-C. KU, W.-H. LIN, Y.-C. LIN, S. KISHIKAWA, M. NOGUCHI, S. SAITO, C.-S. LIN, K.K. YOKOYAMA (Hanzhou, PR China; Kaohsiung, Taiwan, ROC; Tsukuba; Yaita; Tokyo; Sanuki, Japan). Anticancer Res 37:3367-3378, 2017.
Desmoid Tumors in Familial Adenomatous Polyposis. M.L. DE MARCHIS, F. TONELLI, D. QUARESMINI, D. LOVERO, D. DELLA-MORTE, F. SILVESTRIS, F. GUADAGNI, R. PALMIROTTA (Rome; Florence; Bari, Italy). Anticancer Res 37:3357-3366, 2017.
Measuring Intragastric Tumor Markers in Gastric Cancer Patients: a Systematic Literature Review on Significance and Reliability. E. VIRGILIO, A. PROIETTI, R. D’URSO, P. CARDELLI, E. GIARNIERI, M. MONTAGNINI, M.R. GIOVAGNOLI, P. MERCANTINI, G. BALDUCCI, M. CAVALLINI (Rome, Italy). Anticancer Res 37:2817-2822,2017.
Targeted Therapy in Ovarian Cancer. A Comprehensive Systematic Review of Literature. Y. DIAB, M.Z. MUALLEM (Victoria, Australia; Berlin, Germany). Anticancer Res 37:2809-2816,2017.
Cancer Tissue Classification, Associated Therapeutic Implications and PDT as an Alternative. T.K. HORNE, M.J. CRONJE (Johannesburg, South Africa). Anticancer Res 37:2785-2808,2017.
Erdheim–Chester Disease: Comprehensive Review of Molecular Profiling and Therapeutic Advances. F. HAROUN, K. MILLADO, I. TABBARA (Washington, DC, USA). Anticancer Res 37:2777-2784,2017.
Pancreatic Cancer Stem Cells and Therapeutic Approaches. G. ERCAN, A. KARLITEPE, B. OZPOLAT (Izmir, Turkey; Houston, TX, USA). Anticancer Res 37:2761-2776,2017.
68Ga-PSMA-PET/CT Ηas a Role in Detecting Prostate Cancer Lesions in Patients with Recurrent Disease. C. FITZPATRICK, O. LYNCH, L. MARIGNOL (Dublin, Ireland). Anticancer Res 37:2753-2760,2017.
Updates and Critical Evaluation on Novel Biomarkers for the Malignant Progression of Intraductal Papillary Mucinous Neoplasms of the Pancreas. D. MORIS, C. DAMASKOS, E. SPARTALIS, A. PAPALAMPROS, S. VERNADAKIS, D. DIMITROULIS, J. GRINIATSOS, E. FELEKOURAS, N. NIKITEAS (Columbus, OH, USA; Athens, Greece; Riyadh, Kingdom of Saudi Arabia). Anticancer Res 37:2185-2194,2017.
Implications of Different Cancer Stem Cell Phenotypes in Breast Cancer. A.D.C. PAULA, C. LOPES (Porto, Portugal). Anticancer Res 37:2173-2183,2017.
The Kynurenine Pathway: A Primary Resistance Mechanism in Patients with Glioblastoma. P.P. SORDILLO, L.A. SORDILLO, L. HELSON (Quakertown, PA; New York, NY, USA). Anticancer Res 37:2159-2171,2017.
Antitumor and Cancer-preventative Function of Fucoxanthin: A Marine Carotenoid. Y. SATOMI (Suzuka, Japan). Anticancer Res 37:1557-1562, 2017.
Acute Graft Versus Host Disease: A Comprehensive Review. S. NASSEREDDINE, H. RAFEI, E. ELBAHESH, I. TABBARA (Washington, DC; Huntsville, AL, USA). Anticancer Res 37:1547-1555, 2017.
Synchronous Endometrial and Ovarian Cancer in Young Women: Case Report and Review of the Literature. A. DOGAN, B. SCHULTHEIS, G.A. REZNICZEK, Z. HILAL, C. CETIN, G. HÄUSLER, C.B. TEMPFER (Bochum, Germany; Mauerbach, Austria). Anticancer Res 37:969-978, 2017.
The role of IL-7 in Immunity and Cancer. J. LIN, Z. ZHU, H. XIAO, M.R. WAKEFIELD, V.A. DING, Q. BAI, Y. FANG (Des Moines, IA; Columbia, MO, USA; Chenzhou, PR China). Anticancer Res 37:963-967, 2017.
Clinical Target Volume in Biliary Carcinoma: A Systematic Review of Pathological Studies. I. MARINELLI, A. GUIDO, L. FUCCIO, A. FARIOLI, V. PANNI, L. GIACCHERINI, A. ARCELLI, G. ERCOLANI, G. BRANDI, S. CAMMELLI, A. GALUPPI, G. MACCHIA, R. FRAKULLI, G.C. MATTIUCCI, F. CELLINI, M. BUWENGE, M. RENZULLI, F. DEODATO, S. CILLA, V. VALENTINI, V. TOMBOLINI, R. GOLFIERI, A.G. MORGANTI (Rome; Bologna; Campobasso, Italy). Anticancer Res 37:955-961, 2017.
Possible Therapeutic Effects of Ozone Mixture on Hypoxia in Tumor Development. M. LUONGO, A.L. BRIGIDA, L. MASCOLO, G. GAUDINO (Naples, Italy). Anticancer Res 37:425-435, 2017.
Italian Prostate Biopsies Group: 2016 Updated Guidelines Insights. A. FANDELLA, V. SCATTONI, A. GALOSI, P. PEPE, M. FIORENTINO, C. GAUDIANO, M. GIAMPAOLI, R. GUNELLI, P. MARTINO, V. MONTANARO, R. MONTIRONI, T. PIERANGELI, A. STABILE, A. BERTACCINI (Treviso; Milan; Ancona; Catania; Bologna; Forlì; Bari; Naples, Italy). Anticancer Res 37:413-424, 2017.
Potential Predictive Role of MicroRNAs in the Neoadjuvant Treatment of Esophageal Cancer. D. VRANA, M. MATZENAUER, R. AUJESKY, R. VRBA, C. NEORAL, B. MELICHAR, P. SOUČEK (Olomouc; Prague, Czech Republic). Anticancer Res 37:403-412, 2017.
The Evolving Role of Local Treatments for HCC in the Third Millennium. P. MAGISTRI, G. TARANTINO, R. BALLARIN, M. BERRETTA, Α. PECCHI, G. RAMACCIATO, F. DI BENEDETTO (Modena; Rome; Aviano, Italy). Anticancer Res 37:389-401, 2017.
Immune-based Therapies for Non-small Cell Lung Cancer. H. RAFEI, E. EL-BAHESH, A. FINIANOS, S. NASSEREDDINE, I. TABBARA (Washington, DC; Huntsville, AL, USA; Jounieh, Lebanon). Anticancer Res 37:377-387, 2017.
Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer. C. DAMASKOS, S. VALSAMI, M. KONTOS, E. SPARTALIS, T. KALAMPOKAS, E. KALAMPOKAS, A. ATHANASIOU, D. MORIS, A. DASKALOPOULOU, S. DAVAKIS, G. TSOUROUFLIS, K. KONTZOGLOU, D. PERREA, N. NIKITEAS, D. DIMITROULIS (Athens, Greece; Aberdeen, UK; Cleveland, OH, USA). Anticancer Res 37:35-46, 2017.
Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme. J. POLIVKA JR, J. POLIVKA, L. HOLUBEC, T. KUBIKOVA, V. PRIBAN, O. HES, K.  PIVOVARCIKOVA, I. TRESKOVA (Plzen, Czech Republic).  Anticancer Res 37:21-34, 2017.
Three Pathways of Colonic Carcinogenesis in Rats. C.A. RUBIO (Stockholm, Sweden).  Anticancer Res 37:15-20, 2017.
Parenchymal-sparing Hepatectomy as the New Doctrine in the Treatment of Liver-metastatic Colorectal Disease: Beyond Oncological Outcomes. D. MORIS, D. DIMITROULIS, S. VERNADAKIS, A. PAPALAMPROS, E. SPARTALIS, A. PETROU, T.M. PAWLIK, E.  FELEKOURAS (Cleveland; Columbus, OH, USA; Athens, Greece). Anticancer Res 37:9-14, 2017.
Clinical Implications of High-mobility Group Box-1 (HMGB1) and the Receptor for Advanced Glycation End-products (RAGE) in Cutaneous Malignancy: A Systematic Review. A.H. NGUYEN, S.Q. DETTY, D.K. AGRAWAL (Omaha, NE, USA). Anticancer Res 37:1-8, 2017.
Vitamin D and Myofibroblasts in Fibrosis and Cancer: At Cross-purposes with TGF-β/SMAD Signaling. S. SHANY, I. SIGAL-BATIKOFF, S. LAMPRECHT (Beersheva, Israel). Anticancer Res 36:6225-6234, 2016.
Lung Adenocarcinoma in Never Smokers: Problems of Primary Prevention from Aspects of Susceptible Genes and Carcinogens. I. OKAZAKI, S. ISHIKAWA, W. ANDO, Y. SOHARA (Tokyo; Nasushiobara; Okegawa, Japan). Anticancer Res 36:6207-6224, 2016.
Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer. F.E. BURONI, M.G. PERSICO, F. PASI, L. LODOLA, R. NANO, C. APRILE (Pavia, Italy). Anticancer Res 36:5719-5730, 2016.
Potential Anti-metastasis Natural Compounds for Lung Cancer. P. CHANVORACHOTE, S. CHAMNI, C. NINSONTIA, P.P. PHIBOONCHAIYANAN (Bangkok, Thailand).  Anticancer Res 36:5707-5717, 2016.
The Anticancer Activity of the Old Neuroleptic Phenothiazine-type Drug Thioridazine. G. SPENGLER, Á. CSONKA, J. MOLNÁR, L. AMARAL (Szeged, Hungary; Lisbon, Portugal). Anticancer Res 36:5701-5706, 2016.
Heart Peptide Hormones: Adjunct and Primary Treatments of Cancer. D.L. VESELY (Tampa, FL, USA). Anticancer Res 36:5693-5700, 2016.
Targeting Cellular Signaling Pathways in Breast Cancer Stem Cells and its Implication for Cancer Treatment. B.R.B. PIRES, Í.S.S. DE AMORIM, L.D.E. SOUZA, J.A. RODRIGUES, A.L. MENCALHA (Rio de Janeiro, RJ, Brazil).  Anticancer Res 36:5681-5691, 2016.
Regulation of the Expression of Cytoplasmic Polyadenylation Element Binding Proteins for the Treatment of Cancer. Y. CHEN, Y.-H. TSAI, S.-H. TSENG (New Taipei; Taoyuan; Taipei, Taiwan, ROC).  Anticancer Res 36:5673-5680, 2016.
Identification of Important Compounds Isolated from Natural Sources that Have Activity Against Multidrug-resistant Cancer Cell Lines: Effects on Proliferation, Apoptotic Mechanism and the Efflux Pump Responsible for Multi-resistance Phenotype. L. AMARAL, G. SPENGLER, J. MOLNAR (Szeged, Hungary; Lisbon, Portugal). Anticancer Res 36:5665-5672, 2016.
The Antitumor Effect of Singlet Oxygen. G. BAUER (Freiburg, Germany). Anticancer Res 36:5649-5663, 2016.
Molecular Mechanisms of Anti-metastatic Activity of Curcumin. Y. DENG, E. VERRON, R. ROHANIZADEH (Sydney, Australia; Nantes, France). Anticancer Res 36:5639-5647, 2016.
Discovery of Anticancer Agents of Diverse Natural Origin. A.D. KINGHORN, E.J. CARCACHE DE BLANCO, D.M. LUCAS, H.L. RAKOTONDRAIBE, J. ORJALA, D.D. SOEJARTO, N.H. OBERLIES, C.J. PEARCE, M.C. WANI, B.R. STOCKWELL, J.E. BURDETTE, S.M. SWANSON, J.R. FUCHS, M.A. PHELPS, L. XU, X. ZHANG, Y.Y. SHEN (Columbus, OH; Chicago, IL; Greensboro; Hillsborough; Research Triangle Park, NC; New York, NY; Madison, WI; Andover, MA, USA). Anticancer Res 36:5623-5637, 2016.
Immune Blockade Inhibition in Breast Cancer. I.A. VOUTSADAKIS (Sudbury, ON, Canada).  Anticancer Res 36:5607-5622, 2016.
Cancer Immunology and Immunotherapy. A. SUKARI, M. NAGASAKA, A. AL-HADIDI, L.G. LUM (Detroit; Royal Oak, MI; Charlottesville, VA, USA). Anticancer Res 36:5593-5606, 2016.
Therapeutic Innovations for Targeting Hepatoblastoma. A. GARNIER, M. ILMER, R. KAPPLER, M. BERGER (Munich, Germany; Atlanta, GA, USA). Anticancer Res 36:5577-5592, 2016.
MicroRNAs: A Puzzling Tool in Cancer Diagnostics and Therapy. B. D’ANGELO, E. BENEDETTI, A. CIMINI, A. GIORDANO (Philadelphia, PA, USA; L’Aquila; Assergi; Siena, Italy). Anticancer Res 36:5571-5575, 2016.
Non-epithelial Ovarian Cancer: Elucidating Uncommon Gynaecological Malignancies. S. BOUSSIOS, G. ZARKAVELIS, E. SERAJ, I. ZERDES, K. TATSI, G. PENTHEROUDAKIS (Ioannina, Greece). Anticancer Res 36:5031-5042,2016.
Antiangiogenic Therapy in Pancreatic Neuroendocrine Tumors. M. CAPOZZI, C. VON ARX, C. DE DIVITIIS, A. OTTAIANO, F. TATANGELO, G.M. ROMANO, S. TAFUTO (Naples, Italy). Anticancer Res 36:5025-5030,2016.
Histone Deacetylase Inhibitors: A Novel Therapeutic Weapon Αgainst Medullary Thyroid Cancer? C. DAMASKOS, S. VALSAMI, E. SPARTALIS, E.A. ANTONIOU, P. TOMOS, S. KARAMAROUDIS, T. ZOUMPOU, V. PERGIALIOTIS, K. STERGIOS, C. MICHAELIDES, K. KONTZOGLOU, D. PERREA, N. NIKITEAS, D. DIMITROULIS (Athens, Greece; Harlow, UK).  Anticancer Res 36:5019-5024,2016.
Ageing as an Important Risk Factor for Cancer. K. SMETANA JR., L. LACINA, P. SZABO, B. DVOŘÁNKOVÁ, P. BROŽ, A. ŠEDO (Prague; Vestec, Czech Republic; Kosice, Slovak Republic).  Anticancer Res 36:5009-5017,2016.
Molecular Pathology and Novel Clinical Therapy for Uterine Leiomyosarcoma. T. HAYASHI, M. KAWANO, T. ICHIMURA, K. IDA, H. ANDO, D. ZHARHARY, Y. KANAI, H. ABURATANI, S. TONEGAWA, T. SHIOZAWA, N. YAEGASHI, I. KONISHI (Nagano; Chiba; Fukuoka; Osaka; Tokyo; Miyagi; Kyoto, Japan; Rehovot, Israel; Cambridge, MA, USA). Anticancer Res 36:4997-5007,2016.
Re-irradiation for Recurrent Primary Brain Tumors. C. NIEDER, N.H. ANDRATSCHKE, A.L. GROSU (Bodø; Tromsø, Norway; Zurich, Switzerland; Freiburg, Germany). Anticancer Res 36:4985-4995,2016
Procalcitonin: A New Biomarker for Medullary Thyroid Cancer? A Systematic Review. A.K.A. KARAGIANNIS, C. GIRIO-FRAGKOULAKIS, T. NAKOUTI (Athens, Greece; Nottingham, UK).  Anticancer Res 36:3803-3810,2016.
Immunotherapy in Acute Leukemias: Implications and Perspectives Using Wt1 Antigen. G.C.M. CEBINELLI, N.D.S. PEREIRA, M.M. SENA, C.E.C. DE OLIVEIRA, T.C. FUJITA, S.P.D. DA ROCHA, F.J.D.A. OLIVEIRA, P.C. MARINELLO, M.A.E. WATANABE (Londrina-Paraná, Brazil). Anticancer Res 36:3795-3802,2016.
The Role of FOXP3 in Human Cancers. Ł. SZYLBERG, D. KARBOWNIK, A. MARSZAŁEK (Torun; Poznan, Poland). Anticancer Res 36:3789-3794,2016.
Non-routine Tracers for PET Imaging of High-grade Glioma. G. FROSINA (Genoa, Italy). Anticancer Res 36:3253-3260,2016.
The Use of Complementary and Alternative Medicine in Scandinavia: A Review Article. J. NILSSON, M. KÄLLMAN, U. ÖSTLUND, G. HOLGERSSON, M. BERGQVIST, S. BERGSTRÖM (Gavle; Umea, Sweden). Anticancer Res 36:3243-3251,2016.
Current Status of Biological Therapies for the Treatment of Metastatic Melanoma. T. TANG, R. ELDABAJE, L. YANG (San Francisco, CA, USA). Anticancer Res 36:3229-3241,2016.
Sphingosine Kinase Inhibitors as Maintenance Therapy of Glioblastoma After Ceramide-Induced Response. L.A. SORDILLO, P.P. SORDILLO, L. HELSON (Quakertown, PA, USA). Anticancer Res 36:2085-2095,2016.
The NFĸB Signaling Pathway in Papillomavirus-induced Lesions: Friend or Foe? R.M. GIL DA COSTA, M.M.S.M. BASTOS, R. MEDEIROS, P.A. OLIVEIRA (Porto; Vila Real, Portugal). Anticancer Res 36:2073-2083,2016.
Methods to Increase Future Liver Remnant Volume in Patients with Primarily Unresectable Colorectal Liver Metastases: Current State and Future Perspectives. V. TRESKA (Pilsen, Czech Republic). Anticancer Res 36:2065-2071,2016.
PARP Inhibitors in Epithelial Ovarian Cancer: State of Art and Perspectives of Clinical Research. A. GADDUCCI, M.E. GUERRIERI (Pisa, Italy). Anticancer Res 36:2055-2064,2016.
Refining the Performance of Sentinel Lymph Node Biopsy Postneoadjuvant Chemotherapy in Patients with Pathologically Proven Pre-treatment Node-positive Breast Cancer: An Update for Clinical Practice. H.E.H. CHEHADE, H. HEADON, A. KASEM, K. MOKBEL (London, UK). Anticancer Res 36:1461-1471,2016.
From Inflammation to Cancer in Inflammatory Bowel Disease: Molecular Perspectives. M. ROMANO, F. DE FRANCESCO, L. ZARANTONELLO, C. RUFFOLO, G.A. FERRARO, G. ZANUS, A. GIORDANO, N. BASSI, U. CILLO (Padua; Naples; Treviso; Siena, Italy; Philadelphia, PA, USA). Anticancer Res 36:1447-1460,2016.
Extracorporeal Photopheresis for Non-skin GvHD. J. BITTENBRING, J. REICHRATH (Homburg, Germany). Anticancer Res 36:1395-1396,2016.
Light - Instead of UV Protection: New Requirements for Skin Cancer Prevention. L. ZASTROW, J. LADEMANN (Berlin, Germany). Anticancer Res 36:1389-1393,2016.
Vitamin D and Mortality. S. PILZ, M. GRÜBLER, M. GAKSCH, V. SCHWETZ, C. TRUMMER, B.Ó. HARTAIGH, N. VERHEYEN, A. TOMASCHITZ, W. MÄRZ (Graz; Bad Aussee, Austria; Amsterdam, the Netherlands; Bern, Switzerland; New York, NY; New Haven, CT, USA; Mannheim, Germany). Anticancer Res 36:1379-1387,2016.
Photocarcinogenesis and Skin Cancer Prevention Strategies. C. SEEBODE, J. LEHMANN, S. EMMERT (Rostock; Goettingen, Germany). Anticancer Res 36:1371-1378,2016.
Roles of Solar UVB and Vitamin D in Reducing Cancer Risk and Increasing Survival. W.B. GRANT (San Francisco, CA, USA). Anticancer Res 36:1357-1370,2016.
Tumour–Endothelial Cell Communications: Important and Indispensable Mediators of Tumour Angiogenesis. B.M. LOPES-BASTOS, W.G. JIANG, J. CAI (Cardiff, UK). Anticancer Res 36:1119-1126,2016.
Update on Biomarkers in Development of Anti-angiogenic Drugs in Gastric Cancer. S. JIA, J. CAI (Cardiff, UK; Beijing, PR China). Anticancer Res 36:1111-1118,2016.
Phosphoinositide-3-Kinase Enhancers, PIKEs: Their Biological Functions and Roles in Cancer. W. JIA, Y. FENG, A.J. SANDERS, E.L. DAVIES, W.G. JIANG (Cardiff, UK; Guangzhou, PR China). Anticancer Res 36:1103-1109,2016.
Biomarkers in Colorectal Cancer. A.J. YIU, C.Y. YIU (London, UK). Anticancer Res 36:1093-1102,2016.
Anticancer Properties of Capsaicin Against Human Cancer. R. CLARK, S.-H. LEE (College Park, MD, USA). Anticancer Res 36:837-843,2016.
Human Papillomavirus as a Diagnostic and Prognostic Tool in Cancer of Unknown Primary in the Head and Neck Region. L. SIVARS, E. TANI, A. NÄSMAN, T. RAMQVIST, E. MUNCK-WIKLAND, T. DALIANIS (Stockholm, Sweden). Anticancer Res 36:487-493. 2016.
TAS-102 an Emerging Oral Fluoropyrimidine. J. CHEN, M. HAN, M.W. SAIF (St. Lucia; Wollongong, Australia; Boston, MA, USA). Anticancer Res 36:21-26. 2016.
Factors Affecting Survival in Patients with Lung Metastases from Colorectal Cancer. A Short Meta-analysis. F. LUMACHI, G.B. CHIARA, R. TOZZOLI, A. DEL CONTEA, S.M.M. BASSO (Padova; Pordenone, Italy). Anticancer Res 36:13-19. 2016.
Potential of Amifostine for Chemoradiotherapy and Radiotherapy-associated Toxicity Reduction in Advanced NSCLC: A Meta-Analysis. A. DEVINE, L. MARIGNOL (Dublin, Ireland). Anticancer Res 36:5-12. 2016.
Using Epigenetic Therapy to Overcome Chemotherapy Resistance. J. STRAUSS, W.D. FIGG (Bethesda, MD, USA). Anticancer Res 36:1-4. 2016.
Innovative Therapeutic Strategies in the Treatment of Meningioma. G. CARUSO, S.K. ELBABAA, P. GONZALEZ-LOPEZ, V. BARRESI, M. PASSALACQUA, M. CAFFO (Messina, Italy; Saint Louis, MO,
USA; Alicante, Spain). Anticancer Res 35: 6391-6400. 2015
Extracellular Vesicles as Biomarkers and Therapeutic Targets in Breast Cancer. L. SADOVSKA, J. EGLĪTIS, A. LINĒ (Riga, Latvia). Anticancer Res 35: 6379-6390. 2015
Curcumin for the Treatment of Glioblastoma. L.A. SORDILLO, P.P. SORDILLO, L. HELSON (Quakertown PA, USA). Anticancer Res 35: 6373-6378. 2015
Increased Production of Lysozyme Associated with Bacterial Proliferation in Barrett’s Esophagitis, Chronic Gastritis, Gluten-induced Atrophic Duodenitis (Celiac Disease), Lymphocytic Colitis, Collagenous Colitis, Ulcerative Colitis and Crohn’s Colitis. C.A. RUBIO (Stockholm, Sweden). Anticancer Res 35: 6365-6372. 2015
Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia. J. PINILLA- IBARZ, K. SWEET, J. EMOLE, M. FRADLEY (Tampa, FL, USA). Anticancer Res 35: 6355-6364. 2015
Primary Breast Cancer with Synchronous Metastatic Disease – Indications for Local Radiotherapy to the Breast and Chest Wall. S. JANSSEN, D. RADES (Hannover; Lubeck, Germany). Anticancer Res 35: 5807-5812. 2015
Brain Metastases in NSCLC – Are TKIs Changing the Treatment Strategy? W.C.M. DEMPKE, K. EDVARDSEN, S. LU, N. REINMUTH, M. RECK, A. INOUE (Cambridge, UK; Munich; Grosshansdorf, Germany; Shanghai, PR China; Sendai, Japan). Anticancer Res 35: 5797-5806. 2015
Relationship Between Metabolic Reprogramming and Mitochondrial Activity in Cancer Cells. Understanding the Anticancer Effect of Metformin and Its Clinical Implications. M. CAZZANIGA, B. BONANNI (Milan, Italy). Anticancer Res 35: 5789-5796. 2015
Natural Products That Target Cancer Stem Cells. J. MOSELHY, S. SRINIVASAN, M.K. ANKEM, C. DAMODARAN (Louisville, KY, USA). Anticancer Res 35: 5773-5788. 2015
Therapeutic Potential of Thalidomide and Its Analogues in the Treatment of Cancer. G.V. SHERBET (Huntington Beach, CA, USA; Newcastle, UK). Anticancer Res 35: 5767-5772. 2015
Can Imatinib Be Safely Withdrawn in Patients with Surgically Resected Metastatic GIST? I. HOMPLAND, Ø.S. BRULAND (Oslo, Norway). Anticancer Res 35: 5759-5765. 2015
Immunotherapies for NSCLC: Are We Cutting the Gordian Helix? W.C.M. DEMPKE, L. SELLMANN, K. FENCHEL, K. EDVARDSEN (Munich; Mönchengladbach; Hamburg, Germany; Cambridge, UK). Anticancer Res 35: 5745-5757. 2015
Molecular Targeted Therapies in Hepatocellular Carcinoma: Past, Present and Future. M. STOTZ, A. GERGER, J. HAYBAECK, T. KIESSLICH, M.D. BULLOCK, M. PICHLER (Graz; Salzburg, Austria; Houston, TX, USA). Anticancer Res 35: 5737-5744. 2015
Atypical Fibroxanthoma - Histological Diagnosis, Immunohistochemical Markers and Concepts of Therapy. M. KOCH, A.J. FREUNDL, A. AGAIMY, F. KIESEWETTER, J. KÜNZEL, I. CICHA, C. ALEXIOU (Erlangen; Mainz, Germany). Anticancer Res 35: 5717-5735. 2015
Primary Thyroid Sarcoma: A Systematic Review. A. SUROV, S. GOTTSCHLING, A. WIENKE, H. JONAS MEYER, R.P. SPIELMANN, H. DRALLE (Halle-Wittenberg; Leipzig, Germany). Anticancer Res 35: 5185-5191. 2015
Predictive and Prognostic Value of the Tau Protein in Breast Cancer. C. BONNEAU, Z.A. GURARD-LEVIN, F. ANDRE, L. PUSZTAI, R. ROUZIER (Versailles; Paris, France; New Haven, CT, USA). Anticancer Res 35: 5179-5184. 2015
Hypofractionated Radiotherapy for Localized Prostate Cancer: A Challenging Accelerated Hypofractionated Radiotherapy. H. YAMAZAKI, S. NAKAMURA, G. SUZUKI, K. YOSHIDA, Y. YOSHIOKA, M. KOIZUMI, K. OGAWA (Kyoto; Takatsuki City; Suita, Japan). Anticancer Res 35: 5167-5177. 2015
Chronic Lymphocytic Leukemia: Current Concepts. E.-M. YU, A. KITTAI, I.A. TABBARA (Washington, DC, USA). Anticancer Res 35: 5149-5165. 2015
Nitric Oxide and Aggressive Behavior of Lung Cancer Cells. S. LUANPITPONG, P. CHANVORACHOTE
(Bangkok, Thailand). Anticancer Res 35: 4585-4592. 2015
Second-line Treatment of Advanced Gastric Cancer: Current Options and Future Perspectives. P. CHROM, R. STEC, C. SZCZYLIK (Warsaw, Poland). Anticancer Res 35: 4575-4583. 2015
The Role of Methylation in Breast Cancer Susceptibility and Treatment. M.-C. POULIOT, Y. LABRIE, C. DIORIO, F. DUROCHER (Quebec, Canada). Anticancer Res 35: 4569-4574. 2015
Novel Molecular Targets for the Therapy of Urothelial Cancer. B.R.P. JANA, Y. ZHOU (Galveston, TX, USA). Anticancer Res 35: 4557-4567. 2015
Transcriptional Regulation of the p16 Tumor Suppressor Gene. Y. KOTAKE, M. NAEMURA, C. MURASAKI, Y. INOUE, H. OKAMOTO (Fukuoka, Japan). Anticancer Res 35: 4397-4401. 2015
Methods to Prevent or Treat Refractory Diseases by Focusing on Intestinal Microbes Using LPS and Macrophages. G.-I. SOMA, H. INAGAWA (Kagawa; Niigata, Japan). Anticancer Res 35: 4393-4396. 2015
Functional Alteration of Tumor-infiltrating Myeloid Cells in RNA Adjuvant Therapy. T. SEYA, H. SHIME, M. MATSUMOTO (Sapporo, Japan). Anticancer Res 35: 4385-4392. 2015
The Story of MCF-7 Breast Cancer Cell Line: 40 years of Experience in Research. Ş. COMŞA, A.M. CÎMPEAN, M. RAICA (Timisoara, Romania). Anticancer Res 35: 3147-3154. 2015
Anticancer Effects of Sandalwood (Santalum album). S. SANTHA, C. DWIVEDI (Brookings, SD, USA). Anticancer Res 35: 3137-3145. 2015
Histone Deacetylase (HDAC) Inhibitors: Current Evidence for Therapeutic Activities in Pancreatic Cancer. C. DAMASKOS, T. KARATZAS, L. NIKOLIDAKIS, I.D. KOSTAKIS, S. KARAMAROUDIS, G. BOUTSIKOS, Z. DAMASKOU, A. KOSTAKIS, G. KOURAKLIS (Athens, Greece). Anticancer Res 35: 3129-3135. 2015
Emergency Fertility Preservation for Female Patients with Cancer: Clinical Perspectives. M. SALAMA, P. MALLMANN (Cologne, Germany). Anticancer Res 35: 3117-3127. 2015
The Role of Human Papilloma Virus in Urological Malignancies. I. HEIDEGGER, W. BORENA, R.
PICHLER (Innsbruck, Austria). Anticancer Res 35: 2513-2519. 2015
Targeted Therapy for NSCLC–A Double-edged Sword? W.C.M. DEMPKE (Munich, Germany). Anticancer Res 35: 2503-2512. 2015
Randomized Trials of Systemic Medically-treated Malignant Mesothelioma: A Systematic Review. C. BLOMBERG, J. NILSSON, G. HOLGERSSON, P. EDLUND, M. BERGQVIST, L. ADWALL, S. EKMAN, D. BRATTSTRÖM, S. BERGSTRÖM (Gävle; Uppsala; Umeå, Sweden). Anticancer Res 35: 2493-2501. 2015
Radiation-associated Cardiac Injury. R. ELDABAJE, D.L. LE, W. HUANG, L.-X. YANG (San Francisco, CA; Providence, RI, USA). Anticancer Res 35: 2487-2492. 2015
Recent Developments in Radiosensitization. J. LINAM, L.-X. YANG (San Francisco, CA, USA). Anticancer Res 35: 2479-2485. 2015
Diagnostic Potential of Ancillary Molecular Testing in Differentiation of Benign and Malignant Thyroid Nodules. P. BHATIA, A. DENIWAR, P. FRIEDLANDER, R. ASLAM, E. KANDIL (New Orleans, LA,
USA). Anticancer Res 35: 1237-1241. 2015
Topics in Chemotherapy, Molecular-targeted Therapy, and Immunotherapy for Newly-diagnosed Glioblastoma Multiforme. N. OKONOGI, K. SHIRAI, T. OIKE, K. MURATA, S.-E. NODA, Y. SUZUKI, T. NAKANO (Maebashi; Fukushima, Japan). Anticancer Res 35: 1229-1235. 2015
Potential Anticancer Properties and Mechanisms of Action of Curcumin. N.G. VALLIANOU, A. EVANGELOPOULOS, N. SCHIZAS, C. KAZAZIS (Athens; Samos, Greece). Anticancer Res 35: 645-651. 2015
Mode of Action of Anticancer Peptides (ACPs) from Amphibian Origin. C. OELKRUG, M. HARTKE, A. SCHUBERT (Leipzig, Germany). Anticancer Res 35: 635-643. 2015
Targeting the Peritoneum with Novel Drug Delivery Systems in Peritoneal Carcinomatosis: A Review of the Literature. T.R. VAN OUDHEUSDEN, H. GRULL, P.Y.W. DANKER, I.H.J.T. DE HINGH (Eindhoven, the Netherlands). Anticancer Res 35: 627-634. 2015
Mechanisms and Clinical Significance of Histone Deacetylase Inhibitors: Epigenetic Glioblastoma Therapy. P. LEE, B. MURPHY, R. MILLER, V. MENON, N.L. BANIK, P. GIGLIO, S.M. LINDHORST, A.K. VARMA, W.A. VANDERGRIFT III, S.J. PATEL, A. DAS (Charleston, SC; Columbus, OH, USA). Anticancer Res 35: 615-625. 2015
Curcumin and Cancer Stem Cells: Curcumin Ηas Asymmetrical Effects on Cancer and Normal Stem Cells. P.P. SORDILLO, L. HELSON (Quakertown, PA, USA). Anticancer Res 35: 599-614. 2015
Cytokine Networks in Animal Models of Colitis-associated Cancer. E. ANTONIOU, G.A. MARGONIS, A. ANGELOU, G.C. ZOGRAFOS, E. PIKOULIS (Athens, Greece). Anticancer Res 35: 19-24. 2015
Female Genital Tract Chronic Graft-versus-Host Disease: Review of the Literature. A. CIAVATTINI, N. CLEMENTE (Ancona, Italy). Anticancer Res 35: 13-17. 2015
Management of Chronic Myelogenous Leukemia in Pregnancy. A. BHANDARI, K. ROLEN, B.K. SHAH (Lewiston, ID, USA). Anticancer Res 35: 1-11. 2015
Radiotherapeutic Treatment Approaches for Brain Metastases.
F. DE FELICE, D. MUSIO, R. CASSESE, V. TOMBOLINI (Rome, Italy). Anticancer Res 34: (12) 6913-6918. 2014
Nuclear Receptors in Pancreatic Tumor Cells.
C. DAMASKOS, T. KARATZAS, I.D. KOSTAKIS, L. NIKOLIDAKIS, A. KOSTAKIS, G. KOURAKLIS (Athens, Greece). Anticancer Res 34: (12) 6897-6911. 2014
Non Coding RNAs in Head and Neck Squamous Cell Carcinoma (HNSCC): A Clinical Perspective.
N. DENARO, M.C. MERLANO, E. GRAZIOSO RUSSI, C. LO NIGRO (Cuneo, Italy). Anticancer Res 34: (12) 6887-6896. 2014
Transcatheter Arterial Embolic Therapies for Hepatocellular Carcinoma: A Literature Review.
H. NISHIKAWA, R. KITA, T. KIMURA, Y. OSAKI (Osaka, Japan). Anticancer Res 34: 6877-6886. 2014
The Role of Dietary Factors in Prevention and Progression of Breast Cancer.
R.E. ROSSI, M. PERICLEOUS, D. MANDAIR, T. WHYAND, M.E. CAPLIN (London, UK; Milano, Italy). Anticancer Res 34: 6861-6875. 2014
Bacteria: Prospective Savior in Battle against Cancer.
N. NAIR, T. KASAI, M. SENO (Okayama, Japan). Anticancer Res 34: 6289-6296. 2014
Surgical Management of Microscopic Positive Resection Margin After Gastrectomy for Gastric Cancer: A Systematic Review of Gastric R1 Management.
P. AURELLO, P. MAGISTRI, G. NIGRI, N. PETRUCCIANI, L. NOVI, L. ANTOLINO, F. D’ANGELO, G. RAMACCIATO (Rome, Italy). Anticancer Res 34: 6283-6288. 2014
Current Concepts in Colorectal Cancer Prevention with Cyclooxygenase Inhibitors.
G. SINGH RANGER (Waterville, New Brunswick; Halifax, Nova Scotia, Canada). Anticancer Res 34: 6277-6286. 2014
Surgery for Symptomatic Colon Lipoma: A Systematic Review of the Literature.
D. CROCETTI, P. SAPIENZA, A.V. STERPETTI, A. PALIOTTA, A. DE GORI, G. PEDULLÀ, G. DE TOMA (Rome, Italy). Anticancer Res 34: 6271-6276. 2014
Resistance to Abiraterone in Castration-resistant Prostate Cancer: A Review of the Literature.
S. GIACINTI, M. BASSANELLI, A.M. ASCHELTER, A. MILANO, M. ROBERTO, P. MARCHETTI (Rome, Italy). Anticancer Res 34: 6265-6269. 2014
NOTCH Signaling Roles in Acute Myeloid Leukemia Cell Growth and Interaction with other Stemnessrelated Signals.
S. TOHDA (Tokyo, Japan). Anticancer Res 34: 6259-6264. 2014
Chemotherapy of Rare Skin Adnexal Tumors: A Review of Literature.
F.DE IULIIS, L. AMOROSO, L. TAGLIERI, S. VENDITTOZZI, L. BLASI, G. SALERNO, R. LANZA, S. SCARPA (Rome, Italy). Anticancer Res 34: 5263-5268. 2014
Soft Tissue Limb and Trunk Sarcomas: Diagnosis, Treatment and Follow-up.
M. RASTRELLI, S. TROPEA, U. BASSO, A. ROMA, M. MARUZZO, C.R. ROSSI (Padova, Italy). Anticancer Res 34: 5251-5262. 2014
Pharmacogenomics in Lung Cancer Chemotherapy: A Review of What the Oncologist Should Know.
C.D’ANTONIO, A. MILANO, R. RIGHINI, C.E. ONESTI, M. BASSANELLI, R. FALCONE, I. PARIS, S. LAURO, P. MARCHETTI (Rome, Italy). Anticancer Res 34: 5241-5250. 2014
Genes Associated with Succeptibility to Lung Adenocarcinoma Among Never Smokers Suggest the Mechanism of Disease.
I. OKAZAKI, S. ISHIKAWA, Y. SOHARA (Tokyo; Otawara, Tochigi, Japan). Anticancer Res 34: 5229-5240. 2014
Neoadjuvant Strategy as Initial Treatment in Resectable Pancreatic Cancer: Concrete Evidence of Benefit.
F. DE FELICE, D. MUSIO, N. RAFFETTO, V. TOMBOLINI (Rome, Italy). Anticancer Res 34: 4673-4676. 2014
The Intercellular Cell Adhesion Molecule-1 (ICAM-1) in Lung Cancer: Implications for Disease Progression and Prognosis.
E.A. KOTTEAS, P. BOULAS, I. GKIOZOS, S. TSAGKOULI, G. TSOUKALA, K.N. SYRIGOS (Athens, Greece). Anticancer Res 34: 4665-4672. 2014
Sono-Photodynamic Combination Therapy: A Review on Sensitizers.
K.C. SADANALA, P.K. CHATURVEDI, Y.M. SEO, J.M. KIM, Y.S. JO, Y.K. LEE, W.S. AHN (Seoul, South Korea). Anticancer Res 34: 4657-4664. 2014
Factors Associated with Radiosensitivity of Cervical Cancer.
C. QIN, X. CHEN, Q. BAI, M.R. DAVIS, Y. FANG (Shenzhen, P.R. China; Des Moines, IA; Columbia, MO, USA). Anticancer Res 34: 4649-4656. 2014
Vitamin D and Cardiovascular Disease.
A. ZITTERMANN (Bad Oeynhausen, Germany). Anticancer Res 34: 4641-4648. 2014
The RECK Gene and Biological Malignancy–Its Significance in Angiogenesis and Inhibition of Matrix Metalloproteinases.
M. ALEXIUS-LINDGREN, E. ANDERSSON, I. LINDSTEDT, W. ENGSTRÖM (Uppsala, Sweden). Anticancer Res 34: 3867-3873. 2014
Erdheim-Chester Disease: A Comprehensive Review.
A.M. ABDELFATTAH, K. ARNAOUT, I.A. TABBARA (Washington, DC, USA; Alexandria, Egypt). Anticancer Res 34: 3257-3261. 2014
Regulation and Involvement in Cancer and Pathological Conditions of MAGI1, a Tight Junction Protein.
X. FENG, S. JIA, T.A. MARTIN, W.G. JIANG (Hohhot, PR China; Cardiff, UK). Anticancer Res 34: 3251-3256. 2014
Cardiotoxicity of Molecular- targeted Drug Therapy.
D.L. LE, H. CAO, L.-X. YANG (San Francisco, CA, USA). Anticancer Res 34: 3243-3249. 2014
MicroRNAs in Testicular Cancer: Implications for Pathogenesis, Diagnosis, Prognosis and Therapy.
A. BEZAN, A. GERGER, M. PICHLER (Graz, Austria; Houston, TX, USA). Anticancer Res 34: 2709-2713. 2014
Vascularized Bone Graft for Oncological Reconstruction of the Extremities: Review of the Biological Advantages.
K. MURAMATSU, T. HASHIMOTO, Y. TOMINAGA. T. TAGUCHI (Ube, Yamaguchi, Japan). Anticancer Res 34: 2701-2707. 2014
Inefficacy of Therapeutic Cancer Vaccines and Proposed Improvements. Casus of Prostate Cancer.
J.J. L. JACOBS, C. SNACKEY, A.A. GELDOF, D. CHARACIEJUS, R.J.A. VAN MOORSELAAR, W. DEN OTTER (Amsterdam; Haarlem, Netherlands; Vilnius, Lithuania). Anticancer Res 34: 2689-2700. 2014
Gastrectomy for Stage IV Gastric Cancer. A Systematic Review and Meta-analysis.
K. LASITHIOTAKIS, S.A. ANTONIOU, G.A. ANTONIOU, I. KAKLAMANOS, O. ZORAS (Heraklion; Athens, Greece; Newcastle upon Tyne, UK). Anticancer Res 34: 2087-2094. 2014
Gastrectomy for Stage IV Gastric Cancer. A Systematic Review and Meta-analysis.
K. LASITHIOTAKIS, S.A. ANTONIOU, G.A. ANTONIOU, I. KAKLAMANOS, O. ZORAS (Heraklion; Athens, Greece; Newcastle upon Tyne, UK). Anticancer Res 34: 2077-2085. 2014
Advanced Epithelial Ovarian Cancer: From Standard Chemotherapy to Promising Molecular Pathway Targets – Where Are we Now?
J. SYRIOS, S. BANERJEE, S.B. KAYE (London, UK). Anticancer Res 34: 2069-2077. 2014
Molecular Biomarkers and Classification Models in the Evaluation of the Prognosis of Colorectal Cancer.
M. SIDERIS, S. PAPAGRIGORIADIS (London, UK). Anticancer Res 34: 2061-2068. 2014
Targeting Tropomyosin-receptor Kinase Fused Gene in Cancer.
Y. CHEN, S.-H. TSENG (New Taipei; Taoyuan; Taipei, Taiwan, ROC). Anticancer Res 34: 1591-1600. 2014
New Treatment Paradigm for Patients with Anaplastic Oligodendroglial Tumors.
J. POLIVKA JR., J. POLIVKA, V. ROHAN, O. TOPOLCAN (Plzen, Czech Republic). Anticancer Res 34: 1587-1594. 2014
Subcutaneous Administration of Anticancer Agents.
D. LEVEQUE (Strasbourg, France). Anticancer Res 34: 1579-1586. 2014
Malignant Ascites in Ovarian Cancer and the Role of Targeted Therapeutics.
E. SMOLLE, V. TAUCHER, J. HAYBAECK (Graz, Austria). Anticancer Res 34: 1553-1561. 2014
New Possibilities in Hepatocellular Carcinoma Treatment.
M. RASOOL, S. RASHID, M. AROOJ, S.A. ANSARI, K.M. KHAN, A. MALIK, M.I. NASEER, S. ZAHID, A. MANAN, M. ASIF, Z. RAZZAQ, S. ASHRAF, M.H. QAZI, Z. IQBAL, S.H. GAN, M.A. KAMAL, I.A. SHEIKH (Jeddah; Riyadh, Saudi Arabia; Lahore; Quetta, Pakistan; Kelantan, Malaysia). Anticancer Res 34: 1563-1571. 2014
New Anticancer Agents: Role of Clinical Pharmacy Services.
D. LEVEQUE, A. DELPEUCH, B, GOURIEUX (Strasbourg, France). Anticancer Res 34: 1519-1530. 2014
Treatment of Acute Promyelocytic Leukemia.
E. ELBAHESH, N. PATEL, I.A. TABBARA (Washington, DC, USA). Anticancer Res 34: 1507-1517. 2014
New Developments in the Treatment of Metastatic Melanoma: Immune Checkpoint Inhibitors and Targeted Therapies.
K. AZIJLI, E. STELLOO, G.J. PETERS, A.J.M. VAN DEN EERTWEGH (Amsterdam, Netherlands). Anticancer Res 34: 1493-1505. 2014
Pertuzumab: Development Beyond Breast Cancer.
P. BARTHÉLÉMY, J. LEBLANC, V. GOLDBARG, F. WENDLING, J.-E. KURTZ (Strasbourg, France). Anticancer Res 34: 1483-1491. 2014
Targeting Extracellular ROS Signaling of Tumor Cells.
G. BAUER (Freiburg, Germany). Anticancer Res 34: 1467-1482. 2014
Family of Peptides Synthesized in the Human Body Have Anticancer Effects.
D.L. VESELY (Tampa, FL, USA). Anticancer Res 34: 1459-1466. 2014
Endothelial Dysfunction as a Determinant of Trastuzumab-mediated Cardiotoxicity in Patients with Breast Cancer.
A. SANDOO, G.D. KITAS, A.R. CARMICHAEL (Dudley, West Midlands, UK). Anticancer Res 34: 1147-1151. 2014
The Management of Screen-detected Breast Cancer.
M. AHMED, M. DOUEK (London, UK). Anticancer Res 34: 1141-1146. 2014
Mapping Oxidative Changes in Breast Cancer: Understanding the Basic to Reach the Clinics.
A. MENCALHA, V.J. VICTORINO, R. CECCHINI, C. PANIS (Rio de Janeiro; São Paulo; Londrina, Brazil). Anticancer Res 34: 1127-1140. 2014
Predictive and Prognostic Significance of Tumor-infiltrating Lymphocytes in Patients with Breast Cancer Treated with Neoadjuvant Systemic Therapy.
B. MELICHAR, H. ŠTUDENTOVÁ, H. KALÁBOVÁ, D. VITÁSKOVÁ, P. ČERMÁKOVÁ, H. HORNYCHOVÁ, A. RYŠKA (Olomouc; Hradec Králové, Czech Republic). Anticancer Res 34: 1115-1125. 2014
Current Approaches to Managing Partial Breast Defects: The Role of Conservative Breast Surgery Reconstruction.
A.M. MUNHOZ, E. MONTAG, J.R. FILASSI, R. GEMPERLI (São Paulo, Brazil). Anticancer Res 34: 1099-1114. 2014
Clinical Utility of Ultrasound-Needle Biopsy for Preoperative Staging of the Axilla in Invasive Breast Cancer.
N. HOUSSAMI, S.C.E. DIEPSTRATEN, H.S. CODY III, R.M. TURNER, A.R. SEVER (Sydney, NSW, Australia; Utrecht, Netherlands; New York, NY, USA; Maidstone, UK). Anticancer Res 34: 1087-1097. 2014
Glycodelin A – A Famous Lipocalin and its Role in Breast Cancer.
A.C. KÖLBL, U. JESCHKE, D. DIAN, K. FRIESE, U. ANDERGASSEN (Munich, Germany). Anticancer Res 34: 1079-1085. 2014
Genetic and Epigenetic Aspects of Breast Cancer Progression and Therapy.
S. BYLER, S. GOLDGAR, S. HEERBOTH, M. LEARY, G. HOUSMAN, K. MOULTON, S. SARKAR (Boston, MA, USA).Anticancer Res 34: 1071-1077. 2014
Hypoxic Condition and Prognosis in Oral Squamous Cell Carcinoma.
P.O. DE LIMA, C.C. JORGE, D.T. OLIVEIRA, M.C. PEREIRA (Divinópolis, Minas Gerais; Bauru, São Paulo, Brazil). Anticancer Res 34: 605-612. 2014
Histidine Rich Glycoprotein and Cancer: A Multi-faceted Relationship.
L.D.S. JOHNSON, H.A. GOUBRAN, R.R. KOTB (Victoria; Vancouver, BC; Saskatoon, SK, Canada). Anticancer Res 34: 593-603. 2014
Application of FDG-PET in Cervical Cancer and Endometrial Cancer: Utility and Future Prospects.
Y. NOGAMI, M. IIDA, K. BANNO, I. KISU, M. ADACHI, K. NAKAMURA, K. UMENE, K. MASUDA, E. TOMINAGA, K. TANAKA, D. AOKI (Tokyo, Japan). Anticancer Res 34: 585-592. 2014
Chemoembolization in Colorectal Liver Metastases: The Rebirth.
G. FIORENTINI, C. ALIBERTI, L. MULAZZANI, P. COSCHIERA, V. CATALANO, D. ROSSI, P. GIORDANI, S. RICCI (Pesaro; Padova; Ancona, Italy). Anticancer Res 34: 575-584. 2014
Fighting Fire with Fire: The Revival of Thermotherapy for Gliomas.
W.L. TITSWORTH, G.J.A. MURAD, B.L. HOH, M. RAHMAN (Gainesville, FL, USA). Anticancer Res 34: 565-574. 2014
MicroRNAs in Diffuse Large B-Cell Lymphoma: Implications for Pathogenesis, Diagnosis, Prognosis and Therapy.
K. TROPPAN, K. WENZL, A. DEUTSCH, H. LING, P. NEUMEISTER, M. PICHLER (Graz, Austria; Houston, TX, USA). Anticancer Res 34: 557-564. 2014
‘BRCAness’ and Its Implications for Platinum Action in Gynecologic Cancer. F. MUGGIA, T. SAFRA (New York, NY, USA; Tel Aviv, Israel). Anticancer Res 34: 551-556. 2014
Counseling Patients on Cancer Diets: A Review of the Literature and Recommendations for Clinical Practice.
J. HUEBNER, S. MARIENFELD, C. ABBENHARDT, C. ULRICH, K. MUENSTEDT, O. MICKE, R. MUECKE, C. LOESER (Frankfurt am Main; Heidelberg; Gießen; Bielefeld; Bochum; Kassel, Germany). Anticancer Res 34: 39-48. 2014
The Key Role of Bisphosphonates in the Supportive Care of Cancer Patients.
Nutrition and Pancreatic Cancer.
M. PERICLEOUS, R.E. ROSSI, D. MANDAIR, T. WHYAND, M.E. CAPLIN (London, UK; Milan, Italy). Anticancer Res 34: 9-21. 2014
The Interaction Between DAP1 and Autophagy in the Context of Human Carcinogenesis.
U. WAZIR, Z.S. KHANZADA, W.G. JIANG, A.K. SHARMA, A. KASEM, K. MOKBEL (London; Cardiff, Wales, UK). Anticancer Res 34: 1-8. 2014
Delivery Approaches of Gene Therapy in Hepatocellular Carcinoma.

F. DUAN, M.G.E.H. LAM (Beijing, China; Utrecht, Netherlands). Anticancer Res 33: 4711. 2013
State of the Art in the Treatment of Laryngeal Cancer.
F. JENCKE, R. KNECHT (Hamburg, Germany). Anticancer Res 33: 4701. 2013
Therapeutic Value of Quinazoline-based Compounds in Prostate Cancer.
J. BILBRO, M. MART, N. KYPRIANOU (Lexington, KY, USA). Anticancer Res 33: 4695. 2013
The Paradox of the Unfolded Protein Response in Cancer.
Saving Ears and Kidneys from Cisplatin.
K.U. WENSING, G. CIARIMBOLI (Münster, Germany). Anticancer Res 33: 4183. 2013
Musculoskeletal Sarcomas in the Forearm and Hand: Standard Treatment and Microsurgical Reconstruction for Limb Salvage.
K. MURAMATSU, K. IHARA, K. YOSHIDA, Y. TOMINAGA, T. HASHIMOTO, T. TAGUCHI (Ube; Shimonoseki, Yamaguchi, Japan). Anticancer Res 33: 4175. 2013
Chemoprevention of Prostate Cancer by Major Dietary Phytochemicals.
A. BOMMAREDDY, W. EGGLESTON, S. PRELEWICZ, A. ANTAL, Z. WITCZAK, D.F. MCCUNE, A.L. VANWERT (Wilkes-Barre, PA, USA). Anticancer Res 33: 4163. 2013
Epidermal Growth Factor Receptor (EGFR)-targeted Therapies in Esophagogastric Cancer.
S. AYYAPPAN, D. PRABHAKAR, N. SHARMA (Cleveland, OH, USA). Anticancer Res 33: 4139. 2013
The Value of Pemetrexed for the Treatment of Malignant Pleural Mesothelioma: A Comprehensive Review.
C. C.L.M. BOONS, M. W. VAN TULDER, J. A. BURGERS, J. J. BECKERINGH, C. WAGNER, J. G. HUGTENBURG (Amsterdam; Amstelveen; Utrecht, the Netherlands). Anticancer Res 33: 3553. 2013
Mitochondrial DNA Damage Is Uncommon in Cancer but Can Promote Aggressive Behaviour.
B. D. MAYBURY (Cardiff, U.K. ). Anticancer Res 33: 3543. 2013
Ubiquitination and the Ubiquitin – Proteasome System in the Pathogenesis and Treatment of Squamous Head and Neck Carcinoma.
I. A. VOUTSADAKIS (Sault Ste Marie, Canada). Anticancer Res 33: 3527. 2013
DNA Methyltransferase Inhibitors and Their Emerging Role in Epigenetic Therapy of Cancer.
A. GNYSZKA, Z. JASTRZĘBSKI, S. FLIS (Warsaw, Poland). Anticancer Res 33: 2989. 2013
Antineoplastic Activity of Zoledronic Acid and Denosumab.
P. ZWOLAK, A.Z. DUDEK (Chicago, IL, USA). Anticancer Res 33: 2981. 2013
Possible Therapeutic Targets Among the Molecules Involved in the Warburg Effect in Tumor Cells.
S. O. NAM, F. YOTSUMOTO, K. MIYATA, N. SHIRASU, S. MIYAMOTO, M. KUROKI (Fukuoka, Japan). Anticancer Res 33: 2855. 2013
Effects of Interactions between Intestinal Microbiota and Intestinal Macrophages on Health.
K. NAKATA, M. YAMAMOTO, H. INAGAWA, G. -I. SOMA (Soja; Kagawa; Tokushima, Japan). Anticancer Res 33: 2849. 2013
Lymph Node Evaluation and Survival in Colorectal Cancer: Review of Population-based, Prospective Studies.
Y. AKAGI, Y. ADACHI, T. KINUGASA, Y. OKA, T. MIZOBE, K. SHIROUZU (Fukuoka, Japan). Anticancer Res 33: 2839. 2013
Roles of ZFAT in Haematopoiesis, Angiogenesis and Cancer Development.
T. TSUNODA, S. SHIRASAWA (Fukuoka, Japan). Anticancer Res 33: 2833. 2013
Tumor-targeted Photodynamic Therapy.
N. SHIRASU, S. O. NAM, M. KUROKI (Fukuoka, Japan). Anticancer Res 33: 2823. 2013
Novel Curcumin Oral Delivery Systems.
T. KURITA, Y. MAKINO (Kagawa; Noda, Japan). Anticancer Res 33: 2807. 2013
Is there a Benefit from Addiction to Anti-VEGF Therapy in Patients with Colorectal Cancer?
M.W. SAIF(Boston, MA, USA). Anticancer Res 33: 2377. 2013
Endoscopic and Endobronchial Ultrasound-guided Needle Aspiration in the Mediastinal Staging of Non-small Cell Lung Cancer.
T. RAPTAKIS, P. BOURA, S. TSIMPOUKIS, I. GKIOZOS, K.N. SYRIGOS (Ierapetra; Athens, Greece). Anticancer Res 33: 2369. 2013
Inguinal Canal Tumors of Adulthood.
Junctional Adhesion Molecules in Cerebral Endothelial Tight Junction and Brain Metastasis.
W. JIA, T.A. MARTIN, G. ZHANG, W.G. JIANG (Beijing, PR China; Cardiff, UK). Anticancer Res 33: 2353. 2013
Denosumab and Anti-angiogenetic Drug-related Osteonecrosis of the Jaw: An Uncommon but Potentially Severe Disease.
S. SIVOLELLA, F. LUMACHI, E. STELLINI, L. FAVERO (Padova, Italy). Anticancer Res 33: 1793. 2013
Current Status in Chemotherapy for Advanced Pancreatic Adenocarcinoma.
H. CAO, D. LE, L.-X. YANG (San Francisco, CA, USA). Anticancer Res 33: 1785. 2013
In Vitro and In Vivo Experimental Models as Tools to Investigate the Efficacy of Antineoplastic Drugs on Urinary Bladder Cancer.
R. ARANTES-RODRIGUES, A. COLAÇO, R. PINTO-LEITE, P.A. OLIVEIRA (Vila Real, Portugal). Anticancer Res 33: 1273. 2013
The Influence of Glutamate Receptors on Proliferation and Metabolic Cell Activity of Neuroendocrine Tumors.
A Review on Biomarkers for Prediction of Treatment Outcome in Gastric Cancer.
Aryl Hydrocarbon Receptor and Lung Cancer.
J.J. TSAY, K.-M. TCHOU-WONG, A.K. GREENBERG, H. PASS, W.N. ROM (New York, NY, USA). Anticancer Res 33: 1247. 2013
Radiotherapy Targeting Cancer Stem Cells: Current Views and Future Perspectives.
K. OGAWA, Y. YOSHIOKA, F. ISOHASHI, Y. SEO, K. YOSHIDA, H. YAMAZAKI (Osaka; Kyoto, Japan). Anticancer Res 33: 747. 2013
Genistein and Daidzein: Different Molecular Effects on Prostate Cancer.
M. ADJAKLY, M. NGOLLO, J.-P. BOITEUX, Y.-J. BIGNON, L. GUY, D. BERNARD-GALLON (Clermont-Ferrand, France). Anticancer Res 33: 39. 2013
Vaginal Intraepithelial Neoplasia: A Therapeutical Dilemma.
The Mammalian Target of Rapamycin Inhibitors in Breast Cancer: Current Evidence and Future Directions.
P. MALAGUTI, S. VARI, F. COGNETTI, A. FABI (Rome, Italy). Anticancer Res 33: 21. 2013
Anticancer Efficacy of the Metabolic Blocker 3-Bromopyruvate: Specific Molecular Targeting.
S. GANAPATHY-KANNIAPPAN, R. KUNJITHAPATHAM, J.-F. GESCHWIND (Baltimore, MD, USA). Anticancer Res 33: 33. 2013
Neurofibromatosis Type 2 Protein, NF2: An Uncoventional Cell Cycle Regulator.
S. BELTRAMI, R. KIM, J. GORDON (Philadelphia, PA, USA). Anticancer Res 33: 1.2013). Anticancer Res 33: 1. 2013
HSP-Molecular Chaperones in Cancer Biogenesis and Tumor Therapy: An Overview.
Recent Trends in Epidemiology of Brain Metastases: An Overview.
E. TABOURET, O. CHINOT, P.METELLUS, A. TALLET, P. VIENS, A. GONÇALVES (Marseille, France). Anticancer Res 32: 4655
Biomarkers of Pituitary Neoplasms.
A. SAV, F. ROTONDO, L.V. SYRO, B.W. SCHEITHAUER, K. KOVACS (Istanbul, Turkey; Toronto, ON, Canada; Medellin, Colombia; Rochester, MN, USA). Anticancer Res 32: 4639
Utility of Hypertension as a Surrogate Marker for Efficacy of Antiangiogenic Therapy in NSCLC.
T. EVANS (Philadelphia, PA, USA). Anticancer Res 32: 4629
Mind the Gap; Regulation of Gap Junctional, Intercellular Communication by the Src OncogeneProduct and its Effectors.
M. GELETU, A. TROTMAN-GRANT, L. RAPTIS (Kingston, ON,Canada). Anticancer Res 32: 4245
Markers for Efficacy of Mammalian Target of Rapamycin Inhibitor.
Y.-M. LIAO, A. SY, Y. YEN (Taichung; * Taipei, Taiwan, ROC; Duarte, CA, USA). Anticancer Res 32: 4235
Regulation of Cancer Cell Survival by BCL2 Family Members upon Prolonged Mitotic Arrest: Opportunities * for Anticancer Therapy.
S. BARILLÉ-NION, N. BAH, E. VÉQUAUD, P. JUIN (Nantes; Saint Herblain-Nantes, France). Anticancer Res 32: 4225
Integrin Inhibitor Cilengitide for the Treatment of Glioblastoma:
A Brief Overview of Current Clinical Results. C. SCARINGI, G. MINNITI, P. CAPORELLO, R.M. ENRICI (Rome; Pozzilli, Italy). Anticancer Res 32: 4213
Viral and Molecular Aspects of Oral Cancer.
N.S. HILLBERTZ, J.-M. HIRSCH, J. JALOULI, M.M. JALOULI, L. SAND (Uppsala, Sweden). Anticancer Res 32: 4201
New Perspectives in the Treatment of Neuroendocrine Tumours.
E. BAJETTA, L. CATENA, M. VALENTE, N. BIANCO, F. BELLOMO, E. BOMBARDIERI (Monza; Milan, Italy). Anticancer Res 32: 4193
Nutrition in Adult and Childhood Cancer: Role of Carcinogens and Anti-carcinogens.
T.T. MOSBY, M. COSGROVE, S. SARKARDEI, K.L. PLATT, B. KAINA (Memphis, TN, USA; Mainz, Germany). Anticancer Res 32: 4171
The Role of Cetuximab in the Treatment of Metastatic Colorectal Cancer.
L. HOLUBEC, V.LISKA, V.M. MATEJKA, O. FIALA, J. DRESLEROVA, P. MRAZKOVA, V. TRESKA, J. FINEK(Prague, Czech Republic). Anticancer Res 32: 4007
A Review of Dose-dense Temozolomide Alone and in Combination with Bevacizumab in Patients with First Relapse of Glioblastoma.
F. JOHANSSON, S. EKMAN, E. BLOMQUIST, R. HENRIKSSON, S. BERGSTRØM, M. BERGQVIST (Uppsala; Umeå; Stockholm; Gävle, Sweden). Anticancer Res 32: 4001
Prediction of Recurrence after Complete Resection in Patients with NSCLC.
H. URAMOTO, F. TANAKA (Kitakyushu, Japan). Anticancer Res 32: 3953
Update on PEG-Interferon α-2b as Adjuvant Therapy in Melanoma.
MicroRNAs in Renal Cell Carcinoma: Implications for Pathogenesis, Diagnosis, Prognosis andTherapy.
B.M. AL-ALI, A.L. RESS, A. GERGER, M. PICHLER (Graz, Austria). Anticancer Res 32: 3727
From Development to Cancer: Lessons from the Kidney to Uncover New Therapeutic Targets.
V. DORMOY, D. JACQMIN, H. LANG, T. MASSFELDER (Strasbourg, France). Anticancer Res 32: 3609
Role of Androgen Excess in the Development of Estrogen Receptor-positive and Estrogen Receptor-negative Breast Cancer.
G. SECRETO, B. ZUMOFF (Milan, Italy; New York, NY, USA). Anticancer Res 32: 3223
Tumor Progression and Metastasis: Role of Translational Deregulation.
Z. NASR, J. PELLETIER(Montreal, QC, Canada). Anticancer Res 32: 3077
Sex Steroids and Cervical Cancer.
D. HELLBERG (Falun, Sweden). Anticancer Res 32: 3045
New Anticancer Agents: Recent Developments in Tumor Therapy.
R. ALI, Z. MIRZA, G.M.D. ASHRAF, M.A. KAMAL, S.A. ANSARI, G.A. DAMANHOURI, A.M. ABUZENADAH, A.G. CHAUDHARY, I.A. SHEIKH (New Delhi, India; Jeddah, Kingdom of Saudi Arabia). Anticancer Res 32: 2999
The Potential of RECK Inducers as Antitumor Agents for Glioma.
Y. CHEN, S.-H. TSENG (NewTaipei; Taoyuan; Taipei, Taiwan, ROC). Anticancer Res 32: 2991
Inhibitors of Bacterial Efflux Pumps that also Inhibit Efflux Pumps of Cancer Cells.
L. AMARAL,G. SPENGLER, A. MARTINS, A. ARMADA, J. HANDZLIK, K. KIEC-KONONOWICZ, J. MOLNÁR(Lisbon; Krakow, Portugal; Szeged, Hungary). Anticancer Res 32: 2947
New Molecularly Targeted Therapies for Glioblastoma Multiforme.
J. POLIVKA JR., J. POLIVKA,V. ROHAN, O. TOPOLCAN, J. FERDA (Pilsen, Czech Republic). Anticancer Res 32: 2935
Mafosfamide as a New Anticancer Agent: Preclinical Investigations and Clinical Trials.
L. MAZUR, M. OPYDO-CHANEK, M. STOJAK, K. WOJCIESZEK (Kracow, Poland). Anticancer Res 32: 2783
New Frontiers for Astrocytic Tumours.
R. NANO, A. LASCIALFARI, M. CORTI, A. PAOLINI, F. PASI, F. CORBELLA, R. DI LIBERTO (Pavia; Milan, Italy). Anticancer Res 32: 2755
Role of Melatonin in Cancer Treatment.
A. CUTANDO, A. LÓPEZ-VALVERDE, S. ARIAS- SANTIAGO, J. DE VICENTE, R. GÓMEZ DE DIEGO (Granada; Salamanca; Madrid, Spain). Anticancer Res 32: 2747
Tumor Cell-protective Catalase as a Novel Target for Rational Therapeutic Approaches Based on Specific Intercellular ROS Signaling.
G. BAUER (Freiburg, Germany). Anticancer Res 32: 2599
New Therapeutic Agents in Uveal Melanoma.
T.R. VELHO, E. KAPITEIJN, M.J. JAGER (Leiden, Netherlands). Anticancer Res 32: 2591
A Significant Role of Lipogenic Enzymes in Colorectal Cancer.
M. NOTARNICOLA, C. MESSA,M.G. CARUSO (Bari, Italy). Anticancer Res 32: 2585
Death by Design: Where Curcumin Sensitizes Drug-resistant Tumours.
S. SAHA, A. ADHIKARY,P. BHATTACHARYYA, T. DAS, G. SA (Kolkata, India). Anticancer Res 32: 2567
New Anticancer Agents: Hormones Made within the Heart.
D.L. VESELY (Tampa, FL, USA). Anticancer Res 32: 2515
Novel Radiosensitizing Anticancer Therapeutics.
A.G. LINKOUS, E.M. YAZLOVITSKAYA(Bethesda, MD; Nashville, TN, USA). Anticancer Res 32: 2487
Therapeutic Potential of Tranilast, an Anti-allergy Drug, in Proliferative Disorders.
M. ROGOSNITZKY, R. DANKS, E. KARDASH (Telz Stone, Israel; Steep, UK). Anticancer Res 32: 2471
PI3 Kinase Inhibitors in the Clinic: An Update.
J.-E. KURTZ, I. RAY-COQUARD (Strasbourg; Lyon, France). Anticancer Res 32: 2463
New Anticancer Immunotherapies.
H.A. FRANKS, Q. WANG, P.M. PATEL (Nottingham, UK). Anticancer Res 32: 2439
Novel Approaches in the Pharmacotherapy of Skeletal-related Events in Metastatic Castrate-resistant Prostate Cancer.
S. SPENCER, B.L. MARINI, W.D. FIGG (Bethesda, MD; Ann Arbor, MI, USA). Anticancer Res 32: 2391
Functional Design of Chimeric T-Cell Antigen Receptors for Adoptive Immunotherapy of Cancer:Architecture and Outcomes.
N. SHIRASU, M. KUROKI (Fukuoka, Japan). Anticancer Res 32: 2377
Regulatory Mechanisms of the HB-EGF Autocrine Loop in Inflammation, Homeostasis, Development and Cancer.
K. MIYATA, F. YOTSUMOTO, S.O. NAM, M. KUROKI, S. MIYAMOTO (Fukuoka, Japan). Anticancer Res 32: 2347
The Involvement of O-Antigen Polysaccharide in Lipopolysaccharide in Macrophage Activation.
M. SHIMADA, T. KADOWAKI, Y. TANIGUCHI, H. INAGAWA, K. OKAZAKI, G.-I. SOMA (Kagawa; Tokushima, Japan). Anticancer Res 32: 2337
Heat-shock Protein 27 Plays the Key Role in Gemcitabine-resistance of Pancreatic Cancer Cells.
Y. KURAMITSU, Y. WANG, K. TABA, S. SUENAGA, S. RYOZAWA, S. KAINO, I. SAKAIDA, K. NAKAMURA (Yamaguchi, Japan). Anticancer Res 32: 2295
Endometrial Cancer Stem Cells: A New Target for Cancer Therapy.
K. KATO (Tokyo, Japan). Anticancer Res 32: 2283
Reconsideration of Macrophage and Dendritic Cell Classification.
T. KADOWAKI, M. SHIMADA, H. INAGAWA, C. KOHCHI, M. HIRASHIMA, G.-I. SOMA (Kagawa; Chiba; Tokushima, Japan). Anticancer Res 32: 2257
Combining Cetuximab with Killer Lymphocytes Synergistically Inhibits Human Cholangiocarcinoma CellsIn Vitro.
T. MORISAKI, M. UMEBAYASHI, A. KIYOTA, N. KOYA, H. TANAKA, H. ONISHI,M. KATANO (Fukuoka, Japan). Anticancer Res 32: 2249
Cancer Immunotherapy Using NKG2D and DNAM-1 Systems.
T. MORISAKI, H. ONISHI,M. KATANO (Fukuoka, Japan). Anticancer Res 32: 2241
Surgery for Advanced and Metastatic Pancreatic Cancer – Current State and Trends.
M.F. NENTWICH, M. BOCKHORN, A. KÖNIG, J.R. IZBICKI, G. CATALDEGIRMEN (Hamburg, Germany). Anticancer Res 32: 1999
The Interplay between Hemostasis and Malignancy: The Oral Cancer Paradigm.
C. YAPIJAKIS, A. BRAMOS, A.M. NIXON, V. RAGOS, E. VAIRAKTARIS (Athens, Greece). Anticancer Res 32: 1791
Improved Chemotherapy for Hepatocellular Carcinoma.
H. CAO, H. PHAN, L.-X. YANG (San Francisco, CA, USA). Anticancer Res 32: 1379
Multiple Associations Between a Broad Spectrum of Autoimmune Diseases, Chronic InflammatoryDiseases and Cancer.
A.L. FRANKS, J.E. SLANSKY (Aurora, CO, USA). Anticancer Res 32: 1119
Chemoprevention of Asbestos-linked Cancers: A Systematic Review.
M. NERI, D. UGOLINI, S. BOCCIA, P.A. CANESSA, A. CESARIO, G. LEONCINI, L. MUTTI, S. BONASSI (Rome; Genova; Sarzana; Vercelli, Italy). Anticancer Res 32: 1005
Immunotherapy Approaches Targeting Regulatory T-Cells.
H. ONISHI, T. MORISAKI, M. KATANO (Fukuoka, Japan). Anticancer Res 32: 997
Gastrointestinal Surgical Oncology. Personal Experience in the Context of Current Knowledge and Future Perspectives.
L. NESPOLI, F. UGGERI, F. ROMANO, A. NESPOLI, F. BRIVO, L. FUMAGALLI, M. SARGENTI, F. UGGERI, L. GIANOTTI (Monza; Cinisello Balsamo; Lecco; Milan, Italy). Anticancer Res 32: 989
Is Surgical Trauma Prometastatic?
F.J. LEJEUNE (Lausanne, Switzerland). Anticancer Res 32: 947
Improved Radiotherapy for Primary and Secondary Liver Cancer: Stereotactic Body Radiation Therapy.
C. TAO, L.-X. YANG (San Francisco, CA, USA). Anticancer Res 32: 649
Tumor Interstitial Fluid as Modulator of Cancer Inflammation, Thrombosis, Immunity and Angiogenesis.
G. BARONZIO, L. SCHWARTZ, M. KISELEVSKY, A. GUAIS, E. SANDERS, G. MILANESI, M. BARONZIO, I. FREITAS (Milan; Pavia, Italy; Garches; Paris, France; Moscow, Russia). Anticancer Res 32: 405
Role of the Apoptotic and Mitotic Regulator Survivin in Melanoma.
J.A. MCKENZIE, D. GROSSMAN (Salt Lake City, UT, USA). Anticancer Res 32: 397
Optimal Serum Calcidiol Concentration for Cancer Prevention.
P. TUOHIMAA, Y.-R. LOU (Tampere; Helsinki, Finland). Anticancer Res 32: 373
Vitamin D and Cellular Ca2+ Signaling in Breast Cancer.
I.N. SERGEEV (Brookings, SD, USA). Anticancer Res 32: 299
The Roles of Cytochrome P450 Enzymes in Prostate Cancer Development and Treatment.
T.C.CHEN, T. SAKAKI, K. YAMAMOTO, A. KITTAKA (Boston, MA, USA; Toyama; Tokyo; Sagamihara, Kanagawa, Japan). Anticancer Res 32: 291
Vitamin D Receptor Expression in Patients with Vulvar Cancer.
D. SALEHIN, C. HAUGK, M. THILL, T. CORDES, M. WILLIAM, B. HEMMERLEIN, M. FRIEDRICH (Krefeld; Lübeck, Germany). Anticancer Res 32: 283
The Scots’ Paradox: Can Sun Exposure, or Lack of it, Explain Major Paradoxes in Epidemiology?
O. GILLIE (London, UK). Anticancer Res 32: 237
Ecological Studies of the UVB.Vitamin D. Cancer Hypothesis.
W.B. GRANT (San Francisco, CA, USA). Anticancer Res 32: 223
Novel Therapeutic Approaches for Targeting Tumor Angiogenesis.
A.G. LINKOUS, E.M. YAZLOVITSKAYA (Bethesda, MD; Nashville, TN, USA). Anticancer Res 32: 1
Targeting AKT Protein Kinase in Gastric Cancer.
K. ALMHANNA, J. STROSBERG, M. MALAFA(Tampa, FL, USA). Anticancer Res 31: 4387. 2011
Estrogen Pathway Polymorphisms and Mammographic Density.
I. DUMAS, C. DIORIO (QuebecCity, QC, Canada). Anticancer Res 31: 4369. 2011
Impact of Cyclooxygenase-2 in Breast Cancer.
F. HOELLEN, K. KELLING, C. DITTMER, K. DIEDRICH, M. FRIEDRICH, M. THILL (Luebeck; Krefeld, Germany). Anticancer Res 31: 4359. 2011
Electrotransfer of RNAi-based Oligonucleotides for Oncology.
S. CHABOT, S. PELOFY, A. PAGANIN-GIOANNI, J. TEISSIE, M. GOLZIO (Toulouse, France). Anticancer Res 31: 4083. 2011
Rho Kinase Proteins—Pleiotropic Modulators of Cell Survival and Apoptosis.
C.A. STREET, B.A. BRYAN (Worcester, MA; El Paso, TX, USA). Anticancer Res 31: 3645. 2011
The Role of Chemotherapy in Metastatic Gastric Cancer.
F. PASINI, A.P. FRACCON, G. DE MANZONI (Rovigo; Verona, Italy). Anticancer Res 31: 3543. 2011
The Prognostic Role of Lymphovascular Invasion in Urothelial-cell Carcinoma of Upper and LowerUrinary Tract.
E. BRUNOCILLA, R. PERNETTI, G. MARTORANA (Bologna, Italy). Anticancer Res 31: 3503. 2011
No Detection of BK Virus, JC Virus, KI, WU and Merkel Cell Polyomaviruses in Cerebrospinal Fluid of Patients with Neurological Complications after Hematopoetic Stem Cell Transplantation.
J. RUBIN, G. GIRAUD, P. PRIFTAKIS, K. WIDE, B. GUSTAFSSON, T. RAMQVIST, T. DALIANIS (Stockholm; Eskilstuna, Sweden). Anticancer Res 31: 3489. 2011
CT and MR Imaging of the Adrenal Glands in Cortisol-secreting Tumors.
F. LUMACHI, P. MARCHESI, D. MIOTTO, R. MOTTA (Padova, Italy). Anticancer Res 31: 2923. 2011
The Mutational Profile of Sporadic Epithelial Ovarian Carcinoma.
S. KALAMANATHAN, V.BATES, R. LORD, J.A. GREEN (Liverpool; Wirral, Merseyside, UK). Anticancer Res 31: 2661. 2011
Cell-free DNA in the Circulation as a Potential Cancer Biomarker.
C. KOHLER, Z. BAREKATI,R. RADPOUR, X.Y. ZHONG (Basel, Switzerland). Anticancer Res 31: 2623. 2011
Lipopolysaccharide IP-PA1 from Pantoea agglomerans Prevents Suppression of Macrophage Function in Stress-induced Diseases.
K. NAKATA, H. INAGAWA, G.-I. SOMA (Okayama; Kagawa; Tokushima, Japan). Anticancer Res 31: 2437. 2011
Oral Administration of Lipopolysaccharides for the Prevention of Various Diseases: Benefit and Usefulness.
H. INAGAWA, C. KOHCHI, G.-I. SOMA (Kagawa-ken; Chiba-ken; Tokushima-ken, Japan). Anticancer Res 31: 2431. 2011
Sonodynamic Cancer Therapy: A Non-invasive and Repeatable Approach Using Low-intensity Ultrasound with a Sonosensitizer.
H. SHIBAGUCHI, H. TSURU, MOTOMU KUROKI, MASAHIDE KUROKI (Fukuoka, Japan). Anticancer Res 31: 2425. 2011
KRAS-induced Actin-interacting Protein: A Potent Target for Obesity, Diabetes and Cancer.
T. FUJIMOTO, S. SHIRASAWA (Fukuoka, Japan). Anticancer Res 31: 2413. 2011
Endoglin (CD105): A Review of its Role in Angiogenesis and Tumor Diagnosis, Progression andTherapy.
F. NASSIRI, M.D. CUSIMANO, B.W. SCHEITHAUER, F. ROTONDO, A. FAZIO, G.M. YOUSEF, L.V. SYRO, K. KOVACS, R.V. LLOYD (Toronto, ON, Canada; Rochester, MN; Madison, WI,USA; Medellin, Colombia). Anticancer Res 31: 2283. 2011
Disseminated and Circulating Tumor Cells for Monitoring Chemotherapy in Urological Tumors.
S. KRUCK, G. GAKIS, A. STENZL (Tuebingen, Germany). Anticancer Res 31: 2053. 2011
Current Concepts in the Non-operative Management of Rectal Cancer after NeoadjuvantChemoradiation.
G. SINGH-RANGER, D. KUMAR (London, UK). Anticancer Res 31: 1795. 2011
An Epidemic of Oropharyngeal Squamous Cell Carcinoma (OSCC) Due to Human Papillomavirus(HPV) Infection and Aspects of Treatment and Prevention.
T. RAMQVIST, T. DALIANIS (Stockholm, Sweden). Anticancer Res 31: 1515. 2011
The Involvement of Retroperitoneal Lymph Nodes in Primary Serous-papillary Peritoneal Carcinoma.
P.R. STEINHAGEN, J. SEHOULI (Berlin, Germany). Anticancer Res 31: 1387. 2011
The Involvement of Retroperitoneal Lymph Nodes in Primary Serous-papillary Peritoneal Carcinoma. A Systematic Review of the Literature.
P.R. STEINHAGEN, J. SEHOULI (Berlin, Germany). Anticancer Res 31: 1387-1394, 2011.
Potential Tumor-tropic Effect of Genetically Engineered Stem Cells Expressing Suicide Enzymes to Selectively Target Invasive Cancer in Animal Models.
S.U. KIM, E.-B. JEUNG, Y.-B. KIM, M.-H. CHO, K.-C. CHOI (Vancouver, BC, Canada; Chungbuk; Seoul, South Korea). Anticancer Res 31: 1249-1258, 2011.
Body Fluid Biomarkers for Early Detection of Head and Neck Squamous Cell Carcinomas.
K.-D. LEE, H.-S. LEE, C.-H. JEON (Busan; Daegu, South Korea). Anticancer Res 31: 1161-1168, 2011.
Targeting Notch to Eradicate Pancreatic Cancer Stem Cells for Cancer Therapy.
Z. WANG, A. AHMAD, Y. LI, A.S. AZMI, L. MIELE, F.H. SARKAR (Detroit, MI; Jackson, MS, USA). Anticancer Res 31: 1105-1114, 2011.
Full Myeloablative Conditioning and an Unrelated HLA Mismatched Donor Increase the Risk for BK Virus-positive Hemorrhagic Cystitis in Allogeneic Hematopoietic Stem Cell Transplanted Patients.
T. DALIANIS, P. LJUNGMAN (Stockholm, Sweden). Anticancer Res 31: 939-944, 2011.
Influencing the Wnt Signaling Pathway in Multiple Myeloma.
Y. KIM, G. REIFENBERGER, D. LU, T. ENDO, D.A. CARSON, S.-M. GAST, K. MESCHENMOSER, M. NOWAK, I.G.H. SCHMIDT- WOLF (Bonn; Duesseldorf, Germany; La Jolla, CA, USA; Sapporo, Hokkaido, Japan). Anticancer Res 31: 725-730, 2011.
The Need for Third-line Treatment in Non-small Cell Lung Cancer: An Overview of New Options.
K.N. SYRIGOS, M.W. SAIF, E.M. KARAPANAGIOTOU, G. OIKONOMOPOULOS, F. DE MARINIS (Athens, Greece; New Haven; New York, NY, USA; Rome, Italy). Anticancer Res 31: 649-660, 2011.
Prediction of Response in Cancer Immunotherapy.
D. CHARACIEJUS, J.J.L. JACOBS, V. PASUKONIENÖ, N. KAZLAUSKAITÖ, V. DANILEVICIÜTÖ, M. MAURICAS, W. DEN OTTER (Vilnius, Lithuania; Amsterdam, The Netherlands). Anticancer Res 31: 639-648, 2011.
The Role of Pelvic Lymph Node Dissection During Radical Cystectomy for Bladder Cancer.
E. BRUNOCILLA, R. PERNETTI, G. MARTORANA (Bologna, Italy). Anticancer Res 31: 271-276, 2011.
Ectomesenchymal Chondromyxoid Tumour of the Tongue. A Review of Histological and Immunohistochemical Features.
F. ANGIERO (Monza, Italy). Anticancer Res 30: 4685-4690, 2010.
Ras Mutational Status Is a Biomarker for Resistance to EGFR Inhibitors in Colorectal Carcinoma.
W.C.M. DEMPKE, V. HEINEMANN (Riesa; Munich, Germany). Anticancer Res 30: 4673-4678, 2010.
Brivanib, A Novel Dual VEGF-R2/bFGF-R Inhibitor.
W.C.M. DEMPKE, R. ZIPPEL (Riesa, Germany). Anticancer Res 30: 4477-4484, 2010.
Poly-N-acetyl Glucosamine Gel Matrix as a Non-viral Delivery Vector for DNA-based Vaccination.
M.L. SALEM, M. DEMCHEVA, W.E. GILLANDERS, D.J. COLE, J.N. VOURNAKIS (Charleston, SC; Danvers, MA; Saint Louis, MO, USA). Anticancer Res 30: 3889-3894, 2010.
The Evolving Role of Radiofrequency Ablation Therapy of Breast Lesions.
B. SOUKUP, S. BISMOHUN, S. REEFY, K. MOKBEL (London, UK). Anticancer Res 30: 3693-3698, 2010.
Active Surveillance for Low-risk Prostate Cancer.
R. MAZZUCCHELLI, I. NESSERIS, L. CHENG, A. LOPEZ-BELTRAN, R. MONTIRONI, M. SCARPELLI (Ancona, Italy; Ioannina, Greece; Indianapolis, IN, USA; Cordoba, Spain). Anticancer Res 30: 3683-3692, 2010.
Novel Chemoradiosensitizers for Cancer Therapy.
P. PAGE, L.-X. YANG (San Francisco, CA, USA). Anticancer Res 30: 3675-3682, 2010.
Medicinal Electronomics Bricolage Design of Hypoxia-targeting Antineoplastic Drugs and Invention of Boron Tracedrugs as Innovative Future-architectural Drugs.
H. HORI, Y. UTO, E. NAKATA (Tokushima, Japan). Anticancer Res 30: 3233-3242, 2010.
Multiple Roles of the ERCC1-XPF Endonuclease in DNA Repair and Resistance to Anticancer Drugs.
K. KIRSCHNER, D.W. MELTON (Cambridge; Edinburgh, UK). Anticancer Res 30: 3223-3232, 2010.
Recovery from Immunosuppression-related Disorders in Humans and Animals by IP-PA1, An Edible Lipopolysaccharide.
T. HEBISHIMA, Y. MATSUMOTO, G. WATANABE, G.-I. SOMA, C. KOHCHI, K. TAYA, Y. HAYASHI, Y. HIROTA (Tokyo; Tokushima; Kagawa; Gifu, Japan). Anticancer Res 30: 3113-3118, 2010.
Emerging Strategies for ErbB Ligand-based Targeted Therapy for Cancer.
H. TSUJIOKA, F. YOTSUMOTO, K. SHIROTA, S. HORIUCHI, T. YOSHIZATO, M. KUROKI, S. MIYAMOTO (Fukuoka, Japan). Anticancer Res 30: 3107-3112, 2010.
Validation of Blood Testing for K-ras Mutations in Colorectal and Pancreatic Cancer.
M. ROGOSNITZKY, R. DANKS (Telz Stone, Israel; Steep, UK). Anticancer Res 30: 2943-2948, 2010.
Liver Regeneration and its Impact on Post-hepatectomy Metastatic Tumour Recurrence.
K.A. PASCHOS, N.C. BIRD (Sheffield, UK). Anticancer Res 30: 2161-2170, 2010.
An Overview of Nanotechnology-based Functional Proteomics for Cancer and Cell Cycle Progression.
C. NICOLINI, E. PECHKOVA (Genoa; Rome, Italy). Anticancer Res 30: 2073- 2080, 2010.
On the Origin and Growth of Gliomas.
D. SCHIFFER, L. ANNOVAZZI, V. CALDERA, M. MELLAI (Turin, Italy). Anticancer Res 30: 1977-1998, 2010.
Metabolism in Cancer Patients.
J. ARENDS (Freiburg, Germany). Anticancer Res 30: 1863- 1868, 2010.
Evidence-based Complementary Oncology: Innovative Approaches to Optimise Standard Therapy Strategies.
J. BEUTH (Cologne, Germany). Anticancer Res 30: 1767-1772, 2010.
Clear Cell Carcinoma of the Endometrium: A Biological and Clinical Enigma.
A. GADDUCCI, S. COSIO, N. SPIRITO, L. CIONINI (Pisa, Italy). Anticancer Res 30: 1327-1334, 2010.
Erlotinib in the Treatment of Non-small Cell Lung Cancer: Current Status and Future Developments.
C. GRIDELLI, P. MAIONE, M.A. BARESCHINO, C. SCHETTINO, P.C. SACCO, R. AMBROSIO, V. BARBATO, M. FALANGA, A. ROSSI (Avellino, Italy). Anticancer Res 30: 1301- 1310, 2010.
Gamma-glutamyltransferase of Cancer Cells at the Crossroads of Tumor Progression, Drug Resistance and Drug Targeting.
A. CORTI, M. FRANZINI, A. PAOLICCHI, A. POMPELLA (Pisa, Italy). Anticancer Res 30: 1169-1182, 2010.
Role of Regulatory T-cells in H. pylori-induced Gastritis and Gastric Cancer.
A. KANDULSKI, P. MALFERTHEINER, T. WEX (Magdeburg, Germany). Anticancer Res 30: 1093-1104, 2010.
Neoadjuvant Chemotherapy in Barrett's Carcinoma – Prognosis and Response Prediction.
M. SCHAUER, W.T. KNOEFEL (Duesseldorf, Germany). Anticancer Res 30: 1065-1070, 2010.
Environmental Oestrogens and Breast Cancer: Evidence for Combined Involvement of Dietary, Household and Cosmetic Xenoestrogens.
P.D. DARBRE, A.K. CHARLES (Reading, UK). Anticancer Res 30: 815-828, 2010.
Association Between Birt Hogg Dubé Syndrome and Cancer Predisposition.
Reducing Anastomotic Leakage in Oncologic Colorectal Surgery: An Evidence-based Review.
M.A. BOCCOLA, J. LIN, W.M. ROZEN, Y.-H. HO (Queensland, Australia). Anticancer Res February 30: 601-608, 2010.
Epithelial–Stromal Interaction in Squamous Cell Epithelium-derived Tumors: An Important New Player in the Control of Tumor Biological Properties.
J. PLZAK, L. LACINA, M. CHOVANEC, B. DVORANKOVA, P. SZABO, Z. CADA, K. SMETANA, Jr. (Prague, Czech Republic). Anticancer Res 30: 455-462, 2010.
Lessons from Immune Responses and Vaccines against Murine Polyomavirus Infection and Polyomavirus-induced Tumours Potentially Useful for Studies on Human Polyomaviruses.
T. RAMQVIST, T. DALIANIS (Stockholm, Sweden). Anticancer Res 30: 279-284, 2010.
A Novel Strategy by Cryoablation for Advanced Hepatoma.
S. OSADA, K. YOSHIDA, S. SAJI (Gifu, Japan). Anticancer Res 29: 5203-5210, 2009.
Chemotherapy for Glioblastoma: Current Treatment and Future Perspectives for Cytotoxic and Targeted Agents.
G. MINNITI, R. MUNI, G. LANZETTA, P. MARCHETTI, R. MAURIZI ENRICI (Rome; Pozzilli (IS), Italy). Anticancer Res 29: 5171-5184, 2009.
Pathology of Prostate Cancer and Focal Therapy (‘Male Lumpectomy’).
R. MAZZUCCHELLI, M. SCARPELLI, L. CHENG, A. LOPEZ-BELTRAN, A.B. GALOSI, Z. KIRKALI, R. MONTIRONI (Ancona, Italy; Indianapolis, IN, USA; Cordoba, Spain; Izmir, Turkey). Anticancer Res 29: 5155-5162, 2009.
L1-CAM as a Target for Treatment of Cancer with Monoclonal Antibodies.
U.H. WEIDLE, D. EGGLE, S. KLOSTERMANN (Penzberg, Germany). Anticancer Res 29: 4919-4932, 2009.
Efficacy of Ligand-based Targeting for the EGF System in Cancer.
F. YOTSUMOTO, A. SANUI, T. FUKAMI, K. SHIROTA, S. HORIUCHI, H. TSUJIOKA, T. YOSHIZATO, M. KUROKI, S. MIYAMOTO (Fukuoka, Japan). Anticancer Res 29: 4879-4886, 2009.
Improvement of Allergic Dermatitis via Regulation of the Th1/Th2 Immune System Balance by Macrophages Activated with Lipopolysaccharide Derived from Pantoea agglomerans (IP-PA1).
A. YOSHIDA, C. KOHCHI, H. INAGAWA, T. NISHIZAWA, G.-I. SOMA (Tokushima; Kagawa; Chiba; Yamaguchi, Japan). Anticancer Res 29: 4867-4870, 2009.
Intestinal Macrophages Involved in the Homeostasis of the Intestine Have the Potential for Responding to LPS.
N. YOSHIOKA, Y. TANIGUCHI, A. YOSHIDA, K. NAKATA, T. NISHIZAWA, H. INAGAWA, C. KOHCHI, G.-I. SOMA (Tokushima; Kagawa; Okayama; Yamaguchi; Chiba, Japan). Anticancer Res 29: 4861-4866, 2009.
Mechanism for Maintaining Homeostasis in the Immune System of the Intestine.
Y. TANIGUCHI, N. YOSHIOKA, K. NAKATA, T. NISHIZAWA, H. INAGAWA, C. KOHCHI, G.-I. SOMA (Tokushima; Kagawa; Okayama; Yamaguchi; Chiba, Japan). Anticancer Res 29: 4855- 4860, 2009.
Anti-glioma Therapy with Temozolomide and Status of the DNA-Repair Gene MGMT.
T. FUKUSHIMA, H. TAKESHIMA, H. KATAOKA (Miyazaki, Japan). Anticancer Res 29: 4845-4854, 2009.
Tumour Biology: Tumour-associated Inflammation versus Antitumor Immunity.
B. MÜLLERHÜBENTHAL, M. AZEMAR, D. LORENZEN, M. HUBER, M.A FREUDENBERG, C. GALANOS, C. UNGER, B. HILDENBRAND (Freiburg; Duderstadt; Aachen, Germany). Anticancer Res 29: 4795-4806, 2009.
Immunological Similarities between Cancer and Chronic Fatigue Syndrome: The Common Link to Fatigue?
M. MEEUS, W. MISTIAEN, L. LAMBRECHT, J. NIJS (Antwerp; Brussels, Ghent, Belgium). Anticancer Res 29: 4717-4726, 2009.
Cancer Nanotargeted Radiopharmaceuticals for Tumor Imaging and Therapy.
G. TING, C.-H. CHANG, H.-E. WANG (Miaoli; Taoyuan; Taipei, Taiwan, ROC). Anticancer Res 29: 4107-4118, 2009.
Telomeres and Telomerase in Sarcomas.
T. MATSUO, S. SHIMOSE, T. KUBO, J. FUJIMORI, Y. YASUNAGA, M. OCHI (Hiroshima, Japan). Anticancer Res 29: 3833-3836, 2009.
Role of MGMT in Tumor Development, Progression, Diagnosis, Treatment and Prognosis.
S. SHARMA, F. SALEHI, B.W. SCHEITHAUER, F. ROTONDO, L.V. SYRO, K. KOVACS (Toronto, ON, Canada; Rochester, NY, USA; Medellin, Colombia). Anticancer Res 29: 3759-3768, 2009.
Modulation of Vitamin D Synthesis and Catabolism in Colorectal Mucosa: A New Target for Cancer Prevention.
H.S. CROSS, T. NITTKE, M. PETERLIK (Vienna, Austria). Anticancer Res 29: 3705-3712, 2009.
Epidemiology of Vitamin D Insufficiency and Cancer Mortality.
S. PILZ, A. TOMASCHITZ, B. OBERMAYER-PIETSCH, H. DOBNIG, T.R. PIEBER (Graz, Austria). Anticancer Res 29: 3699-3704, 2009.
Calcium, Vitamin D and Cancer.
M. PETERLIK, W.B. GRANT, H.S. CROSS (Vienna, Austria; San Francisco, CA, USA). Anticancer Res 29: 3687-3698, 2009.
How to Optimize Vitamin D Supplementation to Prevent Cancer, Based on Cellular Adaptation and Hydroxylase Enzymology.
R. VIETH (Toronto, ON, Canada). Anticancer Res 29: 2675-2684, 2009.
Current Impediments to Acceptance of the Ultraviolet-B-Vitamin D-Cancer Hypothesis.
W.B. GRANT, B.J. BOUCHER (San Francisco, CA, USA; London, UK). Anticancer Res 29: 3597- 3604, 2009.
The Relevance of Vitamin D Receptor (VDR) Gene Polymorphisms for Cancer: A Review of the Literature.
K. KÖSTNER, N. DENZER, C.S.L. MÜLLER, R. KLEIN, W. TILGEN, J. REICHRATH (Homburg; Kaiserslautern, Germany). Anticancer Res 29: 3511-3536, 2009.
Solar Radiation, Vitamin D and Cancer Incidence and Mortality in Norway.
J. MOAN, A. DAHLBACK, Z. LAGUNOVA, E. CICARMA, A.C. POROJNICU (Oslo, Norway). Anticancer Res 29: 3501-3510, 2009.
Sun and Sun Beds: Inducers of Vitamin D and Skin Cancer.
E. CICARMA, A.C. POROJNICU, Z. LAGUNOVA, A. DAHLBACK, A. JUZENIENE, J. MOAN (Oslo, Norway). Anticancer Res 29: 3495-3500, 2009.
A Genomic Perspective on Vitamin D Signaling.
C. CARLBERG, S. SEUTER (Luxembourg; Kuopio, Finland). Anticancer Res 29: 3485-3494, 2009.
The Impact of 1,25(OH)2D3 and its Structural Analogs on Gene Expression in Cancer Cells - A Microarray Approach.
C. KRIEBITZSCH, L. VERLINDEN, G. EELEN, B.K. TAN, M. VAN CAMP, R. BOUILLON, A. VERSTUYF (Leuven, Belgium). Anticancer Res 29: 3471-3484, 2009.
Current and Future Options in the Treatment of Malignant Ascites in Ovarian Cancer.
H. WOOPEN, J. SEHOULI (Berlin, Germany). Anticancer Res 29: 3353-3360, 2009.
New Molecular Biomarkers for the Prognosis and Management of Prostate Cancer – The Post PSA Era.
B. BICKERS, C. AUKIM-HASTIE (Portsmouth, Hampshire, UK). Anticancer Res 29: 3289-3298, 2009.
Controversies in the Management of Ovarian Cancer – Pros and Cons for Lymph Node Dissection in Ovarian Cancer.
O. CAMARA, J. SEHOULI (Berlin, Germany). Anticancer Res 29: 2837-2844, 2009.
Pros and Cons of Intraperitoneal Chemotherapy in the Treatment of Epithelial Ovarian Cancer.
A.G. ZEIMET, D. REIMER, A.C. RADL, A. REINTHALLER, C. SCHAUER, E. PETRU, N. CONCIN, S. BRAUN, C. MARTH (Innsbruck; Vienna; Graz, Austria). Anticancer Res 29: 2803- 2808, 2009.
Evidence-based Perioperative Management: Strategic Shifts in Times of Fast Track Surgery.
S.S. CHOPRA, S.C. SCHMIDT, C. FOTOPOULOU, J. SEHOULI, G. SCHUMACHER (Berlin, Germany). Anticancer Res 29: 2799-2802, 2009.
Brain Metastases from Epithelial Ovarian Cancer: Overview and Optimal Management.
K. PIETZNER, G. OSKAY-OEZCELIK, K. EL KHALFAOUI, D. BOEHMER, W. LICHTENEGGER, J. SEHOULI (Berlin, Germany). Anticancer Res 29: 2793-2798, 2009.
Colorectal Cancer and Inflammatory Bowel Disease: Epidemiology, Risk Factors, Mechanisms of Carcinogenesis and Prevention Strategies.
J.K. TRIANTAFILLIDIS, G. NASIOULAS, P.A. KOSMIDIS (Athens, Greece). Anticancer Res 29: 2727-2738, 2009.
Novel Strategy of Anti-angiogenic Therapy for Uterine Cervical Carcinomas.
J. FUJIMOTO (Gifu, Japan). Anticancer Res 29: 2665-2670, 2009.
New Markers and Multivariate Models for Prostate Cancer Detection.
C. STEPHAN, H. RITTENHOUSE, H. CAMMANN, M. LEIN, M. SCHRADER, S. DEGER, K. MILLER, K. JUNG (Berlin, Germany; Diego, CA, USA). Anticancer Res 29: 2589-2600, 2009.
Immunobiological and Experimental Aspects of Malignant Astrocytoma.
R. NANO, E. CAPELLI, A. FACOETTI, E. BENERICETTI (Pavia; Parma, Italy). Anticancer Res 29: 2461-2466, 2009.
Proton Transport Inhibitors as Potentially Selective Anticancer Drugs.
S. HARGUINDEY, J.L. ARRANZ, M.L. WAHL, G. ORIVE, S.J. RESHKIN (Vitoria, Spain; Durham, NC, USA; Bari, Italy). Anticancer Res 29: 2127-2136, 2009.
Heat-shock Protein 90 (Hsp90) as a Molecular Target for Therapy of Gastrointestinal Cancer.
C. MOSER, S.A. LANG, O. STOELTZING (Regensburg; Mainz, Germany). Anticancer Res 29: 2031-2042, 2009.
Tissue Transglutaminase Promotes or Suppresses Tumors Depending on Cell Context.
A. CHHABRA, A. VERMA, K. MEHTA (Houston, TX, USA). Anticancer Res 29: 1909-1920, 2009.
Molecular Imaging of Tumor Blood Vessels in Prostate Cancer.
D. TILKI, M. SEITZ, B.B. SINGER, S. IRMAK, C.G. STIEF, O. REICH, S. ERGÜN (Munich; Essen, Germany; New York, NY, USA). Anticancer Res 29: 1823-1830, 2009.
Cancer-induced Hypercalcemia.
F. LUMACHI, A. BRUNELLO, A. ROMA, U. BASSO (Padova, Italy). Anticancer Res 29: 1551-1556, 2009.
Genetic and Molecular Abnormalities in Cholangiocarcinogenesis.
V.J. HASSID, F.A. ORLANDO, Z.T. AWAD, D. TAN, T. KHOURY, B.H. AHMED, S.J. ALRAWI (Jacksonville; Gainesville, FL; Houston, TX; Buffalo, NY, USA). Anticancer Res 29: 1151-1156, 2009.
Oestrogen-synthesising Enzymes and Breast Cancer.
M. KULENDRAN, M. SALHAB, K. MOKBEL (London; Uxbridge, Middlesex, UK). Anticancer Res 29: 1095-1110, 2009.
RUNX1 Translocations in Malignant Hemopathies.
E. DE BRAEKELEER, C. FÉREC, M. DE BRAEKELEER (Brest, France). Anticancer Res 29: 1031-1038, 2009.
The Role of Toll-like Receptor 2 in Survival Strategies of Mycobacterium tuberculosis in Macrophage Phagosomes.
A. YOSHIDA, H. INAGAWA, C. KOHCHI, T. NISHIZAWA, G.-I. SOMA (Tokushima; Chiba; Yamaguchi; Kagawa, Japan). Anticancer Res 29: 907-910, 2009.
Utility and Safety of LPS-based Fermented Flour Extract as a Macrophage Activator.
Y. TANIGUCHI, N. YOSHIOKA, T. NISHIZAWA, H. INAGAWA, C. KOHCHI, G.-I. SOMA (Tokushima; Kagawa; Yamaguchi; Chiba, Japan). Anticancer Res 29: 859-864, 2009.
Potential for Molecularly Targeted Therapy against Epidermal Growth Factor Receptor Ligands.
S. MIYAMOTO, T. FUKAMI, H. YAGI, M. KUROKI, F. YOTSUMOTO (Fukuoka, Japan). Anticancer Res 29: 823-830, 2009.
ROS and Innate Immunity.
C. KOHCHI, H. INAGAWA, T. NISHIZAWA, G.-I. SOMA (Kagawa- ken; Tokushima-ken; Chibaken; Yamaguchi-ken, Japan). Anticancer Res 29: 817-822, 2009.
High-dose Vitamin C (Ascorbic Acid) Therapy in the Treatment of Patients with Advanced Cancer.
S. OHNO, Y. OHNO, N. SUZUKI, G.-I. SOMA, M. INOUE (Ishikawa; Tokushima; Chiba; Kagawa, Japan). Anticancer Res 29: 809-816, 2009.
Inhibition of Cancer Invasion and Metastasis by Targeting the Molecular Chaperone Heat- shock Protein 90.
F. KOGA, K. KIHARA, L. NECKERS (Tokyo, Japan; Bethesda, MD, USA). Anticancer Res 29: 797-808, 2009.
Genetic Polymorphisms of Smoking-related Carcinogen Detoxifying Enzymes and Head and Neck Cancer Susceptibility.
M. LACKO, M.B. OUDE OPHUIS, W.H.M. PETERS, J.J. MANNI (Maastricht; Nijmegen, The Netherlands). Anticancer Res 29: 753-762, 2009.
Therapy-induced Toxicity of the Lungs: An Overview.
A.G. CHARPIDOU, I. GKIOZOS, S. TSIMPOUKIS, D. APOSTOLAKI, K.D. DILANA, E.M. KARAPANAGIOTOU, K.N. SYRIGOS (Athens, Greece). Anticancer Res 29: 631-640, 2009.
Chronic Lymphocytic Leukaemia.
J. BOELENS, S. LUST, B. VANHOECKE, F. OFFNER (Ghent, Belgium). Anticancer Res 29: 605-616, 2009.
Volume-sensitive Cl– Channel as a Regulator of Acquired Cisplatin Resistance.
T. SHIMIZU, E.L. LEE, T. ISE, Y. OKADA (Okazaki, Japan). Anticancer Res 28: 75-84, 2008.
Confocal Endomicroscopy: In Vivo Diagnosis of Neoplastic Lesions of the Gastrointestinal Tract.
M. GOETZ, R. KIESSLICH (Mainz, Germany). Anticancer Res 28: 353-360, 2008.
The ATM Gene and Ataxia Telangiectasia.
A. MAVROU, G.T. TSANGARIS, E. ROMA, A. KOLIALEXI (Athens, Greece). Anticancer Res 28: 401-406, 2008.
DNA Image Cytometry in Bladder Cancer: State of the Art.
C.A. PALMEIRA, P.A. OLIVEIRA, F. SEIXAS, M.A. PIRES, C. LOPES, L. SANTOS (Porto; Vila Real, Portugal). Anticancer Res 28: 443- 450, 2008.
Human Papillomavirus Accounts both for Increased Incidence and Better Prognosis in Tonsillar Cancer.
H. DAHLSTRAND, A. NÄSMAN, M. ROMANITAN, D. LINDQUIST, T. RAMQVIST, T. DALIANIS (Stockholm, Sweden). Anticancer Res 28: 1133-1138, 2008.
The Role of Regulatory T Cells in Malignant Glioma.
A.M. SONABEND, C.E. ROLLE, M.S. LESNIAK (Chicago, IL, USA). Anticancer Res 28: 1143-1150, 2008.
Update on Molecular Pathology in Oral Cancer and Precancer.
Chemotherapy in Gastric Cancer.
E. WÖLL, A. DEVRIES, W. EISTERER, M. HEJNA, F. KEIL, H. STEIN, J. ZACHERL, R. GREIL (Zams; Feldkirch; Innsbruck; Vienna; Leoben; Salzbuirg, Austria). Anticancer Res 28: 1213-1220, 2008.
Taxanes and Gemcitabine Doublets in the Management of HER-2 Negative Metastatic Breast Cancer: Towards Optimization of Association and Schedule.
Present Treatment and Future Expectations in Advanced Pancreatic Cancer.
G.P. STATHOPOULOS, N. ANDROULAKIS, J. SOUGLAKOS, J. STATHOPOULOS, V. GEORGOULIAS (Athens; Heraklion, Greece). Anticancer Res 28: 1303-1308, 2008.
Inherited Cancer Predisposition Syndromes in Greece.
A. APESSOS, E. PAPADOPOULOU, I. BELOGIANNI, S. BARATSIS, J.K. TRIANTAFILLIDIS, P. KOSMIDIS, E. KARYDAS, E. BRIASOULIS, C. PISIOTIS, K. PAPAZISIS, G. NASIOULAS (Maroussi, Athens; Ioannina; Thessaloniki, Greece). Anticancer Res 28: 1341-1348, 2008.
Biological Activity and Clinical Implications of the Matrix Metalloproteinases.
M. RYDLOVA, L. HOLUBEC Jr., M. LUDVIKOVA Jr., D. KALFERT, J. FRANEKOVA, C. POVYSIL, M. LUDVIKOVA (Ostrava; Plzen; Hradec Kra’lovι; Prague, Czech Republic). Anticancer Res 28: 1389-1398, 2008.
The Biological Relevance of FHL2 in Tumour Cells and its Role as a Putative Cancer Target.
K. KLEIBER, K. STREBHARDT, B.T. MARTIN (Frankfurt, Germany). Anticancer Res 27: 55-62, 2007.
Comparative Biology of Human and Canine Osteosarcoma.
F. MUELLER, B. FUCHS, B. KASER- HOTZ (Zürich, Switzerland). Anticancer Res 27: 155-164, 2007.
Apoptosis in Brain Tumors: Prognostic and Therapeutic Considerations.
M. MELLAI, D. SCHIFFER (Vercelli, Italy). Anticancer Res 27: 437-448, 2007.
The Role of Epoetin Beta in the Treatment of Anaemia in Patients with Gynaecological Malignancies.
P. CORNES, I. BOIANGIU (Bristol, UK). Anticancer Res 27: 513-522, 2007.
Actual Chemotherapeutical Possibilities in Hormone-refractory Prostate Cancer (HRPC) Patients.
D. PREZIOSO, R. GALASSO, M. DI MARTINO, G. IAPICCA, E. ANNUNZIATA, F. IACONO (Naples, Italy). Anticancer Res 27: 1095-1104, 2007.
Cancer Treatment-induced Oral Mucositis.
D. ALTERIO, B.A. JERECZEK.-FOSSA, M.R. FIORE, G. PIPERNO, M. ANSARIN, R. ORECCHIA (Milan, Italy). Anticancer Res 27: 1105-1126, 2007.
Applications of Quantitative Pharmacodynamic Effect Markers in Drug Target Identification and Therapy Development.
R.M. STRAUBINGER, W. KRZYZANSKI, C.M. FRANCOFORTE, J. QU (Amherst, NY, USA). Anticancer Res 27: 1237-1246, 2007.
Proteomic Approaches for Serum Biomarker Discovery in Cancer.
P. MAURYA, P. MELEADY, P. DOWLING, M. CLYNES (Dublin, Ireland). Anticancer Res 27: 1247-1256, 2007.
Extracellular Nucleic Acids and their Potential as Diagnostic, Prognostic and Predictive Biomarkers.
L. O'DRISCOLL (Dublin, Ireland). Anticancer Res 27: 1257-1266, 2007.
The Pharmacology of Cancer Resistance.
R. O'CONNOR (Dublin, Ireland). Anticancer Res 27: 1267-1272, 2007.
Clinical Applications of Expression Profiling and Proteomics in Prostate Cancer.
J.R.W. MASTERS (London, UK). Anticancer Res 27: 1273-1276, 2007.
EGFR and HER-2 Antagonists in Breast Cancer.
N. O’DONOVAN, J. CROWN (Dublin, Ireland). Anticancer Res 27: 1285-1294, 2207.
The Potential Clinical Applications of Insulin-like Growth Factor-1 Ligand in Human Breast Cancer.
Y.M. CHONG, A. SUBRAMANIAN, A.K. SHARMA, K. MOKBEL (London, UK). Anticancer Res 27: 1617-1624, 2007.
Dermatofibrosarcoma Protuberans: Clinicopathological Aspects of an Unusual Cutaneous Tumor.
D.P. KORKOLIS, I.E. LIAPAKIS, P.P. VASSILOPOULOS (Athens, Greece). Anticancer Res 27: 1631-1634, 2007.
Preclinical and Clinical Effects of Erythropoietin in the Management of Anaemia in Patients with Non-small Cell Lung Cancer.
W. DEMPKE (Bochum, Germany). Anticancer Res 27: 1745- 1758, 2007.
Clinical Value of Bisphosphonates in Cancer Therapy.
D. LÜFTNER, P. HENSCHKE, K. POSSINGER (Berlin, Germany). Anticancer Res 27: 1759-1768, 2007.
Does Homeobox-related "Positional" Genomic Information Contribute to Implantation of Metastatic Cancer Cells at Non-random Sites?
K.M. ANDERSON, M. DARWEESH, A. JAJAH, P. TSUI, P. GUINAN, M. RUBENSTEIN (Chicago, IL , USA). Anticancer Res 27: 2141-2154, 2007.
Human Papillomavirus Infections in Lung Cancer. Detection of E6 and E7 Transcripts and Review of the Literature.
L. GIULIANI, C. FAVALLI, K. SYRJANEN, M. CIOTTI (Rome, Italy; Turku, Finland). Anticancer Res 27: 2697-2704, 2007.
Palliative Chemotherapy for Recurrent and Metastatic Esophageal Cancer.
B. GRÜNBERGER, M. RADERER, M. SCHMIDINGER, M. HEJNA (Vienna, Austria). Anticancer Res 27: 2705-2714, 2007.
Developments in the Treatment of Non-small Cell Lung Cancer.
I. GKIOZOS, A. CHARPIDOU, K. SYRIGOS (Athens, Greece). Anticancer Res 27: 2823-2828, 2007.
Molecular Mechanisms Regulating the Angiogenic Phenotype in Tumors: Clinical Impact in the Future.
K. AUBRY, G. BARRIERE, H. CHABLE-RABINOVITCH, A. DUTOUR, F. PARAF, J. MONTEIL, M. RIGAUD (Limoges, France). Anticancer Res 27: 3111-3120, 2007.
Non-steroidal Anti-inflammatory Drugs in Cancer Prevention and Therapy.
F. GUADAGNI, P. FERRONI, R. PALMIROTTA, G. DEL MONTE, V. FORMICA, M. ROSELLI (Rome, Italy). Anticancer Res 27: 3147-3162, 2007.
Experimental Models for Therapeutic Studies of Transitional Cell Carcinoma.
U. GABRIEL, C. BOLENZ, M.S. MICHEL (Mannheim, Germany). Anticancer Res 27: 3163-3172, 2007.
Clinical Value of Using Serological Cytokeratins as Therapeutic Markers in Thoracic Malignancies.
S. EKMAN, P. ERIKSSON, S. BERGSTRÖM, P. JOHANSSON, H. GOIKE, J. GULLBO, R. HENRIKSSON, A. LARSSON, M. BERGQVIST (Uppsala; Bromma; Umea, Sweden). Anticancer Res 27: 3545-3554, 2007.
Genetic Association Studies in Digestive System Malignancies.
C. TSIGRIS, A. CHATZITHEOFYLAKTOU, C. XIROMERITIS, N. NIKITEAS, A. YANNOPOULOS (Athens, Greece). Anticancer Res 27: 3577-3588, 2007.
Sonodynamic Therapy of Cancer Using Novel Sonosensitizers.
Cancer-targeting Gene Therapy Using Tropism-modified Adenovirus.
T. TANAKA, MOTOMU KUROKI, H. HAMADA, K. KATO, T. KINUGASA, H. SHIBAGUCHI, J. ZHAO, MASAHIDE KUROKI (Fukuoka; Sapporo, Japan). Anticancer Res 27: 3679-3684, 2007.
Roles of Insulin-Like Growth Factor Binding Protein-2 (IGFBP-2) in Glioblastoma.
TSUYOSHI FUKUSHIMA, H. KATAOKA (Miyazaki, Japan). Anticancer Res 27: 3685-3692, 2007.
Development of a Drug Delivery System using a Model that Mimics Chronic Infection of Mycobacterium bovis Calmette-Guιrin in Alveolar Macrophages.
A. YOSHIDA, H. INAGAWA, C. KOHCHI, T. NISHIZAWA, H. HORI, G.-I. SOMA (Tokushima; Chiba; Yamaguchi; Kagawa, Japan). Anticancer Res 27: 3707-3712, 2007.
New Approach to Cancer Therapy: Heparin Binding-Epidermal Growth Factor-like Growth Factor as a Novel Targeting Molecule.
S. MIYAMOTO, H. YAGI, F. YOTSUMOTO, S. HORIUCHI, T. YOSHIZATO, T. KAWARABAYASHI, MASAHIDE KUROKI, E. MEKADA (Fukuoka; Osaka, Japan). Anticancer Res 27: 3713-3722, 2007.
Suppression of Response to Foreign Substances by Intestinal Macrophages.
K. NAKATA, H. INAGAWA, T. NISHIZAWA, C. KOHCHI, G.-I. SOMA (Osaka; Yamaguchi; Tokushima; Chiba; Kagawa, Japan). Anticancer Res 27: 3723-3728, 2007.
Therapeutic Strategies for Targeting the IL-6/STAT3 Cytokine Signaling Pathway in Inflammatory Bowel Disease.
K. MITSUYAMA, S. MATSUMOTO, J. MASUDA, H. YAMASAKI, K. KUWAKI, H. TAKEDATSU, M. SATA (Kurume; Tokyo, Japan). Anticancer Res 27: 3749-3756, 2007.
Gallium-68 PET: A New Frontier in Receptor Cancer Imaging.
A. AL-NAHHAS, Z. WIN, T. SZYSZKO, A. SINGH, C. NANNI, S. FANTI, D. RUBELLO (London; Uxbridge, UK; Bologna; Rovigo, Italy). Anticancer Res 27: 4087-4094, 2007.
Diabetes and Oral Oncogenesis.
Darbepoetin Alpha Coming of Age.
P. PEDRAZZOLI, S. CINIERI, V. LORUSSO, T. GAMUCCI, S. SECONDINO, N. SILVESTRIS (Milan; Lecce; Sora; Bari, Italy). Anticancer Res 27: 4419-4424, 2007.
Aberrant Crypt Foci.
S.J. ALRAWI, M. SCHIFF, R.E. CARROLL, M. DAYTON, J.F. GIBBS, M. KULAVLAT, D. TAN, K. BERMAN, D.L. STOLER, G.R. ANDERSON (Buffalo, NY; Chicago IL, USA). Anticancer Res 26: 107-120, 2006.
Primary Lymphomas of Bone.
P. KITSOULIS, M. VLYCHOU, A. PAPOUDOU-BAI, G. KARATZIAS, A. CHARCHANTI, N.J. AGNANTIS, M. BAI (Ioannina; Larissa, Greece). Anticancer Res 26: 325-338, 2006.
Prospect for Anti-HER2 Receptor Therapy in Breast Cancer.
F.-X. BRAND, N. RAVANEL, A.-S. GAUCHEZ, D. PASQUIER, R. PAYAN, D. FAGRET, M. MOUSSEAU (Grenoble; St. Martin d'Hères France). Anticancer Res 26: 463-470, 2006.
External Beam Radiotherapy for Prostate Cancer: Current Position and Trends.
M.I. KOUKOURAKIS, S. TOULOUPIDIS (Alexandroupolis, Greece). Anticancer Res 26: 485-494, 2006.
Sequential Versus Concurrent Chemo-radiotherapy in Inoperable Stage III Non-small Cell Lung Cancer.
S.Y. EL SHAROUNI, H.B. KAL, J.J. BATTERMANN, F.M.N.H. SCHRAMEL (Utrecht; Nieuwegein, The Netherlands). Anticancer Res 26: 495-506, 2006.
Stable Disease in Advanced Colorectal Cancer: Therapeutic Implications.
L.M. PASETTO, M.R. D’ANDREA, A. JIRILLO, E. ROSSI, S. MONFARDINI (Padova; Noale, Italy). Anticancer Res 26: 511-522, 2006.
Surgery for Advanced and Metastatic Pancreatic Cancer – Current State and Perspectives.
O. MANN, T. STRATE, C. SCHNEIDER, E.F. YEKEBAS, J.R. IZBICKI (Hamburg-Eppendorf, Germany). Anticancer Res 26: 681-686, 2006.
Prospect for Anti-Her2 Receptor Therapy in Breast Cancer.
F.-X. BRAND, N. RAVANEL, A.-S. GAUCHEZ, D. PASQUIER, R. PAYAN, D. FAGRET, M. MOUSSEAU (Grenoble; St. Martin d'Hères, France). Anticancer Res 26: 715-722, 2006.
Cancer Genetics of Sporadic Colorectal Cancer: BRAF and PI3KCA Mutations, their Impact on Signaling and Novel Targeted Therapies.
E. OIKONOMOU, A. PINTZAS (Athens, Greece). Anticancer Res 26: 1077-1084, 2006.
Molecular Immunological Approaches to Biotherapy of Human Cancers – A Review, Hypothesis and Implications.
Y. BECKER (Jerusalem, Israel). Anticancer Res 26: 1113-1134, 2006.
A Related Donor and Reduced Intensity Conditioning Reduces the Risk of Development of BK Virus-positive Haemorrhagic Cystitis in Allogeneic Haematopoetic Stem Cell- transplanted Patients.
G. BOGDANOVIC, P. PRIFTAKIS, G. GIRAUD, T. DALIANIS (Stockholm, Sweden). Anticancer Res 26: 1311-1318, 2006.
Alkylating Agents and DNA Polymerases.
L.P. BIGNOLD (Adelaide, SA, Australia). Anticancer Res 26: 1327-1336, 2006.
Chemotherapy Treatment Options for Elderly Women with Breast Cancer.
S. KÜMMEL, D. ELLING, S. JESCHKE, P. SCHMID, A. THOMAS (Berlin, Germany). Anticancer Res 26: 1673-1676, 2006.
Options and Limits of Surgery after Pre-operative Chemotherapy in Breast Cancer.
A. THOMAS, R. OHLINGER, M. HAUSCHILD, A. MUSTEA, J.-U. BLOHMER, S. KÜMMEL (Berlin, Germany). Anticancer Res 26: 1677-1682, 2006.
The Orphan Nuclear Receptors, Estrogen Receptor-related Receptors: their Role as New Biomarkers in Gynecological Cancer.
P. SUN, L. WEI, C. DENKERT, W. LICHTENEGGER, J. SEHOULI (Beijing, China; Berlin, Germany). Anticancer Res 26: 1699-1706, 2006.
Postoperative Therapy Modalities for Cervical Carcinoma.
S. KÜMMEL, A. THOMAS, S. JESCHKE, M. HAUSCHILD, J. SEHOULI, W. LICHTENEGGER, J.-U. BLOHMER (Berlin, Germany). Anticancer Res 26: 1707-1714, 2006.
The Role of Capecitabine in the Treatment of Colorectal Cancer in the Elderly.
L.M. PASETTO, S. MONFARDINI (Padova, Italy). Anticancer Res 26: 2381-2386, 2006.
Vitamin D and Cancer.
C.S. SPINA, V. TANGPRICHA, M. USKOKOVIC, L. ADORINIC, H. MAEHR, M.F. HOLICK (Boston, MA; Atlanta, GA; Nutley, NJ, USA). Anticancer Res 26: 2515- 2524, 2006.
Mechanisms of Vitamin D-mediated Growth Inhibition in Prostate Cancer Cells: Inhibition of the Prostaglandin Pathway.
J. MORENO, A.V. KRISHNAN, D.M. PEEHL, D. FELDMAN (Stanford, CA, USA). Anticancer Res 26: 2525-2530, 2006.
Vitamin D Compounds: Activity Against Microbes and Cancer.
A.F. GOMBART, Q.T. LUONG, H. P. KOEFFLER (Los Angeles, CA, USA). Anticancer Res 26: 2531-2542, 2006.
The Antitumor Efficacy of Calcitriol: Preclinical Studies.
C.S. JOHNSON, J.R. MUINDI, P.A. HERSHBERGER, D.L. TRUMP (Buffalo, NY; Pittsburgh, PA, USA). Anticancer Res 26: 2543-2550, 2006.
Vitamin D Compounds: Clinical Development as Cancer Therapy and Prevention Agents.
D.L. TRUMP, J. MUINDI, M. FAKIH, W.-D. YU, C.S. JOHNSON (Buffalo, NY, USA). Anticancer Res 26: 2551-2556, 2006.
Epigenetic Corruption of VDR Signalling in Malignancy.
S.A. ABEDIN, C.M. BANWELL, K.W. COLSTON, C. CARLBERG, M.J. CAMPBELL (Birmingham; London, UK; Kuopio, Finland). Anticancer Res 26: 2557-2566, 2006.
Dysfunction of the Vitamin D Endocrine System as Common Cause for Multiple Malignant and other Chronic Diseases.
M. PETERLIK, H.S. CROSS (Vienna, Austria). Anticancer Res 26: 2581-2588, 2006.
The Impact of Chromatin Organization of Vitamin D Target Genes.
C. CARLBERG, T.W. DUNLOP (Kuopio, Finland). Anticancer Res 26: 2637-2646, 2006.
Calcitriol in the Treatment of Prostate Cancer.
T.M. BEER, A. MYRTHUE (Portland, OR, USA). Anticancer Res 26: 2647-2652, 2006.
Selective Inhibitors of Vitamin D Metabolism – New Concepts and Perspectives.
I. SCHUSTER, H. EGGER, G. HERZIG, G.S. REDDY, J.A. SCHMID, M. SCHÜSSLER, G. VORISEK (Vienna, Austria; Providence, RI, USA). Anticancer Res 26: 2653-2668, 2006.
Effects of 1—,25-Dihydroxyvitamin D3 in Human Colon Cancer Cells.
J.M. GONZÁLEZ- SANCHO, M.J. LARRIBA, P. ORDÓÑEZ-MORÁN, H.G. PÁLMER, A. MUÑOZ (Madrid, Spain; London, UK). Anticancer Res 26: 2669-2682, 2006.
Vitamin D Analogs and Coactivators.
G. EELEN, L. VERLINDEN, P. DE CLERCQ, M. VANDEWALLE, R. BOUILLON, A. VERSTUYF (Leuven; Gent, Belgium). Anticancer Res 26: 2717-2722, 2006.
UV Radiation and Cancer Prevention: What is the Evidence?
R. KRAUSE, B. MATULLA- NOLTE, M. ESSERS, A. BROWN, W. HOPFEN MÜLLER (Berlin, Germany). Anticancer Res 26: 2723-2728, 2006.
Cutaneous Photosynthesis of Vitamin D: An Evolutionary Highly-conserved Endocrine System that Protects against Environmental Hazards Including UV-radiation and Microbial Infections.
L. TREMEZAYGUES, M. STICHERLING, C. PFÖHLER, M. FRIEDRICH, V. MEINEKE, M. SEIFERT, W. TILGEN, J. REICHRATH (Homburg/Saar; Leipzig; Lübeck; München, Germany). Anticancer Res 26: 2743-2748, 2006.
Role of Surgery in Treatment of Locally Advanced Prostate Cancer.
D. PREZIOSO, R. GALASSO, M. DI MARTINO, G. IAPICCA, F. IACONO (Naples, Italy). Anticancer Res 26: 3151- 3158, 2006.
Proteomics in the Diagnosis of Hepatocellular Carcinoma: Focus on High Risk Hepatitis B and C Patients.
A. EL-ANEED, J. BANOUB (St. John’s, NL, Canada). Anticancer Res 26: 3293- 3300, 2006.
New Molecular Mechanisms of Action of Camptothecin-type Drugs.
K. LEGARZA, L.-X. YANG (San Francisco, CA, USA). Anticancer Res 26: 3301-3306, 2006.
Recent Progress in Target Therapy in Colorectal Cancer.
L.M. PASETTO, A. BORTOLAMI, C. FALCI, G. SINIGAGLIA, S. MONFARDINI (Padova; Aviano, Italy). Anticancer Res 26: 3973- 3982, 2006.
The Therapeutic Potential of Immuno-cell Therapy of Cancer in Combination with Aminobisphosphonates.
S. GOTO, A. NOGUCHI, H. JINGUJI, M. TAKAHARA (Tokyo, Japan). Anticancer Res 26: 3989-3996, 2006.
Unique Molecular Characteristics of the Environmental Responses of Mucosal Macrophages.
K. NAKATA, H. INAGAWA, T. NISHIZAWA, C. KOHCHI, Y. TANIGUCHI, N. YOSHIOKA, G.-I. SOMA (Tokushima; Shimonoseki; Chiba, Japan). Anticancer Res 26: 4009- 4014, 2006.
Possible Applications of Antibodies or their Genes in Cancer Therapy.
M. KUROKI, J. HUANG, H. SHIBAGUCHI, T. TANAKA, J. ZHAO, N. LUO, K. HACHIMINE, T. KINUGASA, S.-I. MAEKAWA, S. ENATSU, W. HAMANAKA, T. FUKAMI, M. KUROKI (Fukuoka, Japan). Anticancer Res 26: 4019- 4026, 2006.
HER-2 and NF-κB as the Targets for Therapy-resistant Breast Cancer.
K.M. AHMED, N. CAO, J.J. LI (West Lafayette, IN, USA). Anticancer Res 26: 4235-4244, 2006.
The Emerging World of MicroRNAs.
L. O’DRISCOLL (Dublin, Ireland). Anticancer Res 26: 4271- 4278, 2006.
Anticancer Potential of Silymarin: From Bench to Bed Side.
R. AGARWAL, C. AGARWAL, H. ICHIKAWA, R.P. SINGH, B.B. AGGARWAL (Denver, CO; Houston, TX, USA). Anticancer Res 26: 4457-4498, 2006.
Hepatic Metastases of Colorectal Cancer: Locoregional Intra-arterial Treatment.
L.M. PASETTO, R. MERENDA, P. PILATI, G. SINIGAGLIA, S. MONFARDINI (Padova, Italy). Anticancer Res 26: 4785-4792, 2006.
Ovarian Cancer Screening.
M. KYRGIOU, I. TSOUMPOU, P. MARTIN-HIRSCH, M. ARBYN, W. PRENDIVILLE, G. KOLIOPOULOS, N. DALKALITSIS, P. STAMATOPOULOS, E. PARASKEVAIDIS (London; Edinburgh; Preston; Oxford, UK; Brussels, Belgium; Lyon, France; Dublin, Ireland; Ioannina; Thessaloniki, Greece). Anticancer Res 26: 4793-4802, 2006.
Parathyroid Cancer: Etiology, Clinical Presentation and Treatment.
F. LUMACHI, S.M.M. BASSO, U. BASSO (Padova, Italy). Anticancer Res 26: 4803-4808, 2006.
Adjuvant Chemotherapy for Colon Cancer.
A.G. PALLIS, I.A. MOUZAS (Heraklion, Greece). Anticancer Res 26: 4809-4816, 2006.
B-cell Differentiation, Apoptosis and Proliferation in Diffuse Large B-cell Lymphomas.
M. BAI, A. SKYRLAS, N.J. AGNANTIS, S. KAMINA, A. PAPOUDOU-BAI, P. KITSOULIS, P. KANAVAROS (Ioannina, Greece). Anticancer Res 25: 347-362, 2005.
Prostate Cancer Therapy: Standard Management, New Options and Experimental Approaches.
L. TROJAN, K. KIKNAVELIDZE, T. KNOLL, P. ALKEN, M.S. MICHEL (Mannheim, Germany). Anticancer Res 25: 551-562, 2005.
FOLFOX Versus FOLFIRI: A Comparison of Regimens in the Treatment of Colorectal Cancer Metastases.
L.M. PASETTO, A. JIRILLO, G. IADICICCO, E. ROSSI, M.K. PARIS, S. MONFARDINI (Padova, Italy). Anticancer Res 25: 563-576, 2005.
Molecular Genetic Tumor Markers in Non-small Cell Lung Cancer.
Antibody Therapy for Breast Cancer.
A. WILLEMS, K. GAUGER, C. HENRICHS, N. HARBECK (Munich, Germany). Anticancer Res 25: 1483-1490, 2005.
Current Approaches in Chemotherapy of Advanced and Metastatic Non-small Cell Lung Cancer (NSCLC).
M. RECK (Grosshansdorf, Germany). Anticancer Res 25: 1501-1506, 2005.
The MLL Gene and Translocations Involving Chromosomal Band 11q23 in Acute Leukemia.
M. DE BRAEKELEER, F. MOREL, M.-J. LE BRIS, A. HERRY, N. DOUET-GUILBERT (Brest, France). Anticancer Res 25: 1931-1944, 2005.
Nuclear Phospholipase C Signaling Through Type 1 IGF Receptor and its Involvement in Cell Growth and Differentiation.
I. FAENZA, A.M. BILLI, M. YUNG FOLLO, R. FIUME, A.M. MARTELLI, L. COCCO, L. MANZOLI (Bologna, Italy). Anticancer Res 25: 2039-2042, 2005.
Pharmacokinetics of Therapeutic Monoclonal Antibodies Used in Oncology.
D. LEVΚQUE, S. WISNIEWSKI, F. JEHL (Strasbourg, France). Anticancer Res 25: 2327-2344, 2005.
Contemporary Definitions of Tumor Specific Antigens, Immunogens and Markers as Related to the Adaptive Responses of the Cancer-bearing Host.
J.H. COGGIN JR., A.L. BARSOUM, J.W. ROHRER, M. THURNHER, M. ZEIS (Mobile, AL, USA; Innsbruck, Austria; Hamburg, Germany). Anticancer Res 25: 2345-2356, 2005.
Phytoestrogens in Cancer Prevention and Therapy – Mechanisms of their Biological Activity.
J. WIETRZYK, G. GRYNKIEWICZ, A. OPOLSKI (Wroclaw; Warsaw; Czestochowa, Poland). Anticancer Res 25: 2357-2366, 2005.
A Practical Overview of Aromatase Inhibitors.
J. YOUNUS, T.A. VANDENBERG (London, Ont., Canada). Anticancer Res 25: 2497-2502, 2005.
Murine Polyomavirus Virus-like Particles (VLPs) as Vectors for Gene and Immune Therapy and Vaccines against Viral Infections and Cancer.
K. TEGERSTEDT, A. VLASTOS FRANZΙN, K. ANDREASSON, J. JONEBERG, S. HEIDARI, T. RAMQVIST, T. DALIANIS (Stockholm, Sweden). Anticancer Res 25: 2601-2608, 2005.
The Elastin Connection and Melanoma Progression.
W. HORNEBECK, A. ROBINET, L. DUCA, F. ANTONICELLI, J. WALLACH, G. BELLON (Reims; Lyon, France). Anticancer Res 25: 2617-2626, 2005.
Prostate Cancer and Inositol Hexaphosphate: Efficacy and Mechanisms.
R.P. SINGH, R. AGARWAL (Denver, CO, USA). Anticancer Res 25: 2891-2904, 2005.
Impact of Cytogenetic and Molecular Cytogenetic Studies on Hematologic Malignancies.
A. KOLIALEXI, G.TH. TSANGARIS, S. KITSIOU, E. KANAVAKIS, A. MAVROU (Athens, Greece). Anticancer Res 25: 2979-2984, 2005.
Telomere Attrition as Ageing Biomarker.
S. BEKAERT, T. DE MEYER, P. VAN OOSTVELDT (Ghent, Belgium). Anticancer Res 25: 3011-3022, 2005.
The Biological Role of Smoking, Oral Contraceptive Use and Endogenous Sexual Steroid Hormones in Invasive Squamous Epithelial Cervical Cancer.
D. HELLBERG, U. STENDAHL (Falun; Uppsala; Umea, Sweden). Anticancer Res 25: 3041-3046, 2005.
Progress in Molecular Mechanisms of Tumor Metastasis and Angiogenesis.
A. HARLOZINSKA (Wroclaw, Poland). Anticancer Res 25: 3327-3334, 2005.
Clinical Experience with Bevacizumabn in Colorectal Cancer.
N. SALESI, G. BOSSONE, E. VELTRI, B. DI COCCO, P. MAROLLA, U. PACETTI, G. LAROSA, R. MUNI, A. VECCHIONE (Terracina; Rome, Italy). Anticancer Res 25: 3619-3624, 2005.
Multiple Roles of Cyclooxygenase-2 in Endometrial Cancer.
S. OHNO, Y. OHNO, N. SUZUKI, H. INAGAWA, C. KOHCHI, G.-I. SOMA, M. INOUE (Osaka; Ishikawa; Yamaguchi; Tokushima; Chiba, Japan). Anticancer Res 25: 3679-3688, 2005.
Gc Protein (Vitamin D-binding Protein): Gc Genotyping and GcMAF Precursor Activity.
H. NAGASAWA, Y. UTO, H. SASAKI, N. OKAMURA, A. MURAKAMI, S. KUBO, K.L. KIRK, H. HORI (Tokushima, Japan; Bethesda, MD, USA). Anticancer Res 25: 3689-3696, 2005.
Re-targeting of Cytotoxic T Lymphocytes and/or Natural Killer Cells to CEA-expressing Tumor Cells with Anti-CEA Antibody Activity.
M. KUROKI, K. HACHIMINE, J. HUANG, H. SHIBAGUCHI, T. KINUGASA, S.-I. MAEKAWA, M. KUROKI (Fukuoka, Japan). Anticancer Res 25: 3725-3732, 2005.
Tumor Endothelial Cells are Targets for Selective Therapies: In Vitro and In Vivo Models to Evaluate Antiangiogenic Strategies.
A. DUTOUR, M. RIGAUD (Houston, TX, USA; Limoges, France). Anticancer Res 25: 3799-3808, 2005.
Nuclear Matrix Protein Expression in Prostate Cancer: Possible Prognostic and Diagnostic Applications.
P. BARBORO, A. RUBAGOTTI, F. BOCCARDO, B. CARNEMOLLA, C. D’ARRIGO, E. PATRONE, C. BALBI (Genoa, Italy). Anticancer Res 25: 3999-4004, 2005.
Lymphangiogenesis, Inflammation and Metastasis.
S.F. SCHOPPMANN (Vienna, Austria). Anticancer Res 25: 4503-4512, 2005.
Biological Prognostic Factors in Adult Soft Tissue Sarcomas.
A. OTTAIANO, A. DE CHIARA, F. FAZIOLI, A. AIELLO TALAMANCA, S. MORI, GERARDO BOTTI, A. MILANO, G. APICE (Naples, Italy). Anticancer Res 25: 4519-4526, 2005.
Prostate Cancer in the Elderly.
K.N. SYRIGOS, E. KARAPANAGIOTOU, K.J. HARRINGTON (Athens, Greece; London, UK). Anticancer Res 25: 4527-4534, 2005.
Perspectives of Immunotherapy in Metastatic Breast Cancer.
D. LÜFTNER, D. POLLMANN, S. SCHILDHAUER, J. SEHOULI, K. POSSINGER (Berlin, Germany). Anticancer Res 25: 4599-4604, 2005.

IMPORTANT NOTE: You may submit your article only through our online submission system